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Abstract
Herpes simplex virus type 1 (HSV-1) is a human pathogen which belongs to
the family Herpesviridae. This virus family is characterized by a large genome
encoding many genes, which shape the virus -host interaction. Furthermore, her-
pesviruses are able to remain lifelong in the host in a latent state from which they
can reactivate in order to replicate again. Reactivation of HSV-1 can cause recur-
rent disease, Herpes labialis, characterized by vesicle formation in the skin of the
lips. Sporadically, HSV-1 infection can cause other clinical manifestations, such as
encephalitis with poor prognosis.
Virus infection is controlled at the cellular level as well as by the immune system.
Cells can respond to virus infection by induction of apoptosis, a strictly regulated
form of physiological cell death. This can efficiently limit replication of the virus
and spread of the virus to surrounding cells. However, to resolve peripheral le-
sions and prevent disease in the central nervous system, a specific cytotoxic T cell
immune response to HSV-1 is crucial. The most potent activators of T cells are den-
dritic cells (DCs). Immature dendritic cells (iDCs) patrol in peripheral tissues and
take up antigens. Upon encounter with specific structures of pathogens or inflam-
matory signals, DCs mature, migrate to the draining lymph nodes and are able
to present antigens to T cells and activate them. HSV-1 can infect local iDCs and
severely impair their phenotype, function and viability. However, uninfected by-
stander iDCs take up antigen from HSV-1 infected cells and mount a protective
immune response.
HSV-1 encodes several genes, which serve to efficiently prevent apoptosis in
most infected cell types, thereby ensuring successful virus replication. In contrast,
HSV-1 infected iDCs undergo apoptosis and virus replication in this cell type is low.
So far, the mechanisms underlying apoptosis of HSV-1 infected iDCs are poorly de-
fined. However, it has been shown that the antiapoptotic cellular protein c-FLIP is
reduced in HSV-1 infected iDCs. The mechanism and impact of HSV-1 induced c-
FLIP reduction was not investigated up to now. Furthermore, it is not known why
antiapoptotic HSV-1 genes are not functional in iDCs.
In this work, the amount of c-FLIP was for the first time successfully reduced in
iDCs by RNA interference. This confirmed the importance of c-FLIP for viability of
iDCs. Therefore, it is likely that the reduction of the amount of c-FLIP after HSV-1
infection could also sensitize iDCs to apoptosis.
The mechanism of HSV-1 induced c-FLIP reduction was resolved to a large ex-
tent. It could be demonstrated that a viral or induced cellular protease directly
degrades c-FLIP, while the amount of cytoplasmic c-FLIP mRNA was not reduced.
HSV-1 induced c-FLIP degradation occurred at late stages of infection and was de-
pendent on proper expression of early and leaky late virus genes. Degradation of
c-FLIP after HSV-1 infection was independent from the proteasome and binding to
the death inducing signaling complex. Co-transfection studies indicated that viral
protein kinase US3 and c-FLIP co-localize. This could be an indication that US3 is
involved in HSV-1 induced degradation of c-FLIP.
Surprisingly, c-FLIP reduction after HSV-1 infection was not only observed in
iDCs, but also in human umbilical vein endothelial cells (HUVECs), primary ep-
ithelial cells (keratinocytes), primary connective tissue cells (fibroblasts) and cells
of hematopoietic origin (Hodgkin/Reed-Sternberg cells). However, in these cell
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types no apoptosis was observed after HSV-1 infection. It was hypothesized that
effective antiapoptotic viral factors compensate the HSV-1 induced loss of c-FLIP
in most cell types, but not in iDCs. In order to investigate whether antiapoptotic
HSV-1 genes possibly are insufficiently expressed in iDCs, a microarray analysis
of HSV-1 gene expression in apoptotic iDCs compared to nonapoptotic epithelial
cells was conducted. Intriguingly, the abundance of transcripts of most antiapop-
totic HSV-1 genes was not different in iDCs compared to epithelial cells. However,
latency-associated transcripts (LATs) were significantly lower expressed in iDCs. It
is known that in neurons and epithelial cells, LATs possess a potent antiapoptotic
activity. This could compensate the lack of c-FLIP. Consistent with this hypothesis,
a LAT deletion mutant of HSV-1 induced more apoptosis in iDCs compared to the
respective wild type virus.
In this work it is shown for the first time that in addition to changes in the cellular
apoptosis signaling network, the lack of one antiapoptotic viral factor contributes
to apoptosis of HSV-1 infected iDCs. The expression of HSV-1 antiapoptotic factors
appears to be cell type dependent, as shown here for LATs. The cell type specific
induction or prevention of apoptosis might be one tool of HSV-1, which might con-
tribute to maximize its spread, replication and establishment of latency without
excessive damage to the host.
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Zusammenfassung
Herpes simplex Virus Typ 1 (HSV-1) ist ein humanpathogenes Virus und gehört
zur Familie Herpesviridae. Diese Virusfamilie ist durch ein sehr großes Genom
gekennzeichnet, das viele an der Virus -Wirt Interaktion beteiligte Gene enthält.
Herpesviren sind in der Lage lebenslang im Wirt zu überdauern, in einer latenten
Form aus der sie reaktivieren und erneut replizieren können. Die Reaktivierung
von HSV-1 kann mit wiederkehrenden Krankheitserscheinungen einhergehen, vor
allem den charakteristischen Lippenbläschen (Herpes labialis). Vereinzelt kann ei-
ne HSV-1 Infektion auch andere klinische Manifestationen zeigen, zum Beispiel
Enzephalitis mit schlechter Prognose.
Virusinfektionen werden sowohl auf Zellebene als auch durch das Immunsystem
eingedämmt. Zellen können auf eine Virusinfektion durch Induktion von Apopto-
se reagieren, einer genau regulierten, physiologischen Form des Zelltods. Dadurch
kann die Virusreplikation und die Virusausbreitung auf benachbarte Zellen stark
verringert werden. Für die Heilung peripherer Läsionen und für den Schutz des
Zentralnervensystems vor Schäden ist jedoch eine spezifische zytotoxische T-Zell
Immunantwort gegen HSV-1 entscheidend. Die potentesten Aktivatoren von T-
Zellen sind dendritische Zellen (DCs). Unreife dendritische Zellen (iDCs) patrouil-
lieren in peripheren Geweben und nehmen Antigene auf. Wenn sie auf spezifische
Strukturen von Pathogenen oder auf Entzündungssignale treffen, reifen die DCs,
wandern zu den abführenden Lymphknoten und sind in der Lage, T-Zellen Anti-
gene zu präsentieren und sie zu aktivieren. HSV-1 kann die lokalen iDCs infizieren
und ihren Phänotyp, ihre Funktion und ihre Lebensfähigkeit stark beeinträchtigen.
Nicht infizierte „bystander“ iDCs nehmen jedoch Antigene von HSV-1 infizierten
Zellen auf und induzieren eine schützende Immunantwort.
HSV-1 besitzt mehrere Gene, die dazu dienen, in den meisten infizierten Zell-
typen Apoptose effektiv zu verhindern, um eine erfolgreiche Virusreplikation si-
cherzustellen. Im Gegensatz dazu gehen HSV-1 infizierte iDCs in Apoptose und
die Virusreplikation ist in diesem Zelltyp gering. Bis jetzt sind die Mechanismen,
die der Apoptose in HSV-1 infizierten iDCs zu Grunde liegen, nur unzureichend
aufgeklärt. Es wurde jedoch gezeigt, dass das antiapoptotische zelluläre Protein
c-FLIP in HSV-1 infizierten iDCs reduziert ist. Der Mechanismus und die Auswir-
kungen der HSV-1 induzierten c-FLIP Reduktion wurden bisher nicht untersucht.
Weiterhin ist nichts darüber bekannt, warum die antiapoptotischen HSV-1 Gene in
iDCs nicht funktionieren.
In dieser Arbeit wurde die c-FLIP Menge in iDCs erstmalig mit Hilfe von RNA
Interferenz erfolgreich reduziert. Dies bestätigte die Bedeutung von c-FLIP für die
Lebensfähigkeit von iDCs. Folglich ist es wahrscheinlich, dass auch die Reduktion
der c-FLIP Menge nach HSV-1 Infektion iDCs für Apoptose empfindlich machen
könnte.
Der Mechanismus der HSV-1 induzierten c-FLIP Reduktion wurde weitgehend
aufgeklärt. Es konnte gezeigt werden, dass eine virale oder induzierte zelluläre
Protease c-FLIP direkt abbaut, während die Menge zytoplasmatischer c-FLIP mR-
NA nicht reduziert war. Der HSV-1 induzierte c-FLIP Abbau fand in späten Stadien
der Infektion statt und war abhängig von der ordnungsgemäßen Expression vira-
ler „early“ und „leaky late“ Gene. Der Abbau von c-FLIP nach HSV-1 Infektion
war unabhängig vom Proteasom und der Bindung an den „death inducing signa-
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ling complex“. Kotransfektionsuntersuchungen deuteten darauf hin, dass die vi-
rale Proteinkinase US3 und c-FLIP kolokalisieren. Dies könnte ein Hinweis darauf
sein, dass US3 am HSV-1 induzierten Abbau von c-FLIP beteiligt ist.
Überraschenderweise war eine c-FLIP Reduktion nach HSV-1 Infektion nicht
nur in iDCs zu beobachten, sondern auch in Endothelzellen aus Nabelschnurve-
nen (HUVECs), primären epithelialen Zellen (Keratinozyten), primären Bindege-
webszellen (Fibroblasten) und Zellen hämatopoetischen Ursprungs (Hodgkin/-
Reed-Sternberg Zellen). Jedoch war in diesen Zelltypen keine Apoptose nach HSV-
1 Infektion zu beobachten. Es könnte vermutet werden, dass effektive antiapopto-
tische virale Faktoren den HSV-1 induzierten Verlust von c-FLIP in den meisten
Zelltypen kompensieren, jedoch nicht in iDCs. Um zu untersuchen, ob antiapopto-
tische HSV-1 Gene möglicherweise unzureichend exprimiert sind, wurde eine Mi-
croarray-Analyse der HSV-1 Genexpression in apoptotischen iDCs im Vergleich
zu nicht apoptotischen epithelialen Zellen durchgeführt. Interessanterweise war
die Menge der Transkripte der meisten antiapoptotischen HSV-1 Gene nicht un-
terschiedlich in iDCs im Vergleich zu epithelialen Zellen. Jedoch waren in iDCs
„latency-associated transcripts“(LATs) signifikant geringer exprimiert. Es ist be-
kannt, dass LATs in Neuronen und epithelialen Zellen eine antiapoptotische Ak-
tivität besitzen. Diese könnte den Mangel an c-FLIP kompensieren. Übereinstim-
mend mit dieser Hypothese induzierte eine HSV-1 LAT-Deletionsmutante mehr
Apoptose in iDCs im Vergleich zum entsprechenden Wildtyp -Virus.
In dieser Arbeit wurde erstmals gezeigt, dass zusätzlich zu Veränderungen im
zellulären Apoptosesignalnetzwerk der Mangel an einem antiapoptotischen vira-
len Faktor zur Apoptose von HSV-1 infizierten iDCs beiträgt. Die Expression antia-
poptotischer Faktoren von HSV-1 scheint vom Zelltyp abhängig zu sein, wie hier
für LATs gezeigt. Die zelltypspezifische Induktion oder Verhinderung von Apop-
tose könnte ein Werkzeug von HSV-1 sein, das dazu beiträgt, seine Verbreitung,
seine Replikation und die Etablierung von Latenz zu maximieren, ohne übermäßi-
gen Schaden für den Wirt.
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1 Introduction
Virus infections are controlled by powerful and precisely adjusted defense mechanisms
of the host. In multicellular organisms, each cell possesses strategies to avert the danger
of takeover by a virus. In addition a complex network of specialized cells, the immune
system, has evolved to defend the host organism against damage or death due to ex-
cessive virus replication. Viruses in turn have acquired means to evade the defense
mechanisms of the host in order to maximize their replication and spread within the
organism and between individuals.
Herpes simplex virus type 1 (HSV-1) can infect and impair dendritic cells, which play
a pivotal role in orchestrating the immune system [23, 97, 114, 115, 133, 143]. This is one
of the several immune evasion strategies of HSV-1. In this thesis, crucial mechanisms
of the impairment of dendritic cells by HSV-1 are studied.
1.1 Herpes simplex virus type 1 (HSV-1)
HSV-1 is a human herpesvirus. There exists a second serotype, Herpes simplex virus
type 2 (HSV-2) [150]. HSV-2 differs from HSV-1 in some aspects, for example the pre-
ferred site of infection [120] and sensitivity to antiviral drugs [3, 49]. The experiments
presented in this thesis were exclusively conducted with HSV-1.
HSV-1 is distributed worldwide and the human being is the only host. The frequency
of seropositive individuals is high, ranging in young adults from 50 % in developed
countries to over 80 % in less industrialized countries [142].
1.1.1 HSV-1 infection and disease
HSV-1 infection can occur at different sites of the body. HSV-1 infects skin and mucosa
of lips and mouth and less often genital, perigenital, and anal skin. The virus replicates
in epithelial cells, resulting in cell lysis and release of mature virus progeny. This can
cause primary disease. The released virions can infect sensory nerve endings, which
innervate the infected area of the skin. By retrograde transport virions or deenveloped
virus particles reach the neuron cell bodies located in the trigeminal ganglia or dorsal
root ganglia. There, HSV-1 replicates without destroying the cell and finally establishes
a latent state. During latency, the virus does not replicate and no viral proteins are syn-
thesized. HSV-1 can exist latently in neurons for years. Triggers, which are not fully
understood, periodically cause the virus to replicate again. Progeny viruses are trans-
ported down the axon (anterograde transport) to the epithelial tissues where primary
infection took place. Then, HSV-1 infects epithelial cells again and replicates efficiently,
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which can result in recurrent disease. Recurrent replication increases the probability of
spread of HSV-1 to a new individual [142].
Primary infection and also recurrent replication of HSV-1 often occur without signifi-
cant symptoms. Symptomatic primary disease (oropharyngeal Herpes) is characterized
by sore throat, ulcerative and vesicular lesions, gingivostomatitis and localized lym-
phadenopathy with fever and malaise. Symptomatic recurrent disease (Herpes labi-
alis) is characterized by a prodrome of pain and itching, which is followed by vesicle
formation in the skin of the lips and around the mouth. The vesicles progress to the
pustular, ulcerative and crusting stage and finally heal, which is associated with pain.
Rare, but severe complications of HSV-1 infection are keratoconjunctivitis, encephalitis,
and disseminated infections [142].
Pathology due to replication of HSV-1 is similar for both primary and recurrent in-
fection. The pathologic changes represent a combination of virally mediated cell death
and inflammatory immune response. Infected epithelial cells enlarge and loose intact
plasma membranes, finally forming multinucleated giant cells. When the cells lyse,
clear fluid appears between the epidermis and dermal layer. This vesicular fluid con-
tains large amounts of virus, cell debris, and inflammatory immune cells. In dermal
substructures an intense inflammatory immune response is evident. There are also
vascular changes in the area of infection, such as perivascular cuffing and some hem-
orrhagic necrosis. During healing of the vesicle, more inflammatory immune cells are
recruited and the vesicular fluid becomes pustular. Finally the vesicle scabs and does
usually not leave a scar [142].
Although life-threatening complications of HSV-1 induced disease are rather rare,
many people experience frequent recurrent disease, which is painful and incriminating
[142]. HSV-1 caused disease is therefore a relevant socio-economic factor.
1.1.2 HSV-1 structure and morphology
HSV-1 is a member of the family Herpesviridae, which is defined by certain properties
of the virion. The virion of a herpesvirus has a core, which contains the linear double-
stranded DNA representing the genome of the virus. The core is surrounded with an
icosadeltahedral capsid composed of 162 capsomeres which have a hole running down
the long axis. The capsid is approximately 100 to 110 nm in diameter and is surrounded
with asymmetric material called tegument. The outer lining of the virus particle is a
trilaminar lipid layer, designated envelope, containing viral glycoprotein spikes. The
typical appearance of a herpesvirion in electron microscopy is shown in figure 1.1A,
while in figure 1.1B the components are schematically depicted. All herpesviruses are
characterized by four significant biologic properties: 1) They encode a large array of
enzymes involved in DNA synthesis, nucleic acid metabolism and processing of pro-
teins. 2) Viral DNA replication and assembly of the capsid take place in the nucleus. 3)
Successful replication of the virus results in destruction of the cell. 4) They are able to
remain in their natural hosts in a latent state [142].
The genome of HSV-1 is a linear double-stranded DNA molecule with a length of
approximately 150 kbp [16, 33]. It encodes more than 80 open reading frames (ORFs).
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1.1 Herpes simplex virus type 1 (HSV-1)
Figure 1.1: Characteristics of HSV-1. A) Electron microscopy of a herpesvirion. B) Schematic
depiction of herpesvirion components. C) Schematic depiction of HSV-1 DNA se-
quence arrangement. The HSV-1 DNA molecule consists of two components, the
long (L) region and the short (S) region. Each component consists of a unique se-
quence (UL, unique long; US, unique short) flanked by inverted repeats (TRL, termi-
nal repeat long; IRL, internal repeat long; TRS, terminal repeat short; IRS, internal
repeat short). According to references [139, 142].
Therefore, HSV-1 is a rather huge virus, bringing many of the enzymes needed for
replication with it. Furthermore it contains numerous genes which play a role in the
complex interaction with the host [142].
The genome consists of two components, the long (L) region and the short (S) region.
Each component consists of a unique sequence flanked by inverted repeats, as shown
in figure 1.1C. Genes located in the unique long region are designated UL followed by a
number indicating the position in the order of genes on that segment, for example UL54
(infected cell protein (ICP)27 or α27, a regulatory protein). Genes in the unique short
region are designated US plus number, for example US6 (gD, glycoprotein D). Genes
located in the inverted repeats of the long region are γ34.5 (ICP34.5, counteracts acti-
vation of protein kinase R), α0 (ICP0, a regulatory protein), and the latency-associated
transcript (LAT). Only one gene is located in the inverted repeats of the short region,
that is α4 (ICP4, a regulatory protein) [139].
1.1.3 Replication of HSV-1
Entry and release of viral DNA
The entry of HSV-1 into a cell occurs in three stages. First, the virion attaches to the
surface of the cell by interaction of the viral envelope protein gC with heparan sulfate
on the cell. Second, HSV-1 glycoprotein gD in the envelope of the virion binds to one of
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several coreceptors on the cell surface. There exist three different types of coreceptors:
members of the tumor necrosis factor (TNF) receptor family (herpes virus entry medi-
ator A, HveA), coreceptors of the immunoglobulin superfamily (HveB and HveC), and
3-O-sulfated heparan sulfate [44]. In addition, HSV-1 envelope glycoprotein gB binds to
non-muscle myosin heavy chain IIA (NMHC-IIA), which is expressed in many human
cell types [5]. In the third stage, the HSV-1 envelope fuses with the plasma membrane
of the host cell and the tegument-coated capsid is released into the cytoplasm [44].
The capsid with associated tegument structures is then transported to the cell nucleus
with the help of the microtubular network and dynein. The capsids associate with the
nuclear pore complexes and the viral DNA is released into the nucleus, where it rapidly
circularizes. Some tegument proteins, for example the virion host shutoff (vhs) protein
(UL41), are released into the cytoplasm. Other tegument components stay associated
with the capsid and some are transported into the nucleus, such as the transcription
stimulator VP16/αTIF (UL48) [142].
Transcription of HSV-1 genes
The transcription of viral genes takes place in the nucleus, mediated by host RNA
polymerase II. Several viral gene products may be involved, which modify the activity
and structure of RNA polymerase II. Expression of viral genes occurs sequentially in a
tightly regulated cascade. Very soon after infection (2-4 h post infection with MOI 10 -
20), VP16/αTIF (UL48) stimulates the expression of the first virus genes, the immediate
early (IE) or α genes. These include α4 (ICP4), α0 (ICP0), UL54 (ICP27), US1 (ICP22),
US12 (ICP47), and US1.5. All IE proteins, except ICP47, are regulatory proteins im-
portant for proper expression of the following temporal classes of HSV-1 genes [142].
ICP47 is involved in immune evasion of HSV-1 by blocking antigen presentation to T
cells [185].
The next (4-8 h post infection) viral genes expressed are the early (E) or β genes. They
require at least the transactivating function of the immediate early protein ICP4 but
not the onset of viral DNA synthesis. Almost all early genes encode proteins which
are involved in nucleotide metabolism and DNA replication. Prominent examples are
UL23 (thymidine kinase), UL39 (ICP6, large subunit of ribonucleotide reductase), UL50
(dUTPase), and UL30 (DNA polymerase) [142].
As soon as the early genes are expressed, viral DNA replication takes place. The
expression of the third temporal class of HSV-1 genes, the leaky late or γ1 genes, starts
at low levels before viral DNA replication begins, but is strongly enhanced thereafter.
In contrast, expression of the last set of HSV-1 genes, the true late or γ2 genes, is strictly
dependent on viral DNA replication [142]. γ2 genes are not expressed in the presence
of inhibitors of viral DNA synthesis, for example aciclovir (ACV) [36]. Many late (L)
HSV-1 genes represent virion components, for example US2 (tegument protein [142])
or mediate interaction with the host, like γ134.5 (ICP34.5, precludes shutoff of protein
synthesis by activated PKR [60]), and US3 (protein kinase [39], blocks apoptosis [103]).
Expression of some early and most late HSV-1 genes is dependent on the immedi-
ate early protein ICP27 [146]. Therefore, it represents one of the two essential IE pro-
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teins, besides ICP4. While ICP4 exerts its effect directly at the transcriptional level [47],
ICP27 can act at both the transcriptional and posttranscriptional level. ICP27 appears
to modulate virtually every aspect of mRNA metabolism, including primary transcrip-
tion, polyadenylation, nuclear export of intronless mRNA, splicing, and mRNA sta-
bility and translation. At early times post infection, ICP27 is predominantly found in
the nucleus. However, after 4 h post infection, ICP27 starts to shuttle between the nu-
cleus and the cytoplasm. This is essential for nuclear export and translation of most late
HSV-1 transcripts [146].
DNA replication, virion assembly, and egress
Replication of HSV-1 DNA takes place in the nucleus of the host cell. The new DNA is
synthesized by a rolling-circle mechanism. The resulting concatemers are cleaved into
monomers during assembly of nucleocapsids. The mature, DNA containing capsids
bud through the inner lamella of the nuclear membrane. During this process, the tegu-
ment and a first version of the envelope are acquired. The virion is then transported
through the trans-Golgi network, where the envelope obtains its final composition and
posttranslational modifications of the glycoproteins occur. Viral glycoproteins, for ex-
ample gD, do not only accumulate in intracellular membranes, but also in the plasma
membrane of the cell. This can be used to detect infected cells by staining with gD-
specific antibodies. HSV-1 virions are finally released from the cell through secretory
vesicles [142].
HSV-1 microarray
Wagner and his co-workers have developed a HSV-1 microarray which allows a global
monitoring of HSV-1 gene expression [158, 177]. This technique makes it possible to
analyze the complex HSV-1 transcription program under various conditions of infec-
tion and in different cell types. Differences in the expression of viral genes observed
with the microarray yield new indications about the function and importance of the
respective HSV-1 genes in the biological processes examined. This is of high value, as
the function of several HSV-1 genes is still not known or only poorly defined.
The procedure of HSV-1 microarray analysis is similar to the technique of microarray
analyzes already established and widely used for human or microbe gene expression.
For the HSV-1 microarray analysis, 52 oligonucleotide probes which are complemen-
tary to specific HSV-1 sequences are spotted on glass slides. Total RNA is isolated from
infected cells or tissues and oligo-dT-primed cDNA is synthesized, which is tagged
with a fluorescent dye. The cDNA is hybridized with the probes on the glass slide and
after washing away unbound cDNA, the fluorescence signal is detected with a laser-
based imaging device. The presence of a signal indicates that the respective HSV-1
gene is expressed at the selected time point post infection and under the conditions of
the conducted experiment. The intensity of the fluorescence signal correlates with the
amount of transcripts present in the cell [158, 177].
5
1 Introduction
Because the isolation of mRNA and the generation of cDNA is achieved using the
poly(A) tail, the selection of sequences for the oligonucleotide probes is restricted to the
52 polyadenylation sites known within the genome of HSV-1. Oligonucleotide probe
sequences are located immediately adjacent to the polyadenylation sites because incor-
poration of the fluorescence tags into cDNA is not highly efficient, resulting in cDNA
lengths of only 3-400 nucleotides. Only a bit more than one half of the total viral tran-
scripts are terminated with a unique polyadenylation site and can therefore be uniquely
specified. The remaining HSV-1 genes belong to coterminal transcript families and the
signal obtained with the microarray can not distinguish between the different tran-
scripts. This weakens the utility of the HSV-1 microarray [158, 177].
The HSV-1 microarray was successfully used in different experimental settings and
revealed interesting new aspects of HSV-1 biology. For example it could be shown
that the efficient export of the majority of viral transcripts does require the RNA and
TAP/NXF1 binding activity of ICP27 [79] and that the viral transcriptional program is
not disturbed after inhibition of stress-activated kinase p38 [83].
1.1.4 HSV-1 latency
The host-virus interaction of HSV-1 is predominated by establishment and maintenance
of latency rather than occurrence of disease [142]. The virus invades the host in order
to stay and replicate from time to time without causing severe damage. Thereby, the
virus ensures efficient spread among individuals.
HSV-1 establishes latency in the nucleus of the sensory nerves innervating the skin
area of primary infection. The HSV-1 genome in latently infected neurons displays the
characteristics of endless or circular DNA. However, virus replication is not detected.
No viral function is absolutely required for the establishment of latency. The current
hypothesis assumes that latency is automatically established if the initial, sustained ex-
pression of α genes is missing. Expression of α genes is lacking in neuronal cells because
of several reasons, including absence of trans-activating host factors in the nucleus and
hormonally regulated repression of viral gene expression [142].
During maintenance of latency almost no viral gene expression is detectable. The
only transcripts which are abundantly expressed in latently infected neurons are the
latency-associated transcripts (LATs) [139, 176]. LATs presumably promote latent in-
fection by repression of lytic gene expression and protection of the latently infected
neurons from apoptosis [129, 152].
Reactivation of latent HSV-1 occurs after local or systemic stimuli. Injury or stimu-
lation of cells in the tissue innervated by the latently infected dorsal root neuron can
trigger reactivation. Systemic triggers are physical or emotional stress, hyperthermia,
exposure to UV light, and hormonal imbalance. No single viral gene is responsible for
HSV-1 reactivation. Rather, a joint action of several HSV-1 genes is necessary. After
injury of neurons, the cellular transcription factors oct-1, c-jun, and c-fos-1 rapidly in-
crease. They might play a role in triggering of reactivation, because the promoters of
the viral transactivator ICP0 and the viral repressor LAT contain binding sites for these
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factors. Presumably, the balance between ICP0 and LAT expression regulates reactiva-
tion [142].
Latency-associated transcripts
LATs are the only HSV-1 transcripts abundantly expressed during latency. The cod-
ing region for LATs is located in the inverted repeats of the long region of the HSV-1
genome. The primary transcript is 8.5 kb in length and polyadenylated. It is hardly
detectable in latently infected neurons. Splicing of the primary transcript yields a cir-
cularized 2 kb stable intron, which is not capped or polyadenylated and represents the
major LAT transcript during latency. The remaining 6.5 kb LAT molecule is unstable
and usually not detectable. The 2 kb stable LAT can be spliced further to yield a 1.5 kb
intron [139, 176].
LATs are also expressed during lytic infection. Transcripts of 1.6, 2, and 8.5 kb length
can be detected in lytically infected cells. In contrast to latently infected cells, all LATs
found in lytically infected cells are polyadenylated. The expression of lytic LATs might
be regulated by a different promoter and occurs late during HSV-1 infection [28, 32].
Although open reading frames have been identified within the LAT sequence, no
corresponding protein has been found up to now. It must be assumed that the functions
of LATs are executed by the RNA itself. Recent studies have identified small RNAs
[152] and microRNAs [170] in the LAT region, which influence viral gene expression
and apoptosis.
The expression of LATs significantly enhances the latency-reactivation cycle in small
animal models. Spontaneous reactivation in rabbits and induced reactivation in mice is
severely impaired, though not completely abrogated, after infection with LAT deletion
mutants of HSV-1 [129]. The function important for wild-type reactivation of HSV-1 is
located within the first 1.5 kb of the LAT coding sequence. This part of the sequence
includes the first 837 nucleotides of the stable intron detected in latently infected neu-
rons [130]. The most important function of LATs during the latency-reactivation cycle
appears to be inhibition of apoptosis. The antiapoptotic function of LATs is described
in detail in section 1.2.5.
1.1.5 Impact of HSV-1 infection on the host cell
The infection of cells with HSV-1 results in fundamental structural and biochemical
changes, designated as “cytopathic effect" (CPE), that ultimately lead to cell death.
These changes are caused by irreparable injury due to virus replication and by cellular
responses to infection [142].
Structural changes observed after HSV-1 infection are detachment and rounding up
of the cells, disaggregation of the nucleolus, distortion of the nucleus, formation of
intranuclear inclusion bodies, duplication and folding of intracellular membranes as
well as fragmentation and dispersal of Golgi stacks [142].
HSV-1 also fundamentally alters the metabolism of the host cell. Cellular processes
are shut off or redirected in order to serve the successful replication of the virus. Host
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protein synthesis is inhibited in a multiphase process. The first phase of this shut-
off is mediated by the HSV-1 virion host shutoff vhs protein, encoded by ORF UL41.
vhs causes disintegration of cellular polyribosomes and degradation of present host
mRNA [98, 126]. The second phase of shutoff requires the HSV-1 immediate early pro-
tein ICP27 and reduces the remaining amount of host protein synthesis by inhibition
of pre-mRNA splicing [56, 57]. In addition to inhibition of protein synthesis, selected
cellular proteins are degraded or destabilized and the function of many host proteins is
altered in order to perform virus specific tasks [142].
Finally, after virus replication is completed, infected cells die. Death of cells after
infection with wild-type HSV-1 is considered to be a form of necrosis [123, 142]. How-
ever, if synthesis of viral proteins is blocked after wild-type HSV-1 infection or if cells
are infected with a mutant of HSV-1 which is impaired in expression of post-α genes,
infected cells undergo apoptosis [7, 8, 92]. From these observations it was concluded
that the cell recognizes infection with HSV-1 and induces apoptosis in order to block
virus replication. However, viral proteins synthesized during infection with HSV-1 are
able to prevent the induced apoptosis from taking place, thereby keeping the cells alive
until the virus has completed its replication.
1.2 Apoptosis
In contrast to necrosis, which is a pathological uncontrolled form of cell death, apop-
tosis represents a tightly controlled physiological process. Necrosis is accompanied by
the leakage of cell components out of the cell, which is a strong inflammation inducing
signal. In contrast, the remnants of apoptotic cells are taken up by phagocytes without
inducing inflammation [100].
Apoptosis is characterized by specific morphological and biochemical changes in the
cell. The cells round up, loose cell-cell contacts, and shrink. Because cell junctions are
disintegrated, the plasma membrane becomes convoluted and forms the typical apop-
totic blebs. Finally the cell breaks up into membrane spheres of various sizes contain-
ing packaged cellular contents. These characteristic spheres are called apoptotic bod-
ies. During the process of apoptosis the asymmetry of the plasma membrane breaks
down and lipids which are normally only found on the inner side of the membrane
are exposed to the outer side. One of these lipids, phosphatidylserine, is recognized
by phagocytes which take up the apoptotic bodies. Furthermore, the nucleus is frag-
mented after chromatin condensation and aggregation. The nuclear fragments are also
packed into apoptotic bodies. The DNA is cleaved between nucleosomes by endonu-
cleases leading to DNA fragments, which are multiples of 180 bp in length [100].
Apoptosis is important for the maintenance of multicellular organisms. In order to
adjust the number of cells contained in a certain tissue, the surplus of cells must be
eliminated [100]. Apoptosis is also used as a defense mechanism. By sacrificing trans-
formed or infected cells the organism as a total is saved from death due to cancer or
excessive replication of a pathogen [124].
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1.2.1 Pathways of apoptosis induction and regulation
Apoptosis can be induced either via signals originating from outside the cell (extrinsic
pathway) or from inside the cell (intrinsic pathway). Basic apoptosis signaling events
are depicted in figure 1.2. Extrinsic signals are the so called death ligands, which induce
apoptosis by binding to the respective death receptors. Death ligands known up to
now are Fas ligand (Fas L or CD95L), tumor necrosis factor α (TNF-α), and TNF-related
apoptosis inducing ligand (TRAIL). The intrinsic pathway of induction of apoptosis can
be activated by a variety of stress events, for example oxidative stress, treatment with
cytotoxic drugs, or virus infection [151].
Regardless of the pathway of induction of apoptosis, the apoptosis inducing signal is
transduced within the cell via a cascade of cysteine aspartate proteases, called caspases.
The cytoplasmic part of a death receptor, such as Fas (CD95), contains a protein-protein
interaction domain called the death domain (DD). Upon activation of Fas the adapter
molecule FADD (Fas-associated death domain) is recruited to the death receptor via
the DD. The DD of FADD is located at the carboxyl terminus. At the amino terminus,
FADD contains a second protein-protein interaction motif, the death-effector domain
(DED). Procaspase-8 can bind to the DED of FADD, because it also contains two DED in
its amino terminus. The complex of Fas ligand, Fas, FADD, and procaspase-8 is called
death inducing signaling complex (DISC). Procaspases possess only limited catalytic
activity. However, when two procaspase molecules come into close proximity in the
DISC, they cleave each other to form the active homodimer. Activation of the intrinsic
pathway results in the release of cytochrome c from the mitochondria into the cytosol.
Cytochrom c triggers forming of the apoptosome, composed of each seven molecules of
cytochrome c, Apaf-1 (apoptosis protease-activating factor-1), (d)ATP, and procaspase-
9. This results in formation of active caspase-9 [151].
The above mentioned caspases 8 and 9 represent initiator caspases. Though activated
through different pathways, they all have the same substrate, procaspase-3. Cleavage
of procaspase-3 by one of the initiator caspases results in active caspase-3, which is
the executioner caspase. Caspase-3 cleaves molecules like ICAD (inhibitor caspase-
activated desoxyribonuclease), which leads to activation of CAD (caspase-activated
desoxyribonuclease). This mediates the morphological and biochemical changes as-
sociated with apoptosis, for example fragmentation of DNA [151].
Induction of apoptosis must be tightly regulated in order to avoid excessive cell
death. At several checkpoints in the apoptosis signaling network, antiapoptotic pro-
teins counter-regulate proapoptotic signals. For example, inhibitor of apoptosis pro-
teins (IAPs) can directly bind and inactivate caspases and thereby block apoptosis [20].
Induction of apoptosis via the intrinsic pathway is regulated by the complex interaction
of proapoptotic (Bax, Bak, Bad, tBid) and antiapoptotic (Bcl-2, Bcl-xL) members of the
B-cell lymphoma-2 (Bcl-2) family of proteins [1]. FLICE (Fas-associated death domain-
like interleukin-1-β-converting enzyme) inhibitory protein (FLIP) is a caspase homolog
and can therefore bind to the DISC and interfere with binding and activation of initiator
caspases. FLIP is therefore able to block the extrinsic pathway of apoptosis induction
[66, 96, 148, 169].
9
1 Introduction
Figure 1.2: Intrinsic and extrinsic pathways of apoptosis induction. The extrinsic pathway is in-
duced by binding of death ligands such as Fas ligand (Fas L) to death receptors, for ex-
ample Fas (CD95). Adapter molecules, in this case FADD (Fas-associated death domain),
and procaspase-8 are then recruited via death domains to the cytoplasmic part of the re-
ceptor. Aggregated procaspase-8 molecules can cleave each other to form active caspase-8
(FLICE). In the intrinsic pathway of apoptosis induction, cytochrom c (Cyt-c) is released from
permeabilized mitochondria. Cyt-c, Apaf-1 (apoptosis protease-activating factor-1), (d)ATP,
and procaspase-9 form the apoptosome, which enables activation of caspase-9. The initiator
caspases 8 and 9 then cleave and activate procaspase-3. Cleavage of caspase-3 substrates
ultimately leads to apoptosis. Activation of caspase-8 can be blocked by FLIPs (c-FLIP, cel-
lular FLICE inhibitory protein; v-FLIP, viral FLICE inhibitory protein). Permeabiliziation of
mitochondria is regulated by interaction of proapoptotic (Bax, Bak) and antiapoptotic (Bcl-2,
Bcl-xL) members of the B-cell lymphoma-2 (Bcl-2) family of proteins. Taken from reference
[151], modified.
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There are connections between the intrinsic and the extrinsic pathway of apoptosis
induction. For example, a signal induced by the extrinsic pathway can be amplified
through cleavage of the Bcl-2 family member Bid to proapoptotic tBid by caspase-8,
which leads to release of cytochrome c from mitochondria [151]. Furthermore, factors
released from the mitochondria can modulate the extrinsic pathway, as is the case for
Smac/Diablo, which inhibits IAPs and thereby enhances caspase activity.
1.2.2 FLIP
FLIP is a homolog of procaspase-8. The first FLIP molecules found were encoded by
viruses and therefore called v-FLIP [165]. In human cells, several splice variants of c-
FLIP (cellular FLIP) mRNA have been described, but in most cells only two proteins
are expressed: c-FLIPL and c-FLIPS. The long isoform c-FLIPL has a domain structure
similar to procaspase-8, two DED’s in the amino terminus and a caspase like domain in
the carboxyl terminus. However, c-FLIPL is catalytically inactive, because it lacks the
conserved cysteine residue of caspases [66]. However, c-FLIPL can itself be cleaved by
caspases at Asp376 to yield c-FLIP(p43) and c-FLIP(p12) [148]. c-FLIPS consists only
of the two death effector domains followed by a short unique carboxyl terminus [66].
c-FLIPR, a third isoform with a structure similar to c-FLIPS, is only found in some cell
types of haematopoetic origin [48].
Because of the DEDs, c-FLIP molecules can be incorporated into the DISC (figure 1.3).
In the absence of c-FLIP, procaspase-8 aggregates in the DISC and is cleaved and acti-
vated. If a sufficient amount of c-FLIP is present in the cell, it can successfully compete
with recruitment of procaspase-8 to the DISC. Thereby it can prevent aggregation and
activation of procaspase-8 and apoptosis is blocked [66, 96, 148, 169]. Mathematical
modeling revealed that the amount of c-FLIP can function as a switch in the decision
whether apoptosis takes place or not after stimulation of death receptors [19, 55].
For c-FLIPS and c-FLIPR the prevention of activation of procaspase-8 by binding to
the DISC is the only mode of action and therefore these two isoforms are exclusively
antiapoptotic. c-FLIPL has more diverse functions. First it has been shown that c-FLIPL
can even promote apoptosis when expressed in low amounts, possibly because the c-
FLIPL/caspase-8 heterodimer is also an active protease with comparable activity and
specificity as the caspase-8 homodimer. When present in higher amounts, it has been
shown that c-FLIPL can not only efficiently block apoptosis, but its cleavage products
can activate the NFκB (Nuclear factor kappa-light-chain-enhancer of activated B cells),
ERK (extracellular signal-regulated kinase), and Wnt (wingless type) signaling path-
ways. Thereby, c-FLIPL can divert Fas-mediated death signals into signals that lead to
proliferation or differentiation of the cell [85].
Transcription of c-FLIP is induced after activation of ERK, PI3K(phosphatidylinositol
3-kinase)-Akt, NFκB [93, 111], NFAT (Nuclear factor of activated T cells), and p53 sig-
naling pathways. In contrast, signaling via c-Myc (myelocytomatosis oncogene cellular
homolog) represses c-FLIP mRNA expression. Also signaling through STAT (Signal
transducers and activators of transcription) members was shown to regulate c-FLIP ex-
pression, either negatively (STAT5) or positively (STAT3) [84].
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Figure 1.3: Binding of c-FLIP to the DISC and prevention of procaspase-8 cleavage. Upon
binding of Fas ligand (Fas L) to its receptor (Fas, CD95) several molecules, includ-
ing FADD (Fas-associated death domain), procaspase-8, c-FLIPL, and c-FLIPS are
recruited to the cytoplasmatic tail of Fas and form the death inducing signaling
complex (DISC). If no or little FLIP is present (right part of the figure, on gray back-
ground), procaspase-8 can aggregate and cleave itself to form the active caspase-8
homodimer which promotes apoptosis. Presence of high amounts of the catalyt-
ically inactive caspase homologs c-FLIPS or c-FLIPL (left part of the figure) block
procaspase-8 aggregation and cleavage and apoptosis is prevented. However, c-
FLIPL can be cleaved by procaspase-8 to yield c-FLIP(p43) and c-FLIP(p12). These
c-FLIPL cleavage products promote cell survival. The catalytically active site within
procaspase-8 is indicated with “C". In c-FLIPL, this site is mutated and catalytically
inactive, indicated by “X". Taken from reference [96], modified.
The amount of c-FLIP in the cell is determined not only by the number of mRNAs
expressed, but also by posttranslational regulation of protein stability. c-FLIP isoforms
are short-lived proteins, which are ubiquitinylated and degraded by the proteasome
[41, 89, 128]. The unique carboxyl terminus of c-FLIPS contains a destabilizing sequence
which enhances its ubiquitinylation and proteasomal degradation. Therefore, c-FLIPS
has a shorter half-life compared to c-FLIPL [135].
Furthermore, c-FLIP can be phosphorylated by different kinases, such as protein ki-
nase C (PKC) [64, 86], p38α [168], and Calcium/Calmodulin-dependent protein kinase
II [184]. The phosphorylation status of c-FLIP not only regulates its stability, but also
its recruitment to the DISC.
Several soluble factors and small molecules directly or indirectly modulate the c-
FLIP amount, for example bacterial lipopolysaccharide (LPS), CD40L, reactive oxygen
species (ROS), cycloheximide, and proteasome inhibitors (MG132) [84, 90, 101].
Ishioka et al. observed that c-FLIPL forms aggregates when overexpressed in cells
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[67]. These aggregates block the ubiquitine-proteasome system and are therefore re-
sistant to proteasomal turnover. Ishioka et al. generated mutants of c-FLIPL and an-
alyzed their distribution in transfected cells and their ability to block the ubiquitine-
proteasome system (figure 1.4).
Wild type c-FLIPL and the mutant c-FLIPL D376A form dense aggregates in the per-
inuclear region and block the ubiquitine-proteasome system. The mutant with a trun-
cated C-terminus (c-FLIPL 1-438) still blocks the ubiquitine-proteasome system and
forms aggregates, however these aggregates are more evenly distributed within the
cell. c-FLIPL 1-202 also aggregates, but in a more filamentous pattern and is not able to
block the ubiquitine-proteasome system. Only the two mutants with removed or mu-
tated DEDs (c-FLIPL 203-480 and c-FLIPL F23G/F114G) display a homogeneous dis-
tribution in the transfected cells and are not able to block the ubiquitine-proteasome
system. Taken together, DEDs cause aggregation of overexpressed c-FLIPL. Aggre-
gated c-FLIPL is resistant to proteasomal turnover. If DEDs are mutated, overexpressed
c-FLIPL does not aggregate and is susceptible to turnover by the proteasome.
1.2.3 Detection of apoptosis
A variety of methods has been established to determine whether cells undergo apopto-
sis (reviewed in reference [151]). It is possible to detect the activation of the apoptosis
signaling pathways as well as the resulting biochemical and morphological changes.
The activation of caspases can be shown using fluorigenic substrates. Cleavage of
procaspases and of specific substrates of caspase-3 (for example the DNA repair en-
zyme poly(ADP-ribose)polymerase, PARP) can be assessed by immunoblot analysis.
Permeabilization of the outer mitochondrial membrane is indicated by a shift in the
emission spectra of the fluoresce substance JC-1, which accumulates in mitochondria
after addition to cells.
The characteristic cleavage of DNA can be visualized after isolation of DNA from
cells and subsequent separation in agarose gels, thereby revealing the “laddering" of
the DNA in apoptotic cells. Double strand breaks resulting from DNA cleavage can
be marked with FITC-conjugated dUTP using terminal desoxynucleotidyl transferase
(terminal desoxynucleotidyl transferase nick end-labeling, TUNEL). The condensation
of chromatin and the fragmentation of the nucleus in apoptotic cells can be proved by
staining with DAPI and subsequent microscopic examination.
Loss of membrane assymetry during apoptosis is accompanied with exposure of
phosphatidylserine to the outer side of the cell. FITC labeled AnnexinV binds specif-
ically to phosphatidylserine and thereby apoptotic cells can be detected by flow cy-
tometry. This method allows detection of apoptosis of single cells at early times after
induction of apoptosis, because exposure of phosphatidylserine occurs very soon after
activation of caspases [155]. But, if the plasma membrane is disintegrated, AnnexinV
can reach the inner side of the cell and bind to phosphatidylserine on the inner side of
the plasma membrane. Therefore, cells with permeabilized plasma membrane (necrotic
cells or cells at the late stage of apoptosis) must be excluded by staining with propidium
iodide.
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Figure 1.4: Aggregation of mutated c-FLIPL overexpressed in cells [67]. On the left side, wild type and
mutated forms of c-FLIPL are schematically depicted. c-FLIPL consists of two death effector
domains (DED) at the N-terminus and a caspase-like domain at the C-terminus, composed
of the p20 and p12 subdomains. c-FLIPS is lacking the caspase-like domain and has a unique
C-terminus. c-FLIPL can be cleaved by caspase-8 at Asp376 into two parts (p43 and p12).
c-FLIPL can homodimerize or heterodimerize with caspase-8. This dimerization is mediated
by the DED’s. Mutation of Phe23 and Phe114 abrogates the ability of c-FLIPL to form dimers.
On the right side, microscopic examination of transfected HT-1080 cells shows the cellular
localization of c-FLIPL mutants after immunostaining with anti-myc antibody as published
by Ishioka et al. By accident, c-FLIPL F23G/F114G was assigned c-FLIPL F25G/F114G in
the publication by Ishioka et al. Wild type c-FLIPL and the mutants c-FLIPL D376A and
c-FLIPL 1-438 form dense aggregates in the perinuclear region and block the ubiquitine-
proteasome system. c-FLIPL 1-202 aggregates in a more filamentous pattern and is not able
to block the ubiquitine-proteasome system. Only the two mutants with removed or mutated
DEDs (c-FLIPL 203-480 and c-FLIPL F23G/F114G) display a homogeneous distribution in the
transfected cells and are not able to block the ubiquitine-proteasome system. The different
expression plasmids encoding mutated c-FLIPL molecules were generated by Ishioka et al.
The plasmid encoding c-FLIPS was provided by Krueger et al. [96] and is shown in the lower
right part of the figure. All c-FLIP molecules are tagged on their N-terminus with the myc-
sequence. The epitope of the anti-FLIP antibody (clone NF6) used in immunoblot analysis is
indicated.
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1.2.4 Modulation of apoptosis by viruses
Apoptosis is an important response of cells to infection by viruses, because sacrifice of
some infected cells can save the organism. However, viruses have evolved numerous
strategies to counteract apoptosis of the host cell in order to ensure successful replica-
tion or maintenance of latency.
The counteracting strategies of viruses target different parts of the apoptosis signal-
ing pathway. The receptors for Fas ligand and TRAIL are cleared from the surface and
subsequently degraded by the receptor internalization and degradation complex (RID
or E3-10.4/14.5 K) of adenovirus [105]. Downstream signaling of death receptors is
blocked by viral homologs of FLIP (v-FLIP) encoded for example by Kaposi’s sarcoma-
associated herpesvirus (KSHV) and the poxvirus Molluscum contagiosum [165]. Vi-
ral Bcl-2 homologs, for example BHRF1 of Epstein-Barr virus (EBV) [63] and E1B 19K
of adenovirus [29], block apoptosis signaling via the intrinsic pathway. Murine cy-
tomegalovirus m38.5 protein, which localizes to mitochondria, is another viral inhibitor
of intrinsically induced apoptosis [82]. Also caspases can directly or indirectly be in-
hibited by viral proteins, as it is the case for CrmA of Cowpox virus [190] and IAP of
baculovirus [20]. The proapoptotic function of p53 is targeted by many viruses, for ex-
ample by the E6 protein of Human papillomavirus, the SV40 large T antigen and EBV
BZLF1 [124].
However, some viruses also actively induce apoptosis and caspase activation [124].
For example, induction of apoptosis is essential for release of influenza virus progeny
[183]. In the case of Aleutian mink disease parvovirus (ADV), cleavage of the essential
major nonstructural protein NS1 by effector caspases is essential for its localization to
sites of replication. Therefore, blockage of apoptosis or caspase activation results in
decreased replication of ADV [20].
1.2.5 Modulation of apoptosis by HSV-1
Apoptosis is induced soon after HSV-1 infection. Expression of mRNA of one immedi-
ate early HSV-1 gene, α0, is the crucial proapoptotic event for induction of apoptosis by
HSV-1 [25, 145, 147]. This is supported by the fact, that de novo protein synthesis is not
required for HSV-1 induced apoptosis.
However, wild type HSV-1 infection does not result in apoptosis of epithelial cells,
which represent the main host cells for productive replication of HSV-1. This is because
during 3 h and 6 h post infection effective antiapoptotic events occur (Figure 1.5A) [123].
This time period is called “apoptosis prevention window" and is characterized by ex-
pression of viral proteins, which efficiently block apoptosis [8, 92]. Dependent on the
cell type, infection with HSV-1 also confers resistance against apoptosis induced by
many agents, including sorbitol, staurosporine, and Fas ligand [8, 43]. Protection of the
host cell against apoptosis ensures efficient replication of HSV-1. However, HSV-1 repli-
cation finally results in destruction and death of the infected cells. This is considered to
be a kind of necrotic cell death due to exhaustion of the cell.
Up to now, several antiapoptotic HSV-1 genes have been identified. Three of them
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Figure 1.5: Modulation of apoptosis by HSV-1 in different cell types. HSV-1 induces apop-
tosis early after infection. However, in most cell types, like epithelial cells (A) and
neurons (B), execution of apoptosis is blocked by antiapoptotic viral factors [123].
Consequently, these cells survive and ensure successful virus replication or main-
tenance of latency. In lytically infected epithelial cells, antiapoptotic proteins are
expressed during an apoptosis prevention window between 3 and 6 h after infec-
tion. In contrast, HSV-1 infected immature dendritic cells (iDCs) undergo apoptosis
and virus replication is low (C) [23, 115, 133]. Although downregulation of the cel-
lular antiapoptotic molecule c-FLIP was observed in HSV-1 infected iDCs, it is not
known, whether this contributes to apoptosis. The question arises, why the strong
antiapoptotic factors of HSV-1 fail to block apoptosis in iDCs.
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encode immediate early proteins: ICP4, ICP22, and ICP27. Increased apoptosis is ob-
served in cells infected with HSV-1 mutants lacking one of these proteins [7, 8, 102]. The
involvement of ICP4, ICP22, and ICP27 in prevention of apoptosis is likely indirect, be-
cause they are essential for proper expression of early and late genes [142], including
antiapoptotic genes.
US3 codes for a late expressed viral protein kinase with antiapoptotic activity [72, 103].
It has been shown by Benetti and Roizman [17] that US3 promotes cell survival by
acting like cellular protein kinase A. Furthermore, US3 posttranslationally modifies the
proapoptotic Bcl-2 protein family member Bad and thereby blocks its activation [26,
119, 118]. Besides that, US3 phosphorylates procaspase-3 and prevents its proteolytic
cleavage [18].
US5 encodes the viral glycoprotein gJ, which is expressed late during infection [142].
Many studies demonstrated its involvement in prevention of HSV-1 induced apoptosis
and it was shown that it has a protective effect against apoptosis induced by the effector
molecules of cytotoxic T-cells, granzyme B and perforin, when expressed alone [72, 73,
188]. gJ induces formation of reactive oxygen species (ROS) [10], however it is not clear
whether this contributes to prevention of apoptosis.
US6 encodes the late expressed viral glycoprotein gD. gD possesses antiapoptotic
activity, which is separated from its involvement in receptor binding and membrane
fusion of the virus particle [188, 187, 189]. The mechanism of apoptosis inhibition by
gD remains elusive.
US11 encodes a dsRNA binding protein of HSV-1 [6], which is expressed late during
infection. Many studies have demonstrated its role in the viral response against host
cell defense. Amongst others, US11 interferes with the cellular interferon-inducible an-
tiviral response by efficiently inhibiting activation of protein kinase R (PKR) [27, 87].
The diverse effects of PKR activation include activation of the FADD/caspase-8 apop-
tosis inducing pathway [11]. Furthermore, US11 has a direct antiapoptotic function at
the level of mitochondrial apoptosis signaling pathways or upstream [70].
LATs also possess antiapoptotic activity [2, 24, 65, 74, 131]. LATs can block apoptosis
induced by the extrinsic pathway as well as by the intrinsic pathway [62]. Expression of
LATs promotes survival of neurons in infected rabbits and mice [2, 24, 131] and reduces
apoptosis during lytic infection of tissue culture cells [2, 75]. Furthermore, LAT alone
protects from apoptosis when ectopically overexpressed [2, 65, 74, 131]. Protection of
latently infected neurons against apoptosis might be the main function of LATs in the
latency-reactivation cycle of HSV-1 (figure Figure 1.5B). This is indicated by the fact that
overexpression of other antiapoptotic factors like c-FLIP [77], baculovirus IAP [76] and
bovine herpesvirus LAT homolog [117] can rescue the wild-type reactivation pheno-
type of LAT deletion mutants of HSV-1. Furthermore, both the antiapoptotic function
and the reactivation promoting function of LAT reside within the first 1.5 kb of the LAT
sequence [2, 24, 65, 74, 130, 131].
In contrast to epithelial cells and neurons, HSV-1 infection results in apoptosis in
some cell types of the immune system, such as activated T-cells and immature dendritic
cells (Figure 1.5C) [23, 115, 133, 137]. This might be one strategy of immune evasion of
HSV-1. Efficiency of HSV-1 replication in these cell types is low. The processes, which
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lead to apoptosis instead of protection against apoptosis in these cell types after HSV-1
infection, are not yet unraveled. Infection and impairment of dendritic cells by HSV-1
is discussed in detail in section 1.3.3.
1.3 HSV-1 and the immune system
Skin and mucosal HSV lesions are more severe and more frequent in individuals with
impaired immune response [91, 149]. This indicates that the strength of the host im-
mune response largely determines the outcome of HSV-1 infection.
1.3.1 The immune response to HSV-1
Components of the innate immune system represent the first line of defense against
pathogens. Natural killer (NK) cells [127], natural killer T (NKT) cells [52], and comple-
ment [175] are innate immune factors, which are involved in the control of HSV infec-
tions. However, protective immunity against symptomatic HSV infection is dependent
on a strong adaptive immune response [91, 113, 171].
The adaptive immune response is based on presentation of processed antigens, such
as fragments of viral proteins, on major histocompatibility complex (MHC) molecules
on the surface of cells. T cells specifically recognize these antigen-MHC structures and,
depending on the type of T cell, either directly kill the antigen presenting cell (cytotoxic
T cell) or activate B cells to produce antigen specific antibodies (helper T cell). How-
ever, T cells are not able to execute these effector functions until they are activated by
dendritic cells (DCs) [69].
1.3.2 Dendritic cells
DCs have received their name based on their tree-like or dendritic shape [157]. Den-
dritic cells are found at all body surfaces, including the skin, pharynx, and vagina, as
well as internal or mucosal surfaces, such as the respiratory tract and the gastrointesti-
nal system. Consequently, DCs are positioned at the sites where the organism gets in
contact with invading pathogens for the first time [12, 13].
There exist several different types of DCs. Each type is characterized by a unique set
of markers and functions. The majority of tissue resident DCs, like the Langerhans cells
of the skin, are of myeloid origin. Type I interferon producing plasmacytoid dendritic
cells and some types of DCs in secondary lymphoid organs are of lypmhoid origin
[182]. In the laboratory, DCs are differentiated from monocytes of the blood by addition
of GM-CSF and IL-4 [144]. In the absence of inflammation, this type of myeloid DC
corresponds to mucosal DCs, but not to DCs in lymphoid tissues [173].
DCs differentiate through two major stages. DCs in peripheral tissues represent the
immature stage. Immature dendritic cells (iDCs) are characterized by a high phagocytic
but low migratory and T cell activating capacity. Consequently, they express the phago-
cytosis receptor DEC 205 but only little antigen presenting MHC molecules and co-
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stimulatory molecules on their surface [35]. Maturation of DCs is induced by pathogen-
associated molecular patterns (PAMPs), for example bacterial lipopolysaccharide (LPS),
double stranded RNA, and viral envelope proteins or by pro-inflammatory cytokines
like IL-1 and TNF-alpha. PAMPs are recognized through pathogen recognition recep-
tors (PRRs), for example Toll-like receptors (TLRs) and retinoic-acid-inducible gene I
(RIG-I) [108].
Maturation inducing signals lead to activation of NFκB which induces expression of
many genes, resulting in numerous changes in DC phenotype, surface molecule ex-
pression, and function [94, 122]. Maturing DCs migrate to the draining lymph nodes.
Phagocytic activity is shut down and antigen processing is increased. MHC molecules,
co-stimulatory molecules (such as CD80, CD86) and adhesion molecules are upregu-
lated. This phenotype renders mature DCs (mDCs) potent T cell activators, because T
cells only become activated if they receive appropriate co-stimulatory signals in addi-
tion to the presented antigen [35].
In the absence of infection or inflammation, DCs take up and process tissue anti-
gens or harmless environmental antigens and induce tolerance of the immune system
to these antigens [59, 107, 136]. This is important to avoid autoimmune disease and
allergy.
Survival and death of DCs must be tightly regulated to ensure an orderly course
of the adaptive immune response. Decreased apoptosis of DCs, for example as a re-
sult of caspase mutations or chronic stimulation of the antiapoptotic effector molecule
CD40, can result in excessive activation of the immune system. This can lead to autoim-
munity, chronic inflammation, and lymphoproliferative disease [110, 178]. In contrast,
inflammatory diseases can be treated with immunomodulatory drugs, which induce
premature death of DCs [180].
Regulation of DC survival is mediated by contact with other cells of the immune
system. Activated T cells express ligands (such as CD40L and RANKL) for antiapop-
totic receptors on DCs, CD40 and RANK (receptor activator of nuclear factor-κB), and
are therefore able to give a survival signal to DCs [81, 181]. However, in some cases
activated T cells can also induce death of DCs [40]. DCs express CD95 (Fas), a classi-
cal apoptosis inducing receptor. However, engagement of CD95 can trigger activation
rather than death in DCs [53, 54, 141]. This is probably enabled by the high amount of
c-FLIP expressed in DCs, which blocks the proapoptotic signaling of death receptors in
favor of survival pathways [58, 104, 179]. Receptor induced survival of DCs is mainly
mediated by activation of transcription factor NF-κB, while death signaling occurs via
JNK/AP-1 activation. The balance between NF-κB and JNK/AP-1 activation appears
to decide whether DCs live or die, regardless of the receptor, which triggers these path-
ways [94].
Many viruses infect DCs, including HSV-1, measles virus, vaccinia virus, human im-
munodeficiency virus [132], and pathogenic hantaviruses [138]. Viruses can interfere
with many aspects of DC biology, like migration, antigen processing, maturation, T cell
activation, and viability [132]. It can be assumed that viruses thereby shape the immune
response to serve their needs.
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1.3.3 HSV-1 infection of dendritic cells
HSV-1 can productively infect iDCs but only low titers are achieved [114, 133]. In con-
trast, infection mDCs is abortive [97]. Infection with HSV-1 induces profound changes
in the phenotype of iDCs, as illustrated in figure 1.6. HSV-1 infection results in round-
ing up of iDCs and in a loss of their ability to form the characteristic dendrites [134, 133].
After HSV-1 infection of iDCs, MHC class II antigen presenting surface molecules as
well as the co-stimulatory molecule CD86 are moderately upregulated, which indicates
a partial maturation [133, 143]. In contrast, MHC class I molecules are downregulated
[143], due to the action of HSV-1 ICP47 protein, which blocks loading of antigens to
MHC class I and thereby its transport to the cell surface [185].
Though HSV-1 infection induces a partial maturation of iDCs, maturation in response
to LPS is inhibited [133, 143]. The upregulation of co-stimulatory molecules fails, cy-
tokines are not produced, and responsiveness to chemokines is not acquired [143]. As
a consequence of the inability of HSV-1 infected iDCs to mature, they also display a
strong impairment in the induction of primary and secondary T cell responses [133].
Taken together, HSV-1 is able to efficiently interfere with the function of DCs.
Finally, HSV-1 infected iDCs undergo premature apoptosis and die [23, 115, 133].
HSV-1 induced apoptosis in iDCs involves early and late viral proteins [23] and is asso-
ciated with activation of caspases, downregulation of the antiapoptotic cellular protein
c-FLIP, and upregulation of p53 [23, 115]. Furthermore, expression of TNF-α and TRAIL
is enhanced after HSV-1 infection of iDCs [115]. However, inhibition of death ligand
binding to their receptors could only partially reduce apoptosis observed in HSV-1 in-
fected iDCs [115]. These studies show that HSV-1 can not only impair the function of
DCs, but can also eliminate this cell type, which is critically important for induction of
an antiviral immune response.
Though iDCs at the site of infection are damaged, a protective immune response
against HSV-1 is mounted and the infection is resolved. This is mediated by uninfected
bystander DCs, mainly dermal or submucosal DCs. These uninfected iDCs take up de-
bris of dead infected cells and present the viral antigens to effector cells in the draining
lymph nodes, thereby activating HSV-1 specific effector T cells [23]. The impairment
of local DCs probably delays the immune response to HSV-1. This delay might enable
the virus to gain access to the local sensory nerve endings, infect them and establish
latency.
1.4 Objective of this work
HSV-1 caused disease is a relevant socio-economic factor [142]. On the opposite, HSV-1
as been explored as a vehicle for gene therapy which could in the future cure many
diseases [88, 99, 172]. Therefore, the detailed investigation of HSV biology is of high
relevance. The objective of this thesis is to contribute new insights about the interaction
of HSV-1 with the immune system, in particular about the mechanisms of impairment
of iDCs by HSV-1.
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Figure 1.6: Phenotype of immature and mature DCs and changes induced by HSV-1, accord-
ing to references [23, 35, 115, 134, 133, 143].
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Several studies have revealed important facts about HSV-1 induced apoptosis of iDCs
[23, 115, 133], but the underlying mechanisms are not yet resolved.
Müller et al. [115] observed changes in cellular factors, which might be involved in
apoptosis induction after HSV-1 infection of iDCs. They showed that HSV-1 infection
leads to downregulation of the antiapoptotic cellular protein c-FLIP, but did not dis-
sect the processes, which lead to this downregulation. Therefore, in the first part of
this thesis the impact and mechanism of HSV-1 induced c-FLIP downregulation was
investigated.
Because HSV-1 possesses several genes, which can efficiently block apoptosis in the
host cell [123], it is conceivable that insufficient expression of these genes would con-
tribute to induction of apoptosis after infection of iDCs. Up to now, no studies concern-
ing this hypothesis are published. In the second part of this thesis a microarray analysis
was undertaken to find out whether viral antiapoptotic genes are properly expressed
in HSV-1 infected iDCs.
The data presented in this thesis indicate that HSV-1 expresses or induces factors,
which degrade c-FLIP independent from the proteasome. The importance of c-FLIP
for survival of iDCs was demonstrated. Furthermore, it was shown for the first time
that poor expression of a viral antiapoptotic gene, LAT, is also involved in apoptosis
induction in iDCs after HSV-1 infection.
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2.1 Chemicals
Name Company
Acetic acid Roth (Karslruhe, Germany)
APS Roth (Karslruhe, Germany)
Bromophenolblue Roth (Karslruhe, Germany)
BSA Roth (Karslruhe, Germany)
CaCl2 Roth (Karslruhe, Germany)
Chloroform Roth (Karslruhe, Germany)
Complete Protease Inhibitor Cocktail Roche (Mannheim, Germany)
Coomassie Brilliant Blue Serva (Heidelberg, Germany)
DNase Roche (Mannheim, Germany)
EDTA AppliChem (Darmstadt, Germany)
Ethanol Roth (Karslruhe, Germany)
Formaldehyde Merck (Darmstadt, Germany)
Glycin Roth (Karslruhe, Germany)
Glycerol Roth (Karslruhe, Germany)
Goat serum Dako (Hamburg, Germany)
HEPES Roth (Karslruhe, Germany)
Isopropanol Roth (Karslruhe, Germany)
KCl Roth (Karslruhe, Germany)
KH2PO4 Roth (Karslruhe, Germany)
β-mercaptoethanol Merck (Darmstadt, Germany)
Methanol Roth (Karslruhe, Germany)
Molecular weight marker Fermentas (St. Leon-Rot,Germany)
Mounting medium Dako (Hamburg, Germany)
NaCl Roth (Karslruhe, Germany)
Na2HPO4 Roth (Karslruhe, Germany)
NP 40 Merck (Darmstadt, Germany)
PFA Roth (Karslruhe, Germany)
Phenol Roth (Karslruhe, Germany)
Rotiphorese-acrylamid Roth (Karslruhe, Germany)
SDS Merck (Darmstadt, Germany)
Sodium azide Roth (Karslruhe, Germany)
Sucofin skim milk powder TSI (Zeven, Germany)
TRI REAGENT Sigma-Aldrich (Deisendorf, Germany)
TEMED Roth (Karslruhe, Germany)
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Name Company
Tris-aminomethan Roth (Karslruhe, Germany)
Tris-HCl Roth (Karslruhe, Germany)
Triton X-100 Merck (Darmstadt, Germany)
Tween-20 Roth (Karslruhe, Germany)
2.2 Buffers and Solutions
Name Ingredients
AnnexinV-buffer 10 mM HEPES, pH 7.4
0.14 M NaCl
5 mM CaCl2
5 % FCS
0.02 % sodium azide
Coomassie stain Destain solution with 2.5 % Coomassie
Brilliant Blue
Destain solution 7 % acetic acid
10 % methanol
Ad dd H20
Electrophoresis buffer 0.06 M Tris-aminomethan
0.2 M glycin
0.1 % SDS
pH 8.4
FACS-block PBS with
10 % FCS
0.02 % sodium azide
FACS-wash PBS with
1 % FCS
0.02 % sodium azide
Fixation solution PBS with
0.37 % formaldehyde
IB-wash 150 mM NaCl
100 mM Tris-HCl
pH 8.0
IF-block PBS with
3 % goat serum
1 % triton X-100
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Name Ingredients
Loading buffer 0.5 M Tris-HCl
10 % SDS
10 % glycerol
0.05 % bromophenolblue
5 % β-mercaptoethanol
Lysis buffer 50 mM Tris-HCl
10 mM EDTA
80 mM KCl
1 % NP 40
pH 7.5
plus one tablet Complete Protease
Inhibitor Cocktail
PBS 150 mM NaCl
6.5 mM Na2HPO4
3.5 mM KCl
2 mM KH2PO4
Resolving gel buffer 0.9 M Tris-aminomethan
0.4 % SDS
pH 8.8
Stacking gel buffer 0.3 M Tris-aminomethan
0.4 % SDS
pH 6.8
Transfer buffer 0.8 M Tris-aminomethan
0.4 M glycin
20 % methanol
pH 8.0
Triton lysis buffer 50 mM HEPES
5 mM EDTA
150 mM NaCl
1 % triton X-100
pH 7.5
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2.3 Cell Culture Equipment
Name Company
CaCl2 Tebu-bio (Offenbach, Germany)
DMEM PAA (Marburg, Germany)
DMSO Roth (Karslruhe, Germany)
ECGF PAA (Marburg, Germany)
EDGS Tebu-bio (Offenbach, Germany)
EpiLife Tebu-bio (Offenbach, Germany)
Fetal calf serum (FCS) HyClone Perbio (Bonn, Germany)
Heparin PAA (Marburg, Germany)
HEPES PAA (Marburg, Germany)
L-glutamine PAA (Marburg, Germany)
LPS Sigma-Aldrich (Hamburg, Germany)
MCDB 131 PAA (Marburg, Germany)
MG132 Sigma-Aldrich (Deisendorf, Germany)
Penicillin PAA (Marburg, Germany)
Recombinant hu GM-CSF Immunotools (Friesoythe, Germany)
Recombinant hu IL-4 Immunotools (Friesoythe, Germany)
PBS PAA (Marburg, Germany)
Plastic ware, sterile TPP (Trasadingen, Switzerland)
Nunc (Wiesbaden, Germany)
Greiner (Frickenhausen, Germany)
RPMI 1640 PAA (Marburg, Germany)
Streptomycin PAA (Marburg, Germany)
Trypsin/EDTA GIBCO R© Invitrogen (Karlsruhe, Germany)
2.4 Cell Culture Media
Name Ingredients
F-medium DMEM (500 ml)
10 % heat-inactivated FCS
4 mM L-glutamine
100 U/ml penicillin
100 µg/ml streptomycin
PB-medium RPMI 1640 (500 ml)
10 % heat-inactivated FCS
10 mM HEPES
4 mM L-glutamine
100 U/ml penicillin
100 µg/ml streptomycin
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Name Ingredients
DC-medium RPMI 1640 (500 ml)
10 % heat-inactivated FCS
10 mM HEPES
4 mM L-glutamine
100 U/ml penicillin
100 µg/ml streptomycin
200 U/ml recombinant hu IL-4
500 U/ml recombinant hu GM-CSF
HUVEC-medium MCDB 131 (500 ml)
10 % heat-inactivated FCS
10 mM HEPES
4 mM L-glutamine
100 U/ml penicillin
100 µg/ml streptomycin
50 mg/ml heparin
10 mg/ml ECGF
Ker-medium EpiLife (500 ml)
0.06 mM CaCl2
100 U/ml penicillin
100 µg/ml streptomycin
1 x EDGS
2.5 Kits
Name Company
BCA Protein Assay Kit Pierce (Rockford, USA)
CD14 MicroBeads Miltenyi Biotech
(Bergisch-Gladbach, Germany)
Complete Protease Inhibitor
Cocktail Tablets
Roche (Mannheim, Germany)
Human Monocyte NucleofectorTM Kit Amaxa (Cologne, Germany)
MACS columns, Large cell, LD and MS Miltenyi Biotech
(Bergisch-Gladbach, Germany)
Monocyte Isolation Kit II Miltenyi Biotech
(Bergisch-Gladbach, Germany)
MagNA Pure LC mRNA Isolation Kit-I,
Lysis Buffer Refill
Roche (Mannheim, Germany)
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Name Company
Plasmid Purification Kit, Midi Qiagen (Hilden, Germany)
Super Signal West Dura
Extended Duration Substrate
Perbio (Bonn, Germany)
Venor GEM-Mycoplasma Detection Kit Minerva biolabs (Berlin, Germany)
2.6 Antibodies and Fluorescent Dyes
Antibodies and fluorescent dyes were used in the following applications: FACS, Flow
cytometry; IB, Immunoblot analysis; IF, Immunofluorescence; S, Stimulation of cells
Primary antibodies
Specificity Clone Applic. Company/Source
Actin (beta) AC-15 (mouse) IB Abcam
(Hiddenhausen, Germany)
CD95 (agonistic) CH-11 (mouse) S Beckman Coulter
(Roissy, France)
gD (HSV) DL-6 (mouse) FACS Santa Cruz Biotechnology
(Heidelberg, Germany)
FLIP (cellular) NF6 (mouse) IB, IF Peter Krammer
(DKFZ, Heidelberg, Germany)
Myc-Tag polyclonal rabbit IB Biozol (Eching, Germany)
HSV (McIntyre) polyclonal rabbit
serum
IF Dako (Hamburg, Germany)
Secondary antibodies
Antibody Conjugation Applic. Company
Goat-anti-mouse F(ab’)2 Peroxidase IB Dianova
(Hamburg, Germany)
Goat-anti-rabbit F(ab’)2 Peroxidase IB Dianova
(Hamburg, Germany)
Goat-anti-mouse F(ab’)2 Cy5 FACS Immunotools
(Friesoythe, Germany)
Goat-anti-mouse F(ab’)2 FITC FACS Immunotools
(Friesoythe, Germany)
Goat-anti-mouse F(ab’)2 TexasRed FACS, IF Immunotools
(Friesoythe, Germany)
Goat-anti-rabbit F(ab’)2 FITC IF Immunotools
(Friesoythe, Germany)
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Fluorescent dyes
Name Applic. Company
AnnexinV-FITC FACS Santa Cruz Biotechnology (Heidelberg, Germany)
DAPI IF Invitrogen (Karlsruhe, Germany)
Propidium iodide FACS Santa Cruz Biotechnology (Heidelberg, Germany)
2.7 Technical Equipment
Name Company
CCD camera, Kodak Image Station 4000 MM
Digital Imaging System
Kodak (Stuttgart, Germany)
Cell counting chamber, Neubauer improved Roth (Karlsruhe, Germany)
Centrifuge, Megafuge 2.O R Heraeus (Hanau, Germany)
CO2 Incubator HERACell 150 Heraeus (Hanau, Germany)
Electronic pipetor, Pipetus Hirschmann Laborgeräte
(Eberstadt, Germany)
Electrophoresis System BIO-RAD Laboratories
(München, Germany)
Flow Cytometer, FACSCalibur BD Biosciences
(Heidelberg, Germany)
Fluorescence Microscope, Olympus BX60 Carl Zeiss (Jena, Germany)
Microscope, Axiovert 25 Carl Zeiss (Jena, Germany)
Microscope slides, SuperFrost Ultra Plus Menzel (Braunschweig, Ger-
many)
NucleofectorTM Amaxa (Cologne, Germany)
PVDF membranes Millipore Corporation
(Bedford, USA)
Sterile filters 0,2 µm Schleicher and Schüll
(Dassel, Germany)
Sterile Workbench, HERASafe Heraeus (Berlin, Germany)
Vortex-Genie 2 Scientific Industries
(New York, USA)
Waterbath GFL (Burgwedel, Germany)
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2.8 Plasmids
The following mamalian expression plasmids were used in this work:
Plasmid Parental
Vector
Insert Insertion Site Source/
Reference
pEGFP-N1 pEGFP-N1 none Clontech
FLIPS-EGFP pEGFP-N1 c-FLIPS
lacking last 8 aa
BglII/SacII [153]
FLIPL-EGFP pEGFP-N1 c-FLIPL BglII/SacII [153]
myc-FLIPS pcDNA3 myc-c-FLIPS HindIII/XbaI [96]
myc-FLIPL pcDNA3 myc-c-FLIPL HindIII/XbaI [121]
myc-FLIPL 1-438 pcDNA3 myc-c-FLIPL
bases 1-1314
HindIII/XbaI [67]
myc-FLIPL 1-202 pcDNA3 myc-c-FLIPL
bases 1-606
HindIII/XbaI [67]
myc-FLIPL 203-480 pcDNA3 myc-c-FLIPL
bases 606-1443
HindIII/XbaI [67]
myc-FLIPL D376A pcDNA3 myc-c-FLIPL with
mutated codon 376
HindIII/XbaI [67]
myc-FLIPL F23G/F114G pcDNA3 myc-c-FLIPL with
mutated codons 23 & 114
HindIII/XbaI [67]
US3-EGFP pEGFP-N1 US3 (HSV-1 strain F) XhoI/BamHI MJR
gJ-EGFP pEGFP-N1 gJ (HSV-1 strain F) XhoI/BamHI MJR
FLIPL-EGFP and FLIPS-EGFP were kindly provided by Professor Harald Wajant (De-
partment of Molecular Internal Medicine, Medical Polyclinic, University of Würzburg,
Würzburg, Germany). myc-FLIPS was a kind gift of Professor Peter H. Krammer (Di-
vision of Immunogenetics, German Cancer Research Center, Heidelberg, Germany).
myc-FLIPL, myc-FLIPL 1-438, myc-FLIPL 1-202, myc-FLIPL 203-480, myc-FLIPL D376A
and myc-FLIPL F23G/F114G were kindly made available by Professor Mikihiko Naito
(Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo, Japan).
The sequences of FLIPL and FLIPS are available in the Nucleotide Database under ac-
cession numbers U97074 and U97075, respectively. US3-EGFP and gJ-EGFP were ob-
tained from Martin J. Raftery (MJR, Institute of Virology, Charité Medical School, Berlin,
Germany) with kind permission.
Plasmids were expanded in Escherichia coli strain XL-1 blue and purified using Qia-
gen Midi Plasmid Purification Kit (Qiagen, Hilden, Germany).
2.9 Cells
Cell culture work was carried out following standard sterile working rules in a laminar
flow hood using sterile reagents and equipment. Ingredients of the used culture media
are listed in section 2.4. FCS was inactivated at 56 ◦C for 30 min (water bath) before us-
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age. For passaging or collection, adherent cells were washed twice with PBS, incubated
with trypsin solution (PBS with 0.05 % trypsin and 1 mM EDTA) for 5 min at 37 ◦C and
resuspended in the respective culture medium. Absence of Mycoplasma species from
cell lines was regularly tested using Venor GEM-Mycoplasma Detection Kit.
2.9.1 Cell Lines
Name Origin Medium
A549 epithelial, human lung carcinoma F-medium
HeLa epithelial, human cervix carcinoma F-medium
HEp-2 epithelial, HeLa subpopulation F-medium
HaCaT epithelial, spontaneously immortalized
aneuploid human keratinocyte
F-medium
L428 hematopoietic, human,
Hodgkin/Reed-Sternberg cells
of Hodgkin’s lymphoma
PB-medium
L1236 hematopoietic, human,
Hodgkin/Reed-Sternberg cells
of Hodgkin’s lymphoma
PB-medium
HaCaT cells were kindly provided by N. Fusenig (DKFZ, Heidelberg, Germany). L428
and L1236 were obtained from Stefan Mathas (Max Delbrück Center for Molecular
Medicine, Berlin, Germany). All other cell lines were obtained from ATCC.
2.9.2 Dendritic Cells
Monocytes were obtained from buffy coats of healthy donors (DRK, Berlin, Germany)
by density gradient centrifugation over Ficoll-Paque and subsequent isolation with
Monocyte Isolation Kit II. Monocytes were then differentiated into iDCs by culture in
DC-medium for 6 days.
2.9.3 Other primary cells
Human umbilical vein endothelial cells (HUVECs) were prepared by the recently mod-
ified [166] method of Jaffe et al. [68] and maintained in HUVEC-medium on gelatin-
coated plates. Primary keratinocytes and fibroblasts (isolated as described in [78]) were
obtained from C. Johnen and K. Bräutigam (Department of Surgery, Univer-sitätsmedi-
zin Berlin - Charité, Berlin, Germany). Keratinocytes were maintained in Ker-medium
and fibroblasts in F-medium.
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2.10 Viruses and Infection
HSV-1 wild type strains KOS, F, and 17 as well as a LAT knockout mutant of HSV-1
(∆LAT, 17N/H [22]) were propagated on Vero E6 cells. An ICP27 knockout mutant
of HSV-1 (∆ICP27, 27-LacZ [154]) was propagated on Vero E6 cells which are stably
transfected to complement ICP27 (Vero 2-2). Cell culture supernatant of infected Vero
E6 or Vero 2-2 cells was collected and centrifuged at 2,000 g for 10 min. The cleared
supernatant was frozen in liquid nitrogen at 0.5 ml aliquots. Titers of virus stocks were
determined by measuring TCID50.
For infection experiments, suspension cells were resuspended in and adherent cells
were overlayed with a minimal volume of culture medium. Transfected cells were in-
fected 24-35 h post transfection. The appropriate volume of HSV-1 containing super-
natant necessary to achieve the desired MOI was added to the cells and mixed. Af-
ter incubation for 1 h at 37 ◦C to allow virus adsorption, the virus containing medium
was removed and cells were washed two times with medium. A sufficient volume
of culture medium was added and cells were maintained under normal culture con-
ditions. As controls, infection was performed with heat-inactivated (56 ◦C, 30 min) or
UV-inactivated (10 min) HSV-1. Efficiency of infection was controlled by staining of
cells at 18 h post infection with anti-gD and fluorescence-conjugated secondary anti-
body, followed by flow cytometry. Background staining was determined by staining of
uninfected cells or cells treated with inactivated virus and subtracted.
2.11 Immunoblot analysis
Cells were washed with cold PBS and lysed for 1 h on ice in lysis buffer. After centrifu-
gation at 15,000 g for 30 min, the supernatant containing soluble cytoplasmatic proteins
was mixed with loading buffer, incubated at 95 ◦C for 10 min, and separated by 12-15 %
SDS-PAGE. In order to achieve equal loading of lanes, the protein content of lysates was
determined using BCA protein assay kit. After transfer to PVDF membranes, the blots
were blocked with 5 % BSA or 5 % milk powder in IB-wash and thereafter incubated
with primary antibody. After washing 5 times with IB-wash, blots were incubated with
peroxidase-conjugated secondary antibody. After washing again 5 times with IB-wash,
blots were developed by enhanced chemoluminescence using Super Signal West Dura
Extended Duration Substrate. The signal was detected with a charge-coupled device
(CCD) camera. After stripping off with 0.4 M glycine/0.2 % SDS (pH 2.2), blots were
blocked again and stained against β-actin to check for equal loading. Densitometric
analysis of bands on photographs of immunoblots was performed by using ChemiIm-
ager 4000 software (Alpha155 Innotech Corporation, San Leandro, CA, USA).
2.12 Flow cytometry and detection of apoptosis
For assessment of infection efficiency, cells were harvested at 18 h post infection with
HSV-1 and washed once with FACS-wash. Primary antibody (specific for HSV-1 gly-
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coprotein D, gD) was diluted in FACS-block and added to the cells. After 20-30 min,
primary antibody was washed from the cells with FACS-wash two times. Thereafter,
cells were incubated with secondary antibody in FACS-block for 15-20 min. After a final
wash with FACS-wash, cells were resuspended in fixation solution and stored at 4 ◦C in
the dark until analysis. EGFP expressing cells were not fixed after staining, but left in
FACS-wash and analyzed immediately. For detection of apoptosis, cells were washed
once with AnnexinV-buffer and stained with AnnexinV-FITC for 20 min in the dark.
Thereafter, cells were washed two times with AnnexinV-buffer. Propidium iodide was
added and cells were directly analyzed. Analysis was done with a FACSCalibur flow
cytometer. Data were analyzed with Cellquest Pro software.
2.13 Immunofluorescence
Medium was removed from cells grown on glass plates and washed once with PBS.
Fixation of cells was achieved by incubation in PBS/3.7 % PFA for 5 min at room tem-
perature. After washing three times with PBS, cells were permeabilized and blocked
with IF-block for 5 min. After washing again three times with PBS, first antibody was
added diluted in FACS-block with 5 % goat-serum and left on the cells for 30 min at
room temperature. Then, cells were washed 4 times with PBS and incubated for 1.5 h in
the dark with secondary antibody diluted in FACS-block with 5 % goat-serum. Finally,
cells on glass plates were washed four times with PBS and once with distilled water.
Glass plates were then covered with mounting medium and transferred to glass slides
for fluorescence microscopy.
2.14 Microarray analysis of HSV-1 gene expression
At different time points post infection, cells were harvested and lysed in TRI REAGENT.
Total RNA was extracted with phenol/chlorform and resuspended in sterile water. To-
tal RNA was shipped on dry ice to Rozanne M. Sandri-Goldin and Gayathri Devi-Rao
(Department of Microbiology and Molecular Genetics, School of Medicine, University
of California Irvine, USA), who carried out the microarray analysis. Fluorescein- or
biotin-labeled cDNA was generated from purified poly(A)-containing RNA by random
hexamer-primed polymerization using Superscript II reverse transcriptase (Gibco-BRL,
Invitrogen, Carlsbad, USA) as described in detail in [161]. Generation of HSV-1 mi-
croarrays, as oligonucleotide selection, synthesis and deposition on the chip have been
described previously [158, 177]. Position of oligonucleotide probes which are located
in the LAT region of the HSV-1 genome is illustrated in figure 2.1. Hybridization of
microarrays with labeled cDNA and scanning was carried out as reported recently
[161, 160]. Briefly, microarrays were hybridized with cDNA probes for 18 h and rinsed
for scanning with a proprietary HiLight dual-color kit (Genicon Sciences, San Diego,
USA) at 52 ◦C in a MAUI hybrid mixer assembly (BioMicro Systems, Salt Lake City,
USA). After hybridization, the slides were washed, blocked and bound by the gold
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Figure 2.1: Diagram of the LAT region of the HSV-1 genome showing location of LAT
probes used for microarray analysis and quantitative RT-PCR. Schematic map
of the internal repeat and joint region of the HSV-1 genome. Selected restriction
sites, the region associated with antiapoptotic function of LAT [24] and the dele-
tion in 17N/H [22] are indicated. Position of probes used in the microarray [177]
are marked with filled arrows, position of probes used in quantitative RT-PCR are
marked with open arrows. Below the map of the genome important LAT RNA
species are depicted based on data published by Devi-Rao et al. [32]. For better
orientation, base numbers of the total HSV-1 DNA sequence [accession number:
X14112] are given for selected positions.
and silver RLS method (two-color nucleic acid microarray resonance light-scattering-
based method, Genicon Sciences, San Diego, USA). Microarrays were scanned with a
GSD-501 HiLight reader (designed for RLS, Genicon Sciences, San Diego, USA). First,
for each gene or coterminal transcript family, a median value was calculated from the
net (minus background) hybridization values of the three replicate probe spots on the
chip. These median hybridization values were then expressed in percent of the total
viral signal of the given hybridization (median hybridization value of probe multiplied
with 100, divided by the sum of all hybridization values) to obtain a relative abundance
for the respective detected transcript. Microarray analysis of HSV-1 gene expression in
each cell type was performed three times with RNA from three independent infection
experiments as indicated in table 3.1. Relative abundances of each transcript from the
different infections were pooled to calculate final median values displayed in tables 1-
4. Relative abundances in iDCs and HaCaT or HeLa cells were compared by Student’s
two-tailed t test, assuming unequal variance and with the null hypothesis being that
the true values in the different cell types are identical.
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2.15 LightCycler quantitative real-time PCR
Cells were lysed in MagNA Pure lysis buffer and frozen at -80 ◦C until further pro-
cessing. mRNA isolation, primer design and LightCycler quantitative real-time PCR
was done by Thomas Giese (Institute of Immunology, University of Heidelberg, Hei-
delberg, Germany). mRNA was isolated with a MagnaPure-LC device using standard
protocols. RNA was reverse-transcribed with AMV-RT and oligo(dT) primer (First
Strand cDNA synthesis kit, Roche, Mannheim, Germany). For amplification of tar-
get sequences, LightCycler Primer Sets (Search-LC, Heidelberg, Germany) were used
with LightCycler FastStart DNA Sybr Green I Kit (Roche, Mannheim, Germany). RNA
input was normalized by the average expression of the housekeeping genes encoding
β-actin and cyclophilin B. By plotting a known input concentration of a plasmid to the
PCR cycle number at which the detected fluorescence intensity reached a fixed value, a
virtual standard curve was generated. This standard curve was used to calculate tran-
script copy numbers. The presented relative copy numbers are mean averages of data
of two independent analyzes for each sample and parameter. Primers for detection of
c-FLIP are located at nucleotides 1163 and 1420 of the c-FLIPL open reading frame (ac-
cession number U97074). Locations on the HSV-1 genome (accession number X14112.1)
of probes used to detect different LAT-species (LAT-A: 118987-119182, LAT-B: 119811-
119935, LAT-C: 125612-125692) are illustrated in figure 2.1. Locations on the HSV-1
genome (accession number X14112.1) of primers for detection of other HSV-1 genes are
listed in the table below.
Gene 5’ primer 3’ primer
UL10 23619-23639 23654-23679
UL54 114982-115002 115160-115184
US1 133304-133325 133541-133565
US3 135451-135476 135539-135562
US5 137806-137821 137890-137910
US6 138750-138773 138983-139001
US11 145087-145110 145008-145031
In one set of experiments, quantitative RT-PCR of c-FLIP was performed separately
in nuclei and cytoplasm. Therefore, cells were resuspended in lysis buffer and incu-
bated for 1 h on ice. The lysat was centrifuged and supernatant and pellet separately
resuspended in MagNA Pure lysis buffer. The pellet was washed once with lysis buffer
before resuspension in MagNA Pure lysis buffer, to remove residual cytoplasm.
2.16 Transfection of cells with mammalian expression plasmids
Transfections were performed with HEp2, A549, or HEK cells and different transfection
reagents were used.
For transfection of cells with LipofectamineTM 2000 Transfection Reagent (Invitro-
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gen, Karlsruhe, Germany), adherent cells were trypsinized, washed one time with cul-
ture medium and resuspended in 500 µl DMEM/5 % FCS. Separately, 3 µg plasmid was
added to 50 µl Optimem and gently mixed. In another tube, 50 µl Optimem was mixed
with 5 µl LipofectamineTM 2000. After 5 min, plasmid solution and LipofectamineTM
2000 solution were mixed and incubated 30 min at room temperature. Thereafter, the
transfection mixture was added to the cells, gently mixed and incubated for 3.5 h in
a cell culture incubator (37 ◦C, 5 % CO2). Thereafter, cells were washed twice with
DMEM/5 % FCS, resuspendended in an appropriate amount of DMEM/5 % FCS and
seeded on cell culture dishes.
Transfections with ExGen 500 Universal Transfection Reagent (Fermentas, St. Leon-
Rot, Germany) were carried out as follows. Adherent cells were used at 50 % con-
fluency, washed twice with PBS and overlayed with DMEM without additives. 3 µg
plasmid were mixed with 200 µl PBS and 9.9 µl ExGen 500 and immediately mixed by
vortexing for 10 s. The transfection mixture was then incubated for 10 min at room tem-
perature and thereafter added to the cells, followed by gentle mixing and incubation for
7 h in the cell culture incubator. Then, the transfection medium was exchanged with the
regular cell culture medium.
Transfections with FuGENE R© 6 Transfection Reagent (Roche, Mannheim, Germany)
were performed with adherent cells at 50 % confluency. Before transfection, the cul-
ture medium was exchanged with fresh regular cell culture medium. For each plasmid
the optimal volume FuGENE R© 6 [µl] : mass DNA [µg] ratio was established in preced-
ing optimization experiments. 582 µl DMEM without additives was mixed with 18 µl
FuGENE R© 6 and incubated for 5 min at room temperature. Then, 6 µg (ratio 3 : 1) or
12 µg (ratio 3 : 2) were added, gently mixed and incubated for another 40 min at room
temperature. The transfection mixture was added to the cells in a drop wise manner
and distributed by gentle swirling. The transfection medium was left on the cells until
they were used for assay of gene expression or virus infection.
For some experiments, TurboFectTM in vitro Transfection Reagent (Fermentas, St.
Leon-Rot, Germany) was used to transfect cells. Cells were trypsinized, washed once
with culture medium and resuspended in 100 µl DMEM without additives. Separately,
300 µl DMEM without additives were mixed with 4 µg plasmid, then 6 µl TurboFectTM
were added and mixed by pipetting. After 30 min at room temperature, the cell sus-
pension was added to the transfection mixture and mixed by flicking the tube. After
incubation for 6 h in a cell culture incubator, an appropriate amount of culture medium
was added and the cells were seeded on cell culture dishes.
2.17 Inhibition of the proteasome
In some experiments, the proteasomal turnover of proteins was inhibited by addition
of the proteasome inhibitor MG132. Because MG132 has toxic effects on cells, incuba-
tion time must be minimized. Therefore, MG132 was added to the cells at 1 µM 5 h
before harvesting or at 10 µM 2.5 h before harvesting of the cells for analysis. Because it
was intended to analyze the consequences of proteasome inhibition on HSV-1 induced
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downregulation of c-FLIP, which occurs between 10 h and 12 h post infection, MG132
was added to infected cells at 5.25 h or 7.5 h post infection and analysis was done 2.5 h
or 5 h later.
2.18 c-FLIP protein degradation assay
A549 cells were transfected with plasmids myc-FLIPL F23G/F114G (mutated c-FLIPL
which does not aggregate when overexpressed in cells [67]) or FLIPS-EGFP using Tur-
bofectTM and lysed after 48 h in Triton buffer. After 1 h on ice and sedimentation of
debris by centrifugation, the lysates were divided into four aliquots. One aliquot was
frozen at -20,◦C until SDS-PAGE. Another aliquot was incubated at 37 ◦C for 2 h and
then loaded on SDS-PAGE. The two remaining aliquots were each mixed with an equal
volume of lysate from HSV-1 infected (strain KOS, MOI 10, lysed at 18 h post infection)
but untransfected A549 cells and also incubated at 37 ◦C before loading on SDS-PAGE.
To one of the aliquots mixed with lysates from HSV-1 infected A549 cells, the protea-
some inhibitor MG132 (50 µM) was added before incubation at 37 ◦C. SDS-PAGE and
immunoblot for detection of c-FLIP was performed as described above.
2.19 RNA interference in human monocyte-derived dendritic
cells
RNA interference in DCs was performed by Juliane Lippmann, a diploma student
working under my supervision. Control non-silencing siRNA (siC, target sequence,
TTT ATG TGT GCC CGT GTG GAA) and FLIP specific siRNA (siFLIP, target sequence,
TTG TGC CGG GAT GTT GCT ATA, targeting both c-FLIPL and c-FLIPS) were pur-
chased from MWG (Ebersberg, Germany). Monocytes were isolated from buffy coats of
healthy donors (DRK, Berlin, Germany) with CD14 MicroBeads after density gradient
centrifugation over Ficoll-Paque. Immediately after isolation, monocytes were trans-
fected with 1 µmol siRNA per 2 x 107 cells using Amaxa NucleofectorTM according to
the manufacturer’s protocol (Human Monocyte NucleofectorTM Kit, NucleofectorTM
program Y-001). The transfected cells were then differentiated into iDCs by culture in
DC-medium for 3 to 6 days. Before apoptosis assay, 1 x 105 iDCs were stimulated with
0.125 µg/ml agonistic anti-CD95 monoclonal antibody (clone CH-11) for 12 h or were
left untreated.
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Previous studies showed that iDCs die from apoptosis after infection with HSV-1 [23,
133]. Müller et al. [115] demonstrated the downregulation of the cellular antiapoptotic
protein c-FLIPL after HSV-1 infection and proposed that the lack of c-FLIPL could sensi-
tize iDCs to apoptosis. The first experiments in this work were performed to investigate
this hypothesis.
3.1 siRNA mediated knockdown of c-FLIP in iDCs
After HSV-1 infection, a multitude of changes occurs in many cellular processes, which
influence viability of the cell. To investigate the impact of c-FLIP downregulation on
viability of iDCs separate from other HSV-1 induced effects, the amount of c-FLIP in
uninfected iDCs was reduced by RNA interference.
Monocytes were isolated from PMBC of healthy blood donors with CD14-microbeads
and immediately nucleofected with c-FLIP specific siRNA, control siRNA, or were left
untreated. Afterwards, monocytes were differentiated into iDCs for 3 to 6 days. Im-
munoblot analysis confirmed the specific reduction of c-FLIPL (figure 3.1A) and c-FLIPS
(data not shown).
Viability was assessed by flow cytometry. One representative experiment out of three
is shown in figure 3.1B. Without further treatment, successful reduction of c-FLIP re-
sulted in a prominent loss of viable iDCs (figure 3.1B, upper panel). After nucleofection
with control siRNA (siC) 85 % of iDCs were viable (AnnexinV−/PI−), compared to 20 %
viable iDCs after nucleofection with c-FLIP specific siRNA (siFLIP). This was associated
with an increase in apoptotic (AnnexinV+/PI−) iDCs from 2 % (siC) to 16 % (siFLIP).
However, after nucleofection with siFLIP, most AnnexinV+ iDCs were also PI+ (61 %).
This cell population likely represents iDCs in the late apoptotic state, because analysis
of viability was performed not before 3 to 6 days after nucleofection. Stimulation of the
extrinsic apoptosis pathway with an agonistic CD95 (Fas) antibody (figure 3.1B, lower
panel) resulted in a 4-fold (85 % to 20 %) reduction of viable iDCs nucleofected with siC
and a 20-fold (20 % to 1 %) reduction of viable iDCs nucleofected with siFLIP.
Taken together, reduction of c-FLIP by RNA interference induced apoptosis in the
majority of iDCs and sensitized the remaining iDCs to induction of apoptosis via the
extrinsic pathway. These data suggest a direct correlation between the amount of c-
FLIP and viability of iDCs. Therefore it can be assumed that HSV-1 induced c-FLIP
downregulation could also lead to increased apoptosis in iDCs.
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Figure 3.1: Immunoblot of c-FLIP (A) and flow cytometry analysis of apoptosis (B) in iDCs
after siRNA mediated knockdown of c-FLIP. iDCs were nucleofected with siRNA
specifically targeting c-FLIP (siFLIP) or with unspecific control siRNA (siC) or were
left untreated (co). (A) Specific knockdown of c-FLIP was verified by immunoblot
using anti-FLIP antibody (clone NF-6) and antibody against β-actin as loading
control. (B) Viability of iDCs was analyzed by staining of cells with AnnexinV-
FITC and propidium iodide (PI) and subsequent flow cytometry analysis. One
aliquot of the cells was treated with anti-CD95 agonistic antibody (clone CH-11)
for 12 h before assessment of viability. Data are representative of three independent
experiments.
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Figure 3.2: Time course of HSV-1 induced c-FLIP downregulation in iDCs. iDCs were in-
fected with HSV-1 strain F at MOI 1.5 or with heat-inactivated HSV-1 (hi-HSV).
At different time points post infection, cells were harvested and analyzed by im-
munoblot analysis using anti-FLIP antibody (clone NF-6) and antibody against β-
actin as loading control. (A) One representative blot of three independent experi-
ments is shown. (B) Relative band intensity of c-FLIPL bands was determined by
densitometry and normalized to β-actin. The value obtained with HSV-1 infected
iDCs at 2 h p. i. was set to 100 %. For comparison, the relative band intensity ob-
tained at 2 h p. i. with heat-inactivated virus is also depicted.
3.2 Time course of HSV-1 induced c-FLIP reduction and
apoptosis in iDCs
In the publication by Müller et al. [115] c-FLIP and apoptosis were analyzed exclusively
at 18 h post infection (h p. i.) of iDCs with HSV-1. However, at this time point replication
of HSV-1 is almost completed. Therefore, the temporal pattern of HSV-1 induced c-FLIP
downregulation and apoptosis in iDCs was investigated in more detail.
iDCs were infected with wild type HSV-1 strain F at MOI 1.5 and the amount of c-FLIP
was analyzed by immunoblot at different time points post infection. Up to 10 h p. i.
no reduction of c-FLIPL was detected (figure 3.2). However, at 12 h p. i. the amount
of c-FLIPL dropped below 50 % of the amount detected in iDCs treated with heat-
inactivated virus. At later time points (18 h p. i.) the amount of c-FLIPL was further
decreased, to about 25 % (figure 3.14A, first panel).
In some experiments presented in this thesis, the short form of c-FLIP, c-FLIPS, which
is also expressed in iDCs, was detectable by immunoblot analysis. c-FLIPS was also
downregulated after HSV-1 infection of iDCs, to a comparable extent and at the same
time point as c-FLIPL (figures 3.8 and 3.10).
In different experiments several wild type HSV-1 strains (F, KOS, Patton and 17) were
used and all showed a comparable ability to downregulate c-FLIP. Immunoblot data of
c-FLIP in iDCs after infection with strain F (figures 3.2, 3.10 and 3.14) and KOS (figures
3.10 and 3.8) are presented in this thesis.
Kinetics of c-FLIP downregulation depended on the MOI used for infection. At
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higher MOI (for example MOI 3), reduction of c-FLIP to 40 % occured already at 10 h p. i.
(figure 3.8).
Figure 3.3 shows the time course of apoptosis in HSV-1 infected iDCs (HSV-1 strain
F, MOI 1.5). The number of apoptotic iDCs was determined by flow cytometry af-
ter staining with AnnexinV-FITC and propidium iodide. Flow cytometry diagrams
of one representative experiment are shown in figure 3.3A. While in hi-HSV-1 treated
iDCs the number of apoptotic cells (AnnexinV+/PI−, lower right quadrant) did not
increase between 10 h p. i. (8 %) and 16 h p. i. (6 %), in HSV-1 infected iDCs the num-
ber of apoptotic cells increased from 10 % to 20 %. At 20 h p. i. only 10 % of hi-HSV-1
treated iDCs were apoptotic, but 27 % of HSV-1 infected iDCs. However, at 20 h p. i.
more HSV-1 infected iDCs were in the late apoptotic stage (AnnexinV+/PI+, upper
right quadrant) compared to 16 h p. i. (21 % compared to 8 %). Statistical analysis re-
vealed that up to 12 h p. i. there was no significant difference in the number of apop-
totic iDCs (AnnexinV+/PI−) after HSV-1 infection compared to iDCs treated with heat-
inactivated virus (hi-HSV-1) (figure 3.3B). However, at 14, 16, and 20 h p. i. a signif-
icantly higher number of HSV-1 infected iDCs was apoptotic compared to hi-HSV-1
treated iDCs. In following experiments, analysis of apoptosis in HSV-1 infected cells
was done after 16 h p. i.
These data demonstrate that the reduction of c-FLIP at 12 h p. i. precedes apoptosis in
HSV-1 infected iDCs, which is first detectable at 14 h p. i. This is another indication for a
correlation between the downregulation of antiapoptotic c-FLIP and induction of apop-
tosis in iDCs after infection with HSV-1. Furthermore, these data indicate that c-FLIP
downregulation and apoptosis of iDCs are induced in a late stage of HSV-1 replication.
3.3 Mechanism of c-FLIP reduction by HSV-1
The data presented above strongly indicate that HSV-1 induced downregulation of c-
FLIP could contribute to apoptosis after HSV-1 infection of iDCs. Next, experiments
were conducted in order to resolve how HSV-1 achieves the reduction of c-FLIP.
3.3.1 c-FLIP mRNA after infection of iDCs with HSV-1
HSV-1 could target c-FLIP either at the level of mRNA transcription and stability or
directly at the protein level. As shown by Müller et al. [115], the total amount of c-
FLIPL mRNA is increased after infection of iDCs with HSV-1. This result points toward
a mechanism operating directly on the protein rather than on mRNA. But it is also pos-
sible that HSV-1 impairs the export of c-FLIP mRNA from the nucleus to the cytoplasm.
Therefore, the amount of c-FLIPL mRNA was quantified separately in nuclei and cyto-
plasm of HSV-1 infected iDCs using quantitative real-time PCR.
As shown in figure 3.4, these experiments confirmed the increase in total c-FLIPL
mRNA after infection of iDCs with HSV-1, which was already published by Müller
et al. [115]. Although most of the additional transcripts did accumulate in the nu-
cleus (91± 23 % in HSV-1 infected iDCs compared to 20± 4 % in uninfected cells), the
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Figure 3.3: Time course of apoptosis in iDCs infected with HSV-1. iDCs were infected with
HSV-1 strain F at MOI 1.5 or with heat-inactivated HSV-1 (hi-HSV-1). At differ-
ent time points post infection apoptosis was assessed by staining of iDCs with
AnnexinV-FITC and propidium iodide (PI) and subsequent flow cytometry. (A)
Flow cytometry diagrams are shown for one representative experiment. Numbers
in each quadrant indicate percentage of cells contained in this quadrant. (B) The
number of apoptotic iDCs (AnnexinV+/PI−) at 20 h p. i. was set to 100 %. Median
values ±SD of three independent experiments are shown for different time points
post infection with HSV-1 or hi-HSV-1. Asterisks indicate that at this time point
apoptosis in HSV-1 infected iDCs is significantly higher than in iDCs treated with
hi-HSV-1 (Student’s unpaired two-tailed t test, P ≤ 0.05).
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Figure 3.4: Distribution of c-FLIPL mRNA in iDCs after infection with HSV-1. iDCs were in-
fected for 18 h with HSV-1, heat-inactivated HSV-1 (hi-HSV-1) or UV-inactivated
HSV-1 (uv-HSV-1) or were left uninfected. Relative copy numbers of c-FLIPL
mRNA in the nucleus and the cytosol were determined separately by quantita-
tive RT-PCR. Values obtained with LPS-treated (24 h) iDCs were set to 100 %. Data
shown are mean values ± SD calculated from three independent experiments (ex-
cept uv-HSV-1, two experiments).
number of c-FLIPL mRNA transcripts in the cytoplasm was not decreased after infec-
tion (19± 5 % in HSV-1 infected iDCs compared to 8± 1 % in uninfected cells). UV-
inactivated HSV-1 and LPS also increased the amount of c-FLIPL mRNA in the nu-
cleus and the cytoplasm of iDCs (uv-HSV-1, 62± 3 % in the nucleus and 29± 7 % in
the cytoplasm; LPS, set to 100 % in both cell compartiments). This might be due to
induction of maturation of iDCs, which is known to be associated with elevated c-
FLIPL transcription [58]. Heat-inactivated HSV-1 did not increase the amount of c-
FLIPL mRNA (32± 6 % in the nucleus and 11± 2 % in the cytoplasm) compared to un-
infected cells (20± 4 % in the nucleus and 8± 1 % in the cytoplasm). Because the ratio
cytoplasm/nucleus of the amount of c-FLIPL mRNA was 0.2 in HSV-1 infected cells
compared to 0.5 in uv-HSV-1 infected cells and 0.4 in uninfected control cells, there
might be some retention of c-FLIPL mRNA in the nucleus of infected iDCs. However,
the amount of c-FLIPL mRNA in the cytoplasm was not decreased after HSV-1 infection
of iDCs compared to uninfected iDCs.
Based on these observations it can be concluded that downregulation of c-FLIP by
HSV-1 is not due to disturbances of mRNA-transcription, stability or transport, but
rather due to degradation of the protein itself.
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3.3.2 Impact of HSV-1 infection on overexpressed c-FLIP
Isolation and differentiation of iDCs is labor-intensive and expensive. Furthermore,
flow cytometry of fluorophore-tagged proteins allows a much more direct quantifica-
tion of the protein amount than immunoblot analysis. Therefore, studies on the mech-
anism of c-FLIP downregulation by HSV-1 were planned to be performed in c-FLIP
transfected cell lines instead of iDCs.
Overexpressed c-FLIP is resistant to HSV-1 induced downregulation
HEp-2 cells were transfected with eucaryotic expression plasmids containing EGFP
tagged c-FLIPL (FLIPL-EGFP) or c-FLIPS (FLIPS-EGFP) or EGFP alone. After 32 h, cells
were infected with HSV-1 (strain KOS, MOI 1 - 3) or left uninfected. 18 h p. i., cells were
stained with an antibody against viral glycoprotein gD, which accumulates on the sur-
face of infected cells, and analyzed by flow cytometry. Results are depicted in figure
3.5.
In some experiments, the geo mean fluorescence intensity of FLIPL-EGFP and FLIPS-
EGFP after HSV-1 infection was slightly reduced in gD-positive cells (upper right quad-
rant) compared to gD-negative cells (lower right quadrant) while the geo mean fluores-
cence intensity of EGFP alone was slightly enhanced (85 compared to 92 for FLIPL-
EGFP, 137 compared to 183 for FLIPS-EGFP, 589 compared to 562 for EGFP, figure 3.5A,
lower panel). However, when mean values ± SD were calculated from three inde-
pendent experiments, no reproducible and significant difference in geo mean fluores-
cence intensity of FLIPL-EGFP, FLIPS-EGFP, or EGFP was observed between gD pos-
itive and gD negative cells, which were set to 100 % (FLIPL-EGFP, 105± 23 %; FLIPS-
EGFP, 88± 19 %; EGFP, 135± 43 %; figure 3.5B).
From these data it must be concluded, that overexpressed c-FLIP is to a large extent
resistant to downregulation by HSV-1. There are several possible explanations for this
result: i) The mechanism of HSV-1 induced c-FLIP downregulation is operative only in
iDCs, but not in HEp-2 cells. ii) The EGFP tag protects c-FLIP against degradation by
HSV-1. iii) Stable EGFP tagged degradation products of c-FLIP are formed after HSV-1
infection. iv) The amount of c-FLIP in transiently transfected cells exceeds the capacity
of the HSV-1 induced degradation mechanism.
Immunoblot analysis would be helpful to elucidate the reason why transfected c-
FLIP-EGFP is not downregulated by HSV-1. For example, intermediate degradation
products of c-FLIP-EGFP could be detected and smaller non-fluoresce tags could be
used. However, efficiency of transfection and infection achieved in the experiment
presented above were not sufficient for immunoblot analysis. Transfection efficiency
was low and only one third to half of EGFP-positive cells were infected, as determined
by staining against HSV-1 gD (FLIPL-EGFP, 8 % EGFP+/gD− and 6 % EGFP+/gD+;
FLIPS-EGFP, 7 % EGFP+/gD− and 6 % EGFP+/gD+; EGFP, 6 % EGFP+/gD− and 5 %
EGFP+/gD+; figure 3.5A, lower panel). Therefore, transfection and infection had to be
optimized.
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Figure 3.5: Flow cytometry analysis of EGFP-tagged c-FLIP in HSV-1 infected cells. HEp-2
cells were transfected with pEGFP-N1 (EGFP), FLIPL-EGFP, or FLIPS-EGFP using
ExGen 500 and 32 h later infected with HSV-1 (strain KOS, MOI 1 - 3) or were left
uninfected. 18 h p. i., cells were harvested, stained with anti-gD antibody (stains
glycoprotein gD of HSV-1 on surface of infected cells) and goat-anti-mouse-Cy5
secondary antibody and immediately analyzed by flow cytometry. (A) Dot plots
from one representative experiment are shown. Numbers in each quadrant indicate
percentage of cells contained in this quadrant and in brackets the geo mean fluo-
rescence intensity of the EGFP signal. (B) Mean values ± SD of the geo mean fluo-
rescence intensity of the EGFP signal of gD-positive cells compared to gD-negative
cells (set to 100 %) obtained in three independent experiments.
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Optimization of transfection and infection
Using immunoblot analysis, detection of the impact of HSV-1 infection on overex-
pressed c-FLIP could be difficult when efficiency of infection in transfected cells is low.
To achieve a higher number of EGFP+/gD+ cells, different transfection reagents and
cell types were tested (figure 3.6) and the MOI was titrated.
HEp-2 cells were transfected with pEGFP-N1 using ExGen 500 and 32 h later infected
with HSV-1 (strain KOS, MOI 100) or were left uninfected. Only one third of EGFP-
positive cells were also HSV-1 gD positive, as determined by flow cytometry (5.4 %
EGFP+/gD− and 2.7 % EGFP+/gD+, figure 3.6A, third diagram). From these data it
must be concluded that ExGen 500 transfection can disturb HSV-1 infection, even at
high MOI (MOI 100). Therefore, another transfection reagent, FuGENE R© 6, was tested.
At MOI 100, FuGENE R© 6 transfection allowed high infection efficiency. Almost all
EGFP positive cells were also gD-positive (0.4 % EGFP+/gD− and 10.2 % EGFP+/gD+,
figure 3.6A, fifth diagram). LipofectamineTM 2000 was also used in some experiments,
but it also reduced infectibility of cells (14.6 % EGFP+/gD− and 8.6 % EGFP+/gD+,
data not shown).
To improve transfection efficiency, different cell types were transfected with pEGFP-
N1 using FuGENE R© 6. The highest transfection efficiency was achieved with A549 cells
(26.4 % EGFP positive cells, figure 3.6B, second diagram). HeLa, HaCaT and HEK cells
were also tested but all showed lower transfection efficiencies (data not shown). Based
on these results, all following experiments were conducted in A549 cells, transfected
with FuGENE R© 6.
In order to find the optimal MOI for efficient infection of transfected cells, a titration
of HSV-1 strain KOS was done on pEGFP-N1 transfected A549 cells (figure 3.6C). The
experiment revealed that the number of EGFP+/gD+ cells was still high at MOI 50 and
MOI 10, but was decreased at lower MOI (EGFP+/gD+ cells, 29.3 % at MOI 50, 23.4 %
at MOI 10, 21.7 % at MOI 3, 9.8 % at MOI 1). Therefore, following experiments were
performed at MOI 10 or MOI 50.
HSV-1 induced downregulation of overexpressed c-FLIP is restored by mutation of
the DED
Ishioka and colleagues showed that overexpressed c-FLIPL forms aggregates and is re-
sistant to degradation by the proteasome [67]. This aggregation is mediated by the
death effector domains (DEDs) contained in the c-FLIPL molecule. By mutation of the
DEDs, Ishioka et al. could restore the proteasomal turnover of overexpressed c-FLIPL.
Figure 1.4 shows the mutants used in this publication and their distribution in trans-
fected cells. The tendency of overexpressed c-FLIPL to form insoluble aggregates could
also contribute to its resistance against HSV-1 induced downregulation observed in the
experiments presented above (figure 3.5). In these experiments, similar dot-like aggre-
gates as published by Ishioka et al. [67] were observed in FLIPL-EGFP transfected cells
when analyzed under a microscope (data not shown). Based on these considerations,
it was investigated, whether specific mutation of c-FLIP could also restore the suscep-
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Figure 3.6: Optimization of transfection and infection. Cells were transfected with pEGFP-
N1 and 32 h later infected with HSV-1 (strain KOS) or were left uninfected. 18 h p. i.,
cells were harvested, stained with anti-gD-antibody (detects HSV-1 glycoprotein D
at surface of infected cells) and goat-anti-mouse-Cy5 secondary antibody and im-
mediately analyzed on a flow cytometer. Numbers in or above each quadrant in-
dicate percentage of cells contained in this quadrant. co, non-transfected and unin-
fected control cells. (A) HEp-2 cells were transfected with two different transfection
reagents (ExGen 500 or FuGENE R© 6) and infected with HSV-1 (KOS, MOI 100). (B)
A549 cells were transfected with FuGENE R© 6 and left uninfected or were (C) in-
fected with HSV-1 strain KOS at different MOI as indicated.
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Figure 3.7: Immunoblot analysis of mutated c-FLIP after HSV-1 infection. A549 cells were
transfected with different expression plasmids encoding myc-tagged wild type (wt)
and mutant c-FLIP (described in figure 1.4) using FuGENE R© 6 transfection reagent
and 17 h later each transfection was split into two petri dishes. 24 h after transfec-
tion cells were infected with HSV-1 strain KOS at MOI 50 or were left uninfected
(co). Cells were harvested and lysed at 18 h post infection. Lysates were subjected
to SDS-PAGE separation with subsequent blotting to PVDF membranes. c-FLIP
was detected either with anti-myc-antibody (myc-FLIPL 203-480) or with anti-FLIP-
antibody (clone NF6, all other c-FLIP forms). Subsequent staining of blots with
anti-β-actin antibody served as loading control. Blots shown are representative of
three independent experiments.
tibility of overexpressed c-FLIP to HSV-1 induced downregulation.
Therefore, the c-FLIP mutants generated by Ishioka et al. [67] were transfected into
A549 cells. 24 h after transfection, half of the cells were infected with HSV-1 (wild type
strain KOS, MOI 50). 18 h p. i., cells were harvested and analyzed by immunoblot. Re-
sults are depicted in figure 3.7. In accordance with the results obtained by flow cytom-
etry analysis (figure 3.5), wild type forms of c-FLIP were either not (myc-FLIPL, figure
3.7 lanes 1 and 2) or only weakly (myc-FLIPS, figure 3.7 lanes 3 and 4) downregulated
by HSV-1, although the C-terminal EGFP tag was exchanged with a N-terminal myc
tag. Furthermore, wild type c-FLIP forms detected in uninfected and HSV-1 infected
cells appeared to have the same molecular mass and no stable degradation products
were detected. c-FLIPL with a mutated caspase cleavage site (myc-FLIPL D376A, fig-
ure 3.7 lanes 13 and 14) and truncated c-FLIPL consisting only of DEDs (myc-FLIPL
1-202, figure 3.7 lanes 7 and 8) were also resistant to HSV-1 induced downregulation.
However, mutation (c-FLIPL F23G/F114G, figure 3.7 lanes 5 and 6) or removal (c-FLIPL
203-480, figure 3.7 lanes 9 and 10) of the DEDs restored susceptibility of c-FLIPL to
HSV-1 induced downregulation. Interestingly, certain modifications of the C-terminus
also increased the susceptibility of c-FLIP with functional DEDs to downregulation by
HSV-1, as was the case for truncated myc-FLIPL 1-438 (figure 3.7 lanes 11 and 12) and
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Figure 3.8: Immunoblot of c-FLIP in HSV-1 infected iDCs treated with the proteasome in-
hibitor MG132. iDCs were infected with HSV-1 (KOS, MOI 3) or left uninfected.
MG132 was added at 1 µM at 5.25 h p. i. or at 10 µM at 7.5 h p. i. iDCs were lysed
at 10 h p. i. and subjected to immunoblot analysis using anti-FLIP-antibody (clone
NF-6). Staining of the blots with antibody against β-actin served as a loading con-
trol. (A) One representative blot out of three experiments is shown. (B) Relative
band intensity of c-FLIP bands was determined by densitometry and normalized to
β-actin. The value obtained with uninfected and untreated iDCs was set to 100 %.
for myc-FLIPS (figure 3.7 lanes 3 and 4), which contains a unique C-terminus.
From these results a number of conclusions can be drawn: i) HSV-1 can induce down-
regulation of c-FLIP also when it is overexpressed in cell lines, however, ii) aggregation
of overexpressed c-FLIP mediated via DEDs impairs downregulation by HSV-1. ii) Ex-
periments to study the mechanism of HSV-1 induced c-FLIP downregulation in trans-
fected cells should be conducted with mutated forms of c-FLIP, for example c-FLIPL
F23G/F114G, which are susceptible to downregulation because the DED’s are mutated.
iii) Interference with the ability of c-FLIP to bind to the DISC (by mutation of the DEDs)
does not disturb HSV-1 induced downregulation. iv) The mechanism of HSV-1 induced
downregulation of c-FLIP is presumably operative directly on the protein.
3.3.3 Effect of inhibition of the proteasome on c-FLIP reduction by HSV-1
c-FLIP has been shown to have a short half-life time. Turnover occurs mainly via pro-
teasomal degradation [41, 89, 128, 135]. Therefore it was analyzed whether HSV-1 in-
duced downregulation of c-FLIP could be mediated by enhanced proteasomal turnover.
To block the function of the proteasome, the inhibitor MG132 was added to infected
iDCs (HSV-1 strain KOS, MOI 3) either at 1 µM at 5.25 h p. i. or at 10 µM at 7.5 h p. i.
The amount of c-FLIP was determined at 10 h p. i. by immunoblot analysis. Without
addition of MG132, the amount of c-FLIPL (grey column) was decreased to 43 % and
the amount of c-FLIPS (black column) was decreased to 34 % in HSV-1 infected iDCs
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Figure 3.9: Degradation of c-FLIP by lysates derived from HSV-1 infected cells. (A)
A549 cells were transfected using TurboFectTM with a mutated form of c-FLIPL
(F23G/F114G, upper panel) that does not aggregate when overexpressed in cells
[67] or FLIPS-EGFP (lower panel). Lysates were prepared after 48 h and four
aliquots were generated. One aliquot was kept at -20 ◦C until loading on SDS-
PAGE, another aliquot was incubated for 2 h at 37 ◦C and then loaded on SDS-
PAGE. The two remaining aliquots were each mixed with lysates of untransfected
A549 cells, which were infected with HSV-1 (strain KOS, MOI 10, lysed at 18 h p. i.).
The mixed lysates were incubated at 37 ◦C for 2 h in the presence or absence of
proteasome inhibitor MG132 (50 µM) before loading on SDS-PAGE. After blotting
to PVDF-membranes, c-FLIP was detected with anti-FLIP antibody (clone NF-6).
Staining of the blots with antibody against β-actin served as a loading control. (B)
Relative band intensity of c-FLIP bands was determined by densitometry and nor-
malized to β-actin. The value obtained with lysates kept at -20 ◦C was set to 100 %.
(figure 3.8 lane 2) compared to uninfected iDCs (amount of c-FLIPL and c-FLIPS set to
100 %, figure 3.8 lane 1). Inhibition of the proteasome did not prevent HSV-1 induced
reduction of the amount of c-FLIPL or c-FLIPS regardless whether MG132 was added at
1 µM (c-FLIPL, 18 %; c-FLIPS, 17 %; 3.8 lane 4) or at 10 µM (c-FLIPL, 32 %; c-FLIPS, 26 %;
3.8 lane 6).
Interestingly, addition of MG132 to uninfected cells increased the amount of c-FLIPS
(1 µM, 107 %; 10 µM, 150 %; figure 3.8 lanes 3 and 5). This can be explained with the high
turnover of c-FLIPS by the proteasome, which is published to be higher than turnover
of c-FLIPL [135]. So it is expected that c-FLIPS accumulates in the cells when the pro-
teasome is blocked. Intriguingly, c-FLIPL behaves completely different. It is reduced in
uninfected iDCs treated with MG132 compared to untreated iDCs (1 µM, 48 %; 10 µM,
59 %; figure 3.8 lanes 3 and 5). This observation indicates, that turnover of c-FLIPL
might be mediated by a mechanism other than proteasomal degradation, at least in
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iDCs. When the proteasome is blocked in iDCs by addition of MG132, the amount of
c-FLIPL might be decreased because transcription of c-FLIPL mRNA is dependent on
NFκB [93, 111]. Activation of NFκB is mediated by proteasomal degradation of iκB [45].
The results obtained in the experiment presented above indicate that it is unlikely
that the downregulation of c-FLIP observed in HSV-1 infected cells is mediated by en-
hanced proteasomal turnover. Therefore, another experiment was performed to ana-
lyze whether lysates of HSV-1 infected cells contain a factor, which could directly at-
tack c-FLIP. To proof this, A549 cells were transfected with myc-FLIPL (F23G/F114G)
or FLIPS-EGFP and lysed after 48 h. Lysates of these cells showed a high expression
of transfected c-FLIP in immunoblot analysis, regardless whether lysates were kept at
-20 ◦C (amount of myc-FLIPL (F23G/F114G) and c-FLIPS-EGFP set to 100 %, figure 3.9
lane 1) or were incubated at 37 ◦C for 2 h (myc-FLIPL (F23G/F114G), 179 %; c-FLIPS-
EGFP, 82 %; figure 3.9 lane 2). However, when myc-FLIPL (F23G/F114G) or FLIPS-
EGFP containing lysates were mixed with lysates from HSV-1-infected, untransfected
A549 cells and incubated for 2 h at 37 ◦C, the amount of c-FLIPL (66 %, figure 3.9 lane
3) and c-FLIPS-EGFP (15 %, figure 3.9 lane 3) was strongly decreased. Furthermore,
reduction of c-FLIP induced by HSV-1 lysates could not be prevented by addition of
the proteasome inhibitor MG132 (myc-FLIPL (F23G/F114G), 26 %; c-FLIPS-EGFP, 22 %;
figure 3.9 lane 4).
Taken together, the data presented in this section hint to a viral or cellular factor,
which is expressed in HSV-1 infected cells and directly causes c-FLIP degradation in-
dependent from the proteasome.
3.3.4 Amount of c-FLIP after infection of iDCs with replication defective
HSV-1
Next it was investigated in which part of the HSV-1 replication cycle the c-FLIP down-
regulating factor could be expressed. Kinetic data presented in section 3.2 indicate
that c-FLIP is downregulated in the late part of HSV-1 replication (12 h p. i.). How-
ever, Müller et al. [115] showed that HSV-1 induced c-FLIP downregulation is not dis-
turbed if HSV-1 DNA replication and consequently expression of true late viral genes
is blocked using aciclovir. Hence, one or several leaky late HSV-1 genes most likely
mediate c-FLIP degradation.
Based on these considerations, one experiment was performed with a HSV-1 mutant
(∆ICP27 [154]), which is deleted for the essential regulatory immediate early ICP27
protein. ∆ICP27 shows impaired expression of some early and most late genes, while
immediate early genes are expressed properly or are overexpressed [146, 158].
iDCs were infected with ∆ICP27 or wild type HSV-1 strains F or KOS (MOI 1.5). For
control, iDCs were incubated with the respective heat-inactivated or UV-inactivated
virus or were left uninfected. The amount of c-FLIP was analyzed by immunoblot at
18 h p. i.
As expected, the amount of c-FLIPL and c-FLIPS was strongly reduced in iDCs in-
fected with wt HSV-1 strains F or KOS (figure 3.10, lane 3) compared to uninfected
control iDCs (figure 3.10, lane 4). After infection of iDCs with ∆ICP27, the amount of
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Figure 3.10: Immunoblot analysis of c-FLIP in ∆ICP27 infected iDCs. iDCs were infected
with wt HSV-1 (strain F or KOS as indicated) or a ICP27 knockout mutant of HSV-
1 (∆ICP27) at MOI 1.5. For control, iDCs were either left uninfected (co) or were
treated with heat-inactivated (hi-HSV) or UV-inactivated (uv-HSV) virus. 18 h p. i.
cells were lysed and subjected to immunoblot analysis. FLIP was visualized by
staining with anti-FLIP antibody (clone NF6). After stripping, membranes were
stained with anti-β-actin-antibody in order to control for equal protein loading.
Blots are representative of four experiments.
53
3 Results
c-FLIPL and c-FLIPS was also reduced (figure 3.10, lane 5), but to a lesser extent com-
pared to wild type HSV-1 infected iDCs (figure 3.10, lane 3). Heat-inactivated (figure
3.10, lanes 1 and 7) and UV-inactivated (figure 3.10, lanes 2 and 6) did not induce down-
regulation of c-FLIPL or c-FLIPS.
Attenuated downregulation of c-FLIP after infection of iDCs with ∆ICP27 indicates
that one early or leaky late gene of HSV-1, which is expressed to a lower extent in this
HSV-1 mutant, is involved in c-FLIP downregulation. Furthermore, UV-inactivated
HSV-1 was not able to downregulate c-FLIP in iDCs. This shows that c-FLIP downreg-
ulation is dependent on transcription of viral genes, while attachment of virus particles
and release of viral DNA into the cell are not sufficient to induce c-FLIP downregula-
tion.
3.3.5 Immunofluorescence analysis of c-FLIP in HSV-1 infected cells
In order to further elucidate the factor(s), which cause the degradation of c-FLIP in
HSV-1 infected cells, the cellular distribution of c-FLIP was compared in infected and
uninfected cells by fluorescence microscopy. However, the amount of c-FLIP in iDCs
was too low to be detected with this method. Therefore, experiments were performed in
A549 cells transiently transfected with a mutated form of c-FLIPL (F23G/F114G), which
does not form aggregates when overexpressed in cells [67] and is therefore susceptible
to HSV-1 induced downregulation (see section 3.3.2).
In uninfected cells, overexpressed c-FLIPL (F23G/F114G) was evenly distributed (fi-
gure 3.11A). 11 h p. i. with HSV-1 (strain KOS, MOI 10) exposure time for detection of
c-FLIPL had to be approximately twice as long as in uninfected cells in order to get the
same intensity of the signal. That indicated, that degradation of c-FLIPL had already
started. Furthermore, in the majority of cells c-FLIPL appeared to form more or less
dense accumulations (figure 3.11C and 3.11E). These accumulations were round or oval
shaped in cells with a stronger signal and dot-like in cells with a weaker signal. Based
on these data it is conceivable that for degradation, c-FLIPL must accumulate in special
structures of HSV-1 infected cells.
Co-staining of the transfected cells with anti-HSV-1 serum did not reveal viral pro-
teins in the observed c-FLIPL accumulations (figure 3.11D and 3.11F). Due to the fact
that the anti-serum might not detect all viral proteins expressed in HSV-1 infected cells,
this observation does not exclude the possibility that c-FLIP interacts with a viral factor.
3.3.6 Co-transfection of c-FLIP with HSV-1 proteins US3 and gJ
Based on previous publications, there are two viral proteins, which could directly in-
fluence c-FLIP stability: i) HSV-1 protein kinase US3 can phosphorylate procaspase-3
[18]. Therefore, it could be possible that US3 also phosphorylates the caspase-homolog
c-FLIP. Furthermore, the stability of c-FLIP can be regulated by phosphorylation [86].
ii) HSV-1 glycoprotein gJ induces ROS formation [10] and there is evidence that c-FLIP
stability is influenced by ROS [90, 101]. In addition, both US3 and gJ are leaky late
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Figure 3.11: Immunofluorescence analysis of the distribution of c-FLIP in HSV-1 infected
cells. A549 cells were transfected using FuGENE R© 6 with a mutated form of c-
FLIPL (F23G/F114G) that does not aggregate when overexpressed in cells [67].
After 14 h cells were seeded on glass slides. 35 h post transfection half of the slides
were infected with HSV-1 (strain KOS, MOI 10), the remaining slides were left
uninfected (co). 10 µM MG132 was added at 7.5 h p. i. to stop proteasomal degra-
dation of proteins. 11 h p. i. cells were fixed with 3.7 % PFA and stained with anti-
FLIP (clone NF6) followed by anti-mouse-TexasRed (TxR) secondary antibody
and with anti-HSV rabbit serum followed by anti-rabbit-FITC secondary antibody.
Representative analyses out of two experiments are shown (100 x magnification).
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Figure 3.12: Immunofluorescence analysis of c-FLIPL co-transfected with EGFP, US3-EGFP,
or gJ-EGFP. HEK cells were transfected using TurboFectTM with a mutated form
of c-FLIPL (F23G/F114G) that does not aggregate when overexpressed in cells
[67] and pEGFP-N1, US3-EGFP, or gJ-EGFP as indicated. After 30 h cells were
plated on poly-L-Lysin coated glass-slides. 48 h post transfection cells were fixed
with 3.7 % PFA and stained with anti-FLIP (clone NF6) followed by anti-mouse-
TexasRed (TxR) secondary antibody. Representative analyses out of two experi-
ments are shown (60 x magnification).
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HSV-1 genes, which show reduced expression by the ∆ICP27 HSV-1 mutant. There-
fore, in view of the results presented in section 3.3.4, US3 and gJ are good candidates
for a c-FLIP downregulating factor of HSV-1.
In order to investigate whether US3 or gJ could directly downregulate c-FLIP, HEK
cells were co-transfected using TurboFectTM with myc-FLIPL (F23G/F114G) and US3-
EGFP or gJ-EGFP. For comparison, myc-FLIPL (F23G/F114G) was co-transfected with
EGFP. Expression of the transfected proteins was analysed by immunofluorescence.
None of the three co-transfected proteins reduced the amount of c-FLIPL. All three
co-transfections showed a strong c-FLIPL signal also in EGFP-positive cells (figure 3.12).
However, co-localization of US3-EGFP and c-FLIPL was observed. In double-transfec-
ted cells, c-FLIPL accumulated in the same area of the cells where the characteristic dot-
like aggregates were localized, which are formed by US3-EGFP when overexpressed
in HEK cells, see figure 3.12C and 3.12D. Furthermore, these structures were similar
to the aggregates of c-FLIPL observed in HSV-1 infected cells (figure 3.11C,E). In co-
transfections of c-FLIPL with EGFP or gJ-EGFP no such obvious co-localization was
observed, see figures 3.12A,B and 3.12E,F.
Taken together, it was demonstrated here that HSV-1 kinase US3, but not HSV-1 gly-
coprotein gJ, co-localizes with c-FLIP when co-transfected into cells. These data indicate
that US3 might interact with c-FLIP. However, co-transfection of US3 in the absence of
HSV-1 infection was not sufficient to downregulate c-FLIP.
3.3.7 Mechanism of c-FLIP downregulation by HSV-1: Summary
In this thesis the mechanism of HSV-1 induced c-FLIP downregulation was resolved
to a large extent. First it was demonstrated, that the decrease in c-FLIP observed in
HSV-1 infected iDCs is not due to reduced availability of mRNA for translation. It was
furthermore shown that downregulation of c-FLIP after HSV-1 infection is independent
from the proteasome and the ability of c-FLIP to bind to the DISC. Instead, c-FLIP was
degraded directly by factor(s) contained in lysates of HSV-1 infected cells. It was found
that c-FLIP downregulation occurs in the late stage of viral replication and is dependent
on proper expression of early and leaky late HSV-1 genes. Co-localization indicates
that the HSV-1 kinase US3 interacts with c-FLIP. However, in the absence of HSV-1
infection US3 did not downregulate c-FLIP. Therefore, further viral or cellular factors
are required for downregulation of c-FLIP after HSV-1 infection of cells.
3.4 c-FLIP amount and apoptosis after HSV-1 infection of
different cell types
The experiments presented above demonstrate that HSV-1 can not only downregulate
naturally expressed c-FLIP in iDCs, but also c-FLIP which is expressed in cell lines from
a transfected vector. Next it was investigated, whether HSV-1 can also induce down-
regulation of naturally expressed c-FLIP in cells other than iDCs and whether HSV-1
infection induces apoptosis in these cells. The following cells were tested: epithelial
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Figure 3.13: Efficiency of HSV-1 infection in different cell types, determined by staining
against gD. Cells were infected with HSV-1 strain F at MOI 1 (iDCs), MOI 1.5 (fi-
broblasts, keratinocytes), MOI 3 (HUVEC), or MOI 5 (L428, L1236). 18 h p. i. (fi-
broblasts, 16.5 h p. i.) cells were harvested and the number of HSV-1 positive cells
was determined by flow cytometric analysis after staining against the viral gly-
coprotein gD (background staining as determined by staining of uninfected cells
was subtracted). Data are representative of four experiments (iDCs, HUVEC) or
three experiments (primary keratinocytes, L428) or two experiments (primary fi-
broblasts, L1236).
cells (primary keratinocytes), connective tissue cells (primary fibroblasts), endothelial
cells (HUVEC) and hematopoetical cells (Hodgkin/Reed-Sternberg cell lines L428 and
L1236). Cells were infected with HSV-1 strain F at MOI 1 (iDCs), MOI 1.5 (fibroblasts,
keratinocytes), MOI 3 (HUVEC), or MOI 5 (L428, L1236) and after 16.5 or 18 h, efficiency
of infection, amount of c-FLIP, and apoptosis were determined.
Efficiency of infection was assessed by staining of cells with antibody against HSV-
1 glycoprotein gD and subsequent flow cytometry, results are shown in figure 3.13.
All cell types showed high percentages of gD positive cells after infection with HSV-1
(iDCs, 86 %; keratinocytes, 40 %; fibroblasts, 91 %; HUVECs, 89 %; L428, 83 %; L1236,
67 %).
Figure 3.14A shows immunoblot and densitometry analysis of the amount of c-FLIPL
after HSV-1 infection. The amount of c-FLIPL was considerably lower in all tested cell
types compared to uninfected cells, which were set to 100 % (iDCs 31 %, keratinocytes
36 %, fibroblasts 61 %, HUVECs 27 %, L428 30 %, L1236 22 %). No reduction respec-
tively an increase of the amount of c-FLIPL was observed in cells treated with heat-
inactivated virus (iDCs, 116 %; keratinocytes, 94 %; fibroblasts, 91 %; HUVECs, 125 %;
L428, 301 %; L1236, 102 %) or UV-inactivated virus (fibroblasts, 98 %). Most tested cells
(iDCs, primary keratinocytes, HUVEC, L428, L1236) also expressed c-FLIPS, which was
also downregulated after HSV-1 infection (data not shown).
Apoptosis was analyzed by flow cytometry of AnnexinV-FITC and propidium io-
dide (PI) stained cells. Figure 3.14B shows representative dot blots of HSV-1 infected,
58
3.4 c-FLIP amount and apoptosis after HSV-1 infection of different cell types
Figure 3.14: Amount of c-FLIP (A) and extent of apoptosis (B) in different cell types after infection
with HSV-1. Cells were infected with HSV-1 strain F at MOI 1 (iDCs), MOI 1.5 (fibroblasts,
keratinocytes), MOI 3 (HUVEC), or MOI 5 (L428, L1236). As a control, cells were either left
uninfected or were incubated with heat-inactivated (hi-HSV-1) or UV-inactivated (uv-HSV-
1) virus. (A) 18 h p. i. (fibroblasts, 16.5 h p. i.) cells were lysed and subjected to immunoblot
analysis with c-FLIP specific antibody (clone NF-6) and β-actin specific antibody as a load-
ing control. Below the blots, relative band intensity is depicted, as determined by densito-
metry of c-FLIP bands, normalized to β-actin. The value obtained with uninfected cells was
set to 100 %. (B) Before lysis, one aliquot of cells was stained with AnnexinV-FITC/PI and
apoptosis was analyzed by flow cytometry. Numbers in each quadrant indicate percent-
age of cells contained in this quadrant. Data are representative of four experiments (iDCs,
HUVEC) or three experiments (primary keratinocytes, L428) or two experiments (primary
fibroblasts, L1236).
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hi-HSV-1 treated, and uninfected cells. As expected, after HSV-1 infection of iDCs the
number of viable cells (AnnexinV−/ PI−, lower left quadrant) was drastically reduced
(53 % compared to 91 % in uninfected iDCs or iDCs treated with hi-HSV-1). This reduc-
tion was mainly due to an increase in the number of apoptotic (AnnexinV+/PI−, lower
right quadrant) iDCs, from 5 % in uninfected or hi-HSV-1 treated iDCs to 34 % after
HSV-1 infection. The number of necrotic iDCs (AnnexinV−/PI+ and AnnexinV+/PI+,
upper left and upper right quadrant) was only slightly increased (4 % respective 9 % af-
ter HSV-1 infection compared to 1 % respective 3 % in hi-HSV-1 treated and uninfected
iDCs).
Although in primary keratinocytes, one of the main host cells for HSV-1 replication,
c-FLIPL was also downregulated (figure 3.14A, second panel), the number of apop-
totic cells was not increased after HSV-1 infection (5 % compared to 5 % in hi-HSV-1
treated cells and 4 % in uninfected cells, figure 3.14B, second panel). However, there
was a reduction in the number of viable keratinocytes after HSV-1 infection (41 % com-
pared to 68 % in uninfected cells and 57 % in hi-HSV-1 treated cells). This reduction
was due to an increase of necrotic cells. After HSV-1 infection 13 % of keratinocytes
were AnnexinV−/PI+ compared to 5 % in uninfected and 8 % in hi-HSV-1 treated ker-
atinocytes. The number of AnnexinV+/PI+ keratinocytes was 41 % after HSV-1 infec-
tion but only 23 % in uninfected and 30 % in hi-HSV-1 treated cells.
Similar to primary keratinocytes, numbers of apoptotic cells were also not increased
or only slightly increased after infection of other cells (primary fibroblasts, HUVEC,
L428 and L1236). However, there was a certain degree of loss of viable cells due to
necrosis (figure 3.14B). This necrotic death was probably a consequence of high viral
replication causing exhaustion of these cells.
Collectively, these data indicate that downregulation of antiapoptotic c-FLIP is not
sufficient for induction of apoptosis in HSV-1 infected cells and additional events must
occur in iDCs.
3.5 Microarray analysis of HSV-1 gene expression in apoptotic
iDCs and nonapoptotic epithelial cells
Although the antiapoptotic cellular protein c-FLIP was downregulated in all cell types
after HSV-1 infection, apoptosis was only observed in HSV-1 infected iDCs (figure 3.14).
In most cell types powerful antiapoptotic viral factors might counteract induction of
apoptosis caused by c-FLIP downregulation, as was already demonstrated for other
apoptosis inducing events [43, 71, 123]. HSV-1 genes encoding antiapoptotic factors
might not be expressed properly in iDCs resulting in susceptibility of iDCs to apoptosis
induced by c-FLIP downregulation. Therefore, a HSV-1 microarray [158, 177] was used
to globally analyze HSV-1 gene expression in epithelial cells (HeLa and HaCaT), which
do not become apoptotic after HSV-1 infection and in iDCs, which become apoptotic
after infection with HSV-1.
iDCs, HeLa and HaCaT cells were infected with HSV-1 strain KOS at MOI 1.5 or with
heat-inactivated HSV-1 (hi-HSV-1) and at 2-3, 6, 10, and 18 h p. i. aliquots of the infected
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Table 3.1: iDCs, HaCaT or HeLa cells were infected with HSV-1 strain KOS at MOI 1.5 and aliquots
of the cells were taken at 2-3, 6, 10 and 18 h post infection for RNA extraction. At 18 h p. i.,
one additional aliquot was taken for flow cytometry analysis of gD expression and apopto-
sis. The number of gD positive cells was determined by staining with anti-gD monoclonal
antibody and FITC-conjugated secondary antibody. Background staining was determined by
analysis of cells treated with hi-HSV-1 and subtracted. The number of apoptotic cells was
determined by staining with AnnexinV-FITC. Propidium iodide positive cells were excluded.
Background apoptosis was determined by analysis of cells treated with hi-HSV-1 and sub-
tracted. Microarray analysis was performed with samples from three independent infections.
Values are shown for each infection and cell type. For each microarray analysis, RNA of iDCs
from 4 or 5 blood donors was pooled.
cells were subjected to Trizol lysis for RNA preparation. Additionally, at 18 h p. i. cells
were analyzed by flow cytometry for infection efficiency and apoptosis. Microarray
analysis of HSV-1 gene expression in the different cell types was performed three times
with RNA obtained from three independent infections. In order to get enough RNA,
RNA from iDCs of 4 or 5 different donors was pooled for each microarray analysis.
3.5.1 Efficiency of infection and amount of apoptosis in iDCs, HeLa and
HaCaT cells used for microarray analysis
One representative flow cytometry diagram for efficiency of HSV-1 infection (number
of gD+ cells) and apoptosis induction (number of AnnexinV+/PI− cells) is shown for
each cell type in figures 3.15A and 3.15B, respectively. In this experiment, the number of
gD+ cells after HSV-1 infection was 87 % in iDCs, 99 % in HeLa and 93 % in HaCaT (fig-
ure 3.15A). The number of apoptotic (AnnexinV+/PI−, lower right quadrant) cells was
severely increased after HSV-1 infection of iDCs (74.1 % compared to 5.8 % in hi-HSV-1
treated iDCs). In contrast, there was no difference in the number of apoptotic cells be-
tween HSV-1 infected and hi-HSV-1 treated HeLa or HaCaT cells (9.4 % compared to
8.5 % in HeLa, 10.5 % compared to 10.5 % in HaCaT, figure 3.15B).
Infection and apoptosis data from all samples used for microarray analysis are shown
in table 3.1. Efficiency of infection was generally high, ranging for HeLa and HaCaT
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Figure 3.15: Representative flow cytometry diagrams of the percentage of HSV-1 infected and apop-
totic iDCs, HeLa or HaCaT cells used for microarray analysis. (A, B) Cells were infected
with wild type HSV-1 (strain KOS, MOI 1.5, open curve) or heat-inactivated virus (hi-HSV-
1, filled curve). Infection (A) and apoptosis (B) were analyzed 18 h p. i. by flow cytom-
etry after staining of cells with gD/FITC, respectively AnnexinV-FITC/PI. (C) Cells were
infected with an apoptosis inducing HSV-1 mutant (∆ICP27, MOI 1.5) or left uninfected.
Apoptosis was analyzed at 18 h p. i. One representative experiment out of three is shown.
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cells between 90 % and 97 % and for iDCs between 39 % and 91 %. While iDCs showed
a pronounced increase in apoptotic cells after HSV-1 infection (ranging between 30 %
and 71 %), no increase in the number of apoptotic cells was observed after infection
of HeLa or HaCaT cells (ranging between -2 % and 2 %). Taken together, iDCs did
undergo apoptosis after HSV-1 infection, while epithelial cells (HeLa and HaCaT) were
resistent to HSV-1 induced apoptosis. These results are in accordance with observations
presented earlier in this thesis (section 3.4) and data published in the literature [8, 9, 43,
116].
In order to demonstrate that HeLa and HaCaT cells used in these experiments are
in principle susceptible to HSV-1 induced apoptosis, cells were infected with the HSV-
1 mutant ∆ICP27 in a separate experiment. As published by others, infection with
∆ICP27 induces apoptosis in most cell types [7, 8], because antiapoptotic HSV-1 genes
are not sufficiently expressed in this mutant. iDCs, HeLa and HaCaT were infected
with the apoptosis-inducing HSV-1 mutant ∆ICP27 at MOI 1.5 or left uninfected and
18 h p. i. stained with AnnexinV-FITC/PI. As shown in figure 3.15C, not only the num-
ber of apoptotic (AnnexinV+/PI−) iDCs, but also the number of apoptotic HeLa and
HaCaT cells was drastically increased after infection with ∆ICP27 compared to unin-
fected cells (iDCs, 45.8 % compared to 7.4 %; HeLa, 35.1 % compared to 1.7 %; HaCaT,
45.5 % compared to 2.7 %). These data indicate, that HSV-1 infection can result in apop-
tosis also in HeLa and HaCaT cells, if antiapoptotic HSV-1 genes are not expressed
properly, as is the case for the HSV-1 mutant ∆ICP27.
3.5.2 Pattern of HSV-1 gene expression in iDCs, HeLa and HaCaT cells
Relative abundance of HSV-1 transcripts obtained by microarray analysis of infected
iDCs, HeLa and HaCaT are shown in tables 1, 2, 3, and 4.
The first line of the tables shows the median ± SD of the total viral signal (sum
of hybridization values of all probes, corresponds to the accumulation of total HSV-
1 transcripts) for each time point and cell type. Median maximum numbers of total
viral transcripts reached in the three cell types were comparable: iDCs 640253± 123599
(18 h p. i.), HaCaT 618127± 293075 (18 h p. i.), HeLa 561168± 166110 (10 h p. i.). How-
ever, there were some differences in the time course of accumulation of transcripts.
While in HaCaT cells the total viral signal increased continuously from 3 to 18 h p. i.,
in HeLa cells it reached its maximum already at 10 h p. i. and declined thereafter. In
iDCs, the total viral signal reached a first maximum at 6 h p. i., was lower at 10 h p. i.
and showed the highest value at 18 h p. i. Therefore, the total viral signal was signifi-
cantly higher in iDCs compared to HeLa cells at 18 h p. i. (640253± 123599 compared
to 359646± 54179, P = 0.0428).
In order to allow a fast and convenient overview of differences in the expression of
HSV-1 genes between iDCs and HeLa or HaCaT, the log10 of the ratio iDCs/HaCaT or
iDCs/HeLa of relative transcript abundances listed in tables 1, 2, 3 and 4 was calculated
and is depicted in figures 3.16, 3.17, 3.18 and 3.19.
The data obtained by microarray analysis showed that the timing and extent of tran-
scription of HSV-1 genes was very similar in iDCs, HeLa and HaCaT. There were only
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Figure 3.16: Differential expression of HSV-1 genes in iDCs compared to HaCaT (upper panel) or
HeLa (lower panel) at 3 h p. i. Total RNA was extracted at 3 h p. i. with HSV-1 strain KOS
(MOI 1.5) and subjected to HSV-1 microarray analysis. The median relative abundance
of each HSV-1 transcript in iDCs was divided by the median relative abundance of the
corresponding transcript in HaCaT or HeLa (median relative abundances are listed in table
1). Log10 values of the obtained ratios are shown. A log10 of 0.3 corresponds to a 2-fold
difference in relative abundance. Probes are depicted in the order of the respective genes
on the HSV-1 genome. Significant differences (with P≤ 0.05) are marked with an asterisk.
For some probes, a signal was detected only with RNA from one cell type, while the other
cell type showed no signal. Therefore, no ratio could be calculated. This is indicated by
hatched columns.
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Figure 3.17: Differential expression of HSV-1 genes in iDCs compared to HaCaT (upper panel) or
HeLa (lower panel) at 6 h p. i. Total RNA was extracted at 6 h p. i. with HSV-1 strain KOS
(MOI 1.5) and subjected to HSV-1 microarray analysis. The median relative abundance
of each HSV-1 transcript in iDCs was divided by the median relative abundance of the
corresponding transcript in HaCaT or HeLa (median relative abundances are listed in table
2). Log10 values of the obtained ratios are shown. A log10 of 0.3 corresponds to a 2-fold
difference in relative abundance. Probes are depicted in the order of the respective genes
on the HSV-1 genome. Significant differences (with P≤ 0.05) are marked with an asterisk.
For some probes, a signal was detected only with RNA from one cell type, while the other
cell type showed no signal. Therefore, no ratio could be calculated. This is indicated by
hatched columns.
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Figure 3.18: Differential expression of HSV-1 genes in iDCs compared to HaCaT (upper panel) or
HeLa (lower panel) at 10 h p. i. Total RNA was extracted at 10 h p. i. with HSV-1 strain KOS
(MOI 1.5) and subjected to HSV-1 microarray analysis. The median relative abundance
of each HSV-1 transcript in iDCs was divided by the median relative abundance of the
corresponding transcript in HaCaT or HeLa (median relative abundances are listed in table
3). Log10 values of the obtained ratios are shown. A log10 of 0.3 corresponds to a 2-fold
difference in relative abundance. Probes are depicted in the order of the respective genes
on the HSV-1 genome. Significant differences (with P≤ 0.05) are marked with an asterisk.
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Figure 3.19: Differential expression of HSV-1 genes in iDCs compared to HaCaT (upper panel) or
HeLa (lower panel) at 18 h p. i. Total RNA was extracted at 18 h p. i. with HSV-1 strain KOS
(MOI 1.5) and subjected to HSV-1 microarray analysis. The median relative abundance
of each HSV-1 transcript in iDCs was divided by the median relative abundance of the
corresponding transcript in HaCaT or HeLa (median relative abundances are listed in table
4). Log10 values of the obtained ratios are shown. A log10 of 0.3 corresponds to a 2-fold
difference in relative abundance. Probes are depicted in the order of the respective genes
on the HSV-1 genome. Significant differences (with P≤ 0.05) are marked with an asterisk.
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a few significant differences between iDCs and HeLa or HaCaT, which were more than
two-fold (log10 ratio > 0.3). At 6 h p. i. (figure 3.17), some late genes showed signifi-
cantly higher abundances in iDCs compared to HeLa: UL22 (log10 ratio 0.56, P = 0.0282),
UL24 (log10 ratio 0.51, P = 0.0079), UL36 (log10 ratio 0.73, P = 0.0001), UL38 (log10 ratio
0.8, P = 0.0243), UL41 (log10 ratio 0.69, P = 0.0191), UL51 (log10 ratio 0.45, P = 0.0162), US2
(log10 ratio 0.58, P = 0.0085), US3/4 (log10 ratio 0.39, P = 0.0125), and RLXY (log10 ratio
1.55, P = 0.0317). Several of these genes were also more than two-fold higher expressed
in iDCs compared to HaCaT, although these differences were not significant: UL22
(log10 ratio 0.54, P = 0.2655), UL24 (log10 ratio 0.43, P = 0.4471), UL36 (log10 ratio 0.65,
P = 0.1627), US3/4 (log10 ratio 0.46, P = 0.0924), and RLXY (log10 ratio 0.5, P = 0.2259).
This indicates a faster progression of the viral transcription cascade in iDCs at early
time points, as already indicated by the high total viral signal at 6 h p. i. (see above).
This could be linked with the observed higher expression of some genes involved in
nucleotide metabolism in iDCs compared to HeLa at 3 h p. i. (figure 3.16): UL39/40 (no
signal in HeLa, relative abundance 6.4 %± 0.38 % in iDCs, P = 0.0266), UL50 (log10 ra-
tio 1.89, P = 0.0034). Intriguingly, at later time points (10 and 18 h p. i., figures 3.18 and
3.19) the only significant difference between iDCs and HeLa or HaCaT was the much
lower abundance of LATs (described in more detail in section 3.5.3). Importantly, the
abundance of the proapoptotic HSV-1 transcript α0 was not significantly different in
the three cell types at any time point (figures 3.16, 3.17, 3.18, and 3.19).
3.5.3 Expression of apoptosis-relevant genes in iDCs, HeLa and HaCaT cells
Microarray analysis was performed in order to investigate whether antiapoptotic HSV-
1 genes (UL54, α4, US1, US3, US5, US6, US11 and LAT [70, 123]) are differentially ex-
pressed in iDCs. The time course of their relative abundance is depicted in detail in
figures 3.20 and 3.21. The data revealed, that the expression pattern of UL54 (ICP27),
α4 (ICP4), US1 (ICP22), US10/11/12, US3/4 (Kinase/gG) and US5/6/7 (gJ/gD/gI) in
the three cell types was quite similar. However, US3/4 had a significantly higher rel-
ative abundance in iDCs compared to HeLa at 6 h p. i. (1.59 %± 0.06 % compared to
0.64 %± 0.09 %, P = 0.0125).
Unfortunately, it can not finally be concluded, that US3 is higher expressed in iDCs
at 6 h p. i., because an unknown proportion of the detected signal originates from the
US4 transcript. The HSV-1 genome contains only 52 polyadenylation sites, but encodes
more than 80 open reading frames. Only approximately half of the viral transcripts are
terminated with a unique polyadenylation site, the remaining HSV-1 genes belong to
coterminal transcript families. Probes of the microarray are designed to bind immedi-
ately adjacent to the polyadenylation sites of transcripts, therefore it is not possible to
discriminate between transcripts which belong to a coterminal transcript family. For
the same reason, it is still possible that US6 is differentially expressed in iDCs com-
pared to HeLa or HaCaT, although there was no significant difference in the signal of
the US5/6/7 probe (figure 3.20). Expression of the antiapoptotic late gene US11 can
only be detected with the microarray probe US10/11/12, and as shown in figure 3.20,
the signal of this probe is dominated throughout the course of infection by the detec-
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Figure 3.20: Time course of expression of known apoptosis modulating HSV-1 genes in
iDCs in comparison to HaCaT or HeLa cells. The median relative abundance
detected with the HSV-1 microarray for each gene or coterminal transcript family
at different time points is shown as percentage of total HSV-1 transcripts (based
on data in tables 1-4). Significant differences (with P≤ 0.05) in relative abundance
of transcripts in iDCs compared to HeLa are marked with an asterisk.
tion of the immediate early transcript US12, which shares the polyadenylation site with
US11 and US10.
Interestingly, LATs showed a significantly different expression pattern in iDCs com-
pared to HeLa or HaCaT (figure 3.21). Five different LATs can be discriminated with
probes on the microarray (LAT5C, LATI, RH6, LATX and LAT3, see figure 2.1 for lo-
cation of LAT probes on the HSV-1 genome). In the epithelial HeLa and HaCaT cells,
the abundance of latency associated transcripts increased strongly in an exponential
manner between 6 and 10 h p. i. and either further increased until 18 h p. i. (LATI and
RH6) or remained at the level detected at 10 h p. i. (LAT5C, LATX, and LAT3). In con-
trast, expression of LATs in iDCs showed only a moderate linear increase in abundance
between 6 and 18 h p. i. As a result of this difference in the course of expression, rela-
tive abundances of LATs in iDCs were much lower than in HaCaT or HeLa at 10 and
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Figure 3.21: Time course of expression of LATs in iDCs in comparison to HaCaT or HeLa
cells. The median relative abundance detected with the HSV-1 microarray for
LATs at different time points is shown as percentage of total HSV-1 transcripts
(based on data in tables 1-4). Significant differences (with P≤ 0.05) in relative
abundance of transcripts in iDCs compared to HeLa are marked with an asterisk
and compared to HaCaT with a number sign.
18 h p. i. As can be seen in figure 3.18, at 10 h p. i. LATs were 2.3 fold (log10 ratio -0.37,
LAT3) to 6 fold (log10 ratio -0.81, LAT5C) lower abundant in iDCs compared to HeLa
and 1.4 fold (log10 ratio -0.16, LAT3) to 7.9 fold (log10 ratio -0.89, RH6) lower abundant
compared to HaCaT. Differences reached statistical significance for LAT3 (log10 ratio
-0.37, P = 0.0107) and LATX (log10 ratio -0.48, P = 0.0098) at 10 h p. i. in iDCs compared
to HeLa and for LATI (log10 ratio -0.46, P = 0.0187) at 18 h p. i. compared to HaCaT.
Taken together, global analysis of HSV-1 gene expression in iDCs compared to epithe-
lial cells (HeLa and HaCaT) revealed no significant differences in expression of most
known apoptosis modulating viral genes. However, at late time points post infection
with HSV-1, the expression of LATs was significantly lower in iDCs compared to ep-
ithelial cells.
A role for LATs in protection against HSV-1 induced apoptosis was not only pub-
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lished for latently infected neurons [2, 65, 74, 131], but also for lytically infected cells
[2, 75]. Therefore, it is conceivable that the higher susceptibility of iDCs for HSV-1 in-
duced apoptosis could be due to the lower expression of LATs.
3.6 LAT expression and apoptosis of HSV-1 infected iDCs
Next, the impact of LAT expression on HSV-1 induced apoptosis of iDCs was further
investigated. As determined by microarray analysis (see section 3.5.3), there was a
residual expression of LATs in iDCs after infection with wild type HSV-1. If LAT is
further reduced, for example after infection with a LAT knockout mutant of HSV-1, the
amount of apoptosis would be expected to be higher compared to wild type HSV-1.
To proof this, iDCs isolated from five different blood donors (D1-D5) were infected
with the LAT knockout HSV-1 mutant 17N/H (∆LAT) [22] or the respective wild type
HSV-1 strain 17. LPS was added to some cells immediately after infection, because it
has been shown that LPS triggers signaling pathways in DCs, which are involved in
regulation of survival [4, 140]. Apoptosis was analyzed at 18 h p. i. by staining of iDCs
with AnnexinV-FITC/PI and subsequent flow cytometry.
In four (D1, D2, D4 and D5) out of five donors, ∆LAT induced more apoptosis in
iDCs than wild type HSV-1. Figure 3.22A shows flow cytometry diagrams obtained
from donor D5. The number of apoptotic iDCs (AnnexinV+/PI−, lower right quad-
rant), which increased from 4 % after treatment with hi-HSV-1 to 31 % after infection
with wild type HSV-1, was further increased to 42 % after infection with ∆LAT. After
additional treatment with LPS, 33 % of wild type HSV-1 infected iDCs were apoptotic,
but 50 % of ∆LAT infected iDCs. Similar results were obtained after infection of iDCs
from all other tested donors (figure 3.22B), except D3, which showed no difference in
the number of apoptotic iDCs after infection with ∆LAT (23 %) compared to infection
with wild type HSV-1 (23 %). However, when iDCs from donor D3 were treated with
LPS after infection, there were more apoptotic iDCs after ∆LAT infection (30 %) com-
pared to infection with wild type HSV-1 (24 %). Increased apoptosis can not be ex-
plained by differences in infection efficiency, as flow cytometry analysis of the viral
glycoprotein gD on the surface of infected iDCs revealed no difference in the number
of infected cells after ∆LAT infection compared to wt HSV-1 (figure 3.22C).
In order to proof whether the knockout in ∆LAT is complete, one aliquot of infected
iDCs was lysed after 18 h and subjected to quantitative real time PCR of LAT expression
(see figure 2.1 for location of probes in the LAT region). ∆LAT infected iDCs showed no
signal for primer pairs LAT-A and LAT-B, as expected (figure 3.23A). However, there
was a signal with probe LAT-C in ∆LAT infected iDCs, which was comparable to the
signal obtained with extracts from HSV-1 wild type infected iDCs. Probe LAT-C detects
aberrant LAT sequences, which are known to be expressed downstream of the deletion
in ∆LAT [22]. However, these sequences are located in a region not associated with the
antiapoptotic function of LAT [22, 24].
The higher number of apoptotic iDCs after infection with ∆LAT compared to in-
fection with wild type virus could also be caused by differences in the expression of
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Figure 3.22: Apoptosis in iDCs infected with a HSV-1 LAT deletion mutant. iDCs from five
different blood donors (D1-D5) were infected with either HSV-1 wild type (wt,
strain 17) or a LAT deletion mutant (∆LAT, 17N/H) at MOI 1.5 or treated with
a mix of heat-inactivated wt and mutant virus (hi-HSV-1). LPS (1 µg/ml) was
added immediately after infection to some cells as indicated. 18 h p. i. apoptosis
was analyzed by flow cytometry after staining of iDCs with AnnexinV-FITC and
propidium iodide (PI). (A) Flow cytometry diagrams of one representative donor
(D5) are shown. Numbers in each quadrant indicate percentage of cells contained
in this quadrant. (B) The number of apoptotic iDCs (AnnexinV+/PI−) is depicted
for all tested donors. (C) The number of infected cells was determined by staining
with anti-gD antibody (stains HSV-1 glycoprotein gD on surface of infected cells)
and subsequent flow cytometry. Unspecific background staining as determined
by staining of uninfected cells was subtracted.
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Figure 3.23: Quantitative RT-PCR of expression of LAT (A) and other antiapoptotic virus
genes (B) in iDCs infected with a HSV-1 LAT deletion mutant. iDCs from five
different blood donors (D1-D5) were infected with either HSV-1 wild type (wt,
strain 17) or a LAT deletion mutant (∆LAT, 17N/H) at MOI 1.5. At 18 h p. i., cells
were lysed and subjected to quantitative RT-PCR analysis. (A) Mean values ± SD
of relative copy numbers obtained with three different probes for LAT (LAT-A,
LAT-B, LAT-C; see figure 2.1 for location in the LAT region) are shown. (B) Mean
values ± SD of relative copy numbers of six antiapoptotic HSV-1 genes (US3, pro-
tein kinase; US5, gJ; US6, gD; UL54, ICP27; US1, ICP22; US11, tegument protein)
and for comparison one not apoptosis modulating virus gene (UL10, gM) were
determined.
other apoptosis-regulating HSV-1 genes. Quantitative RT-PCR (figure 3.23B) revealed
a slight, but not significant higher expression of some antiapoptotic HSV-1 genes (US3,
US6, US1, US11) in lysates of ∆LAT infected iDCs, compared to wild type HSV-1 in-
fected iDCs. This was also seen with a probe for one HSV-1 gene not associated with
apoptosis (UL10). There were no differences in the expression of US5, while UL54 was
slightly lower expressed in ∆LAT infected iDCs compared to wild type HSV-1 infected
iDCs. Based on these results it can be assumed that the higher ability of ∆LAT to induce
apoptosis in iDCs compared to wild type HSV-1 is due to the knockout of LAT and not
due to reduced expression of other antiapoptotic HSV-1 genes.
Taken together, the absence of LAT expression in HSV-1 infected iDCs resulted in
increased apoptosis. Therefore, it can be concluded that LAT has a antiapoptotic func-
tion in iDCs. It is conceivable that the antiapoptotic function of LAT can compensate
the downregulation of c-FLIP at late time points post infection with HSV-1. Epithelial
cells which express high amounts of LATs are protected against apoptosis. In contrast,
iDCs express only low amounts of LATs. Therefore, the loss of c-FLIP is not efficiently
counter regulated in iDCs and apoptosis can occur. Consequently, the data presented
in this thesis indicate that LAT has an important antiapoptotic role not only in latently
infected neurons, but also in lytic infection of cells.
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HSV-1 can productively infect iDCs [114, 133], but yield of virus progeny is low. After
HSV-1 infection, maturation of iDCs is blocked [133, 143] and a high number of iDCs
undergo apoptosis [23, 115, 133]. Because iDCs play a central role in the induction of the
antiviral immune response [23, 132, 156], the impairment of their function and viability
might be one strategy of HSV-1 to modulate the immune response to its advantage.
The mechanisms underlying induction of apoptosis in iDCs by HSV-1 are still a co-
nundrum, in view of the fact that HSV-1 possesses several strong antiapoptotic factors
[43, 123]. In many cell types, such as epithelial cells, antiapoptotic factors dominate and
the cells are kept alive until replication of HSV-1 is successfully completed [8, 9, 43].
Müller et al. [115] showed that the amount of two proteins of the cellular apoptosis
signaling network, p53 and c-FLIPL, is changed after HSV-1 infection of iDCs. How-
ever, the mechanism and relevance of these changes was not investigated. Therefore,
the mechanism of c-FLIP downregulation after HSV-1 infection of iDCs was studied
in detail in the first part of this thesis. Furthermore it was investigated here, whether
c-FLIP downregulation could be sufficient for induction of apoptosis in HSV-1 infected
iDCs.
Insufficient availability of viral antiapoptotic factors could also contribute to induc-
tion of apoptosis in HSV-1 infected iDCs. This hypothesis was not investigated up to
now. In the second part of this thesis it was therefore examined, whether antiapoptotic
factors of HSV-1 are properly expressed in infected iDCs.
4.1 Correlation between amount of c-FLIP and iDC viability
After infection of iDCs with HSV-1 a strong downregulation of the cellular antiapop-
totic protein c-FLIPL was observed by Müller et al. [115]. This result was confirmed by
experiments conducted in this thesis. 18 h p. i. with HSV-1, the amount of c-FLIPL was
reduced to 25 % of the amount expressed in uninfected iDCs (figure 3.14A, first panel).
In addition, c-FLIPS was also efficiently downregulated after HSV-1 infection of iDCs
(figures 3.8 and 3.10).
Müller et al. [115] suggested, that the observed reduction of the amount of c-FLIP
could be the direct cause for induction of apoptosis in iDCs after HSV-1 infection. This
conclusion is well founded, because a large number of publications have established
a direct correlation of the amount of c-FLIP with resistance of cells to death receptor
induced apoptosis [66, 96, 148, 169]. In particular, mathematical modeling revealed the
amount of c-FLIP as the main switch for the decision of life and death in the extrinsic
pathway of apoptosis induction [19, 55].
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In iDCs, a publication by Willems et al. [179] provided the first indication for a corre-
lation of the amount of c-FLIPL with resistance to CD95-mediated apoptosis. However,
the amount of c-FLIP was reduced by treatment of iDCs with the substances cyclo-
heximide and bisindolylmaleimide. Cycloheximide blocks protein synthesis [37] and
bisindolylmaleimide is an inhibitor of protein kinase C [167]. Therefore, many other
effects could contribute to apoptosis of iDCs after treatment with these substances.
In this thesis, c-FLIP in iDCs was for the first time specifically knocked down by RNA
interference, thereby avoiding side effects of chemical inhibitors. Furthermore, this
approach allows assessment of the impact of c-FLIP reduction on viability of iDCs in
the absence of viral factors, which could modulate apoptosis. c-FLIP was already suc-
cessfully reduced by RNA interference in fibroblast, epidermal, and Hodgkin/Reed-
Sternberg cell lines, resulting in increased susceptibility to induction of apoptosis [109,
153].
The amount of both c-FLIPL and c-FLIPS was successfully reduced in iDCs nucleo-
fected with siRNA specifically targeting c-FLIP (figure 3.1A and data not shown). In-
terestingly, this was sufficient to dramatically reduce the number of viable iDCs (An-
nexinV−/ PI−) in comparison to iDCs nucleofected with control siRNA (from 85 % to
20 %, figure 3.1B). After addition of a CD95 (Fas) agonistic antibody, the number of
viable iDCs was reduced to 1 %. Presumably, in a large percentage of iDCs the caspase-
8-mediated apoptosis pathway is pre-activated independent from binding of a ligand,
as it was published for breast cancer cells [31]. c-FLIP must be expressed in a sufficient
amount in these cells in order to block constitutive death signaling and keep the cells
alive. c-FLIP specific RNA interference neutralizes this block and apoptosis-inducing
signals are transduced into the cell. These findings are in agreement with data pre-
sented in the publication by Müller et al. [115]. Prevention of binding of the three main
death ligands CD95 (Fas) ligand, TRAIL and TNF-α to their receptors could reduce
apoptosis after HSV-1 infection of iDCs only in some donors and only partially. Be-
cause apoptosis signaling downstream of death receptors is blocked by high amounts
of c-FLIP in DCs, activation of these receptors can result in survival, maturation and
cytokine release rather than apoptosis, as recently shown for CD95 [53, 54, 141].
The reduction in viability of iDCs after siRNA mediated knockdown of c-FLIP was in
part due to an increase in apoptotic cells (AnnexinV+/PI−) compared to control siRNA
nucleofected iDCs (16 % compared to 2 % ). However, the majority of non-viable iDCs
was AnnexinV+/PI+ (61 %). Because analysis of viability was done as late as 3-6 days
after nucleofection, it is likely that this population represents cells in the late stage of
apoptosis [155].
This is the first time that c-FLIP was specifically reduced in iDCs by RNA interference
and the results indicate that c-FLIP is essential for viability of iDCs. This supports the
hypothesis that HSV-1 induced c-FLIP downregulation could contribute to induction
of apoptosis in iDCs.
76
4.2 c-FLIP reduction in HSV-1 infected iDCs before onset of apoptosis
4.2 c-FLIP reduction in HSV-1 infected iDCs before onset of
apoptosis
In HSV-1 infected iDCs, a reduction of the amount of c-FLIP was not found before
12 h p. i. at MOI 1.5 (figure 3.2). At this time point it was reduced below 50 % of the
amount detected in iDCs treated with heat-inactivated HSV-1. At later time points
(18 h p. i.) a reduction to 25 % was found (figure 3.14). The time course of HSV-1 in-
duced c-FLIP reduction in iDCs was dependent on the MOI used for infection. At
MOI 3 a reduction of the amount of c-FLIP to 40 % was already detectable at 10 h p. i.
(figure 3.8). Different HSV-1 strains (F, KOS, 17 and Patton) used in the experiments
all showed a comparable extent of c-FLIP reduction in iDCs. Notably, reduction of c-
FLIP preceded the occurence of apoptosis after infection of iDCs with HSV-1, as the
number of apoptotic iDCs started to increase significantly at 14 h p. i. (figure 3.3). Col-
lectively, these data provide another indication, that reduction of c-FLIP might directly
contribute to apoptosis observed in HSV-1 infected iDCs.
Interestingly, reduction of c-FLIP and apoptosis in iDCs occurred at later stages of
the HSV-1 replication cycle than the pro- and antiapoptotic events described by other
researchers in other cell types. The first proapoptotic event after HSV-1 infection of
cells is the expression of the immediate early gene α0, which occurs before 3 h p. i.
[25, 145, 147]. Between 3 h and 6 h post infection (apoptosis prevention window), anti-
apoptotic HSV-1 genes are expressed and prevent execution of apoptosis [8, 92]. There-
fore, HSV-1 induced downregulation of c-FLIP in iDCs at 12 h p. i. appears to be a
second, independent proapoptotic event.
4.3 Degradation of c-FLIP by viral or virus-induced cellular
factor(s)
The results of the experiments discussed above strongly indicate that downregulation
of c-FLIP is a crucial event for induction of apoptosis in HSV-1 infected iDCs. There-
fore, several experiments were conducted to elucidate the mechanism of HSV-1 induced
downregulation of c-FLIP.
Quantitative RT-PCR revealed that after HSV-1 infection of iDCs the number of c-
FLIPL mRNA transcripts was significantly increased (figure 3.4), despite c-FLIPL down-
regulation on the protein level. This observation is consistent with data presented by
Müller et al. [115] and can be explained by induction of maturation processes in iDCs
after HSV-1 infection. Although complete maturation of iDCs is prevented after in-
fection with HSV-1, a partial maturation is still induced [134, 133, 143]. This partial
maturation is sufficient to activate NFκB [134], which is known to increase the expres-
sion of c-FLIPL [93, 111]. In line with this notion, the amount of c-FLIPL mRNA was also
increased after treatment of iDCs with LPS or UV-inactivated HSV-1 (figure 3.4), both
of which induce maturation of iDCs [51]. However, after infection of iDCs with viable
HSV-1, c-FLIPL mRNA transcripts showed a tendency to accumulate in the nucleus,
compared to iDCs treated with UV-inactivated HSV-1. This might be due to the abil-
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ity of HSV-1 to inhibit splicing of mRNA precursors, which prevents maturation and
nuclear export of many cellular mRNAs [56, 57]. Importantly, the amount of c-FLIPL
mRNA detected in the cytoplasm of HSV-1 infected iDCs was not decreased but rather
moderately increased compared to uninfected cells (figure 3.4). Because probes used in
quantitative RT-PCR are located in the middle of the c-FLIPL transcript, it is very likely
that the transcripts detected in the cytoplasm are intact and suitable for translation.
Based on these observations it can be concluded that HSV-1 does not downregulate c-
FLIP by impairment of c-FLIP mRNA transcription, transport or stability. This result
indicates that HSV-1 downregulates c-FLIP directly on the protein level.
Studies on the mechanism of HSV-1 induced c-FLIP downregulation on the protein
level could be conducted much more easily in cell lines overexpressing c-FLIP. iDCs
are primary cells, which must be freshly prepared in a time consuming and expensive
procedure and yield only low amounts of protein for immunoblot analysis. Further-
more, cell lines could be transfected with tagged or mutated forms of c-FLIP. Therefore,
c-FLIP was overexpressed in HEp2 cells from a eucaryotic vector and tested for its sus-
ceptibility to HSV-1 induced downregulation. The first experiments were carried out
with EGFP-tagged c-FLIP and the amount was analyzed by flow cytometry, which is
less time consuming and allows more direct quantification than immunoblot analysis.
Surprisingly, neither c-FLIPL-EGFP nor c-FLIPS-EGFP were downregulated after HSV-
1 infection of transfected HEp2 cells (figure 3.5). There could be several reasons for this
result: i) The mechanism of HSV-1 induced c-FLIP downregulation is operative only in
iDCs, but not in HEp2 cells. ii) The EGFP tag protects c-FLIP against degradation by
HSV-1. ii) The amount of c-FLIP in transiently transfected cells exceeds the capacity of
the HSV-1 induced degradation mechanism.
In order to elucidate the reason why HSV-1 can downregulate naturally expressed
c-FLIP in iDCs, but not overexpressed c-FLIP-EGFP in HEp2 cells, it would be help-
ful to perform immunoblot analysis of untagged c-FLIP or c-FLIP with a smaller tag.
However, the effect of HSV-1 on c-FLIP would not be visible in immunoblot analysis if
only one third of the transfected cells are infected, as was the case in the experiments
described above (figure 3.5). Therefore, an optimization of transfection and infection
had to be performed.
To increase infectibility of transfected cells, different transfection reagents were eval-
uated. Transfection with LipofectamineTM 2000 (data not shown) did not yield better
results compared to transfection with ExGen 500. However, when FuGENE R© 6 was
used, almost all transfected cells could be infected with HSV-1 (figure 3.6A). Probably
these results can be explained by different mechanisms used by different transfection
reagents to transport plasmid DNA into cells. All three tested transfection reagents are
non-liposomal. It is published that both ExGen 500 and LipofectamineTM 2000 use the
endocytosis pathway and destabilize endosomes [46, 106]. Maybe this impairs entry
of HSV-1 into the cell, although endocytosis does not seem to play an important role
in entry of HSV-1 [44]. Unfortunately, the mechanism of DNA transfer into cells by
FuGENE R© 6 is not known. In order to further increase the efficiency of transfection and
infection, different cell types and MOIs were tested. The best results were achieved
with A549 cells, transfected with FuGENE R© 6 and infected with HSV-1 at MOI 10 or
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higher (figure 3.6B,C).
Immunoblot analysis of myc-tagged c-FLIP after infection of transfected A549 cells
with HSV-1 (strain KOS, MOI 50) confirmed the resistance of c-FLIPL to downregulation
by HSV-1, while c-FLIPS was partially downregulated (figure 3.7). This result excludes
the possibility that the EGFP-tag is responsible for the resistance of overexpressed c-
FLIP to downregulation by HSV-1. The position of the tag is not critical, as the EGFP-
tag was located on the C-terminus of c-FLIP, while the myc-tag was located on the
N-terminus. When transfected cells were analyzed under a microscope, the c-FLIPL-
EGFP signal was not evenly distributed in the cells, as observed after transfection with
EGFP alone, but was rather aggregated in dot like structures (data not shown). This
was also observed by Ishioka et al. [67]. In this publication it was demonstrated that
overexpressed c-FLIPL forms insoluble aggregates, which are resistant to proteasomal
turnover and block the function of the proteasome in general. This aggregation is me-
diated by the DEDs contained in the c-FLIP molecule. Mutants of c-FLIPL constructed
by Ishioka et al., which lacked the DED part of the molecule or had mutated DEDs were
distributed diffusely in the cells and did no longer block the proteasome. The tendency
of c-FLIPL to form aggregates when overexpressed in cells could also confer resistance
to downregulation by HSV-1. Therefore, c-FLIPL mutants generated by Ishioka et al.
were transfected in A549 cells and analyzed by immunoblot after infection of the cells
with HSV-1.
Indeed, c-FLIPL with mutated or lacking DEDs (F23G/F114G and 203-480) was ef-
ficiently downregulated after infection with HSV-1 (figure 3.7). In contrast, a mutant
with intact DEDs but with a mutation in the caspase cleavage site (D376A) was resis-
tant to HSV-1 induced degradation. Interestingly, a mutant with intact DEDs, but with
a truncated C-terminus (1-438) was also susceptible to HSV-1 induced degradation. Ac-
cording to the publication by Ishioka et al. [67], this mutant still forms aggregates, but
they are not as dense as the aggregates formed by wild type c-FLIPL and they are dis-
tributed throughout the cell instead of being condensed in the perinuclear region. A
c-FLIPL mutant (1-202) which consists of both DEDs but lacks the complete caspase-
like domain is completely resistant to HSV-1 mediated downregulation. Interestingly,
c-FLIPL 1-202 has the same molecular structure as c-FLIPS, except that c-FLIPS has a
short unique C-terminus in addition. c-FLIPS is partially downregulated after HSV-1
infection. To summarize these findings, mutation or removal of the DEDs as well as
modifications of the C-terminus restore the susceptibility of overexpressed c-FLIP to
HSV-1 induced downregulation. This seems to be linked to the density of aggregates
formed by c-FLIP mutants after overexpression in cells.
Importantly, susceptibility to HSV-1 induced reduction was not correlated with the
ability of c-FLIP mutants to block the function of the proteasome. Ishioka et al. found
that wild type c-FLIPL as well as the mutants 1-438 and D376A block the proteasome,
while 1-202, 203-480 and F23G/F114G do not. In contrast, HSV-1 downregulation was
operative with the c-FLIPL mutants 1-438, 203-480 and F23G/F114G and with c-FLIPS.
An overview of the ability of c-FLIPL wild type and mutants to form aggregates, to
block the proteasome and to resist HSV-1 induced downregulation is shown in figure
4.1. The following conclusions can be drawn from these observations: i) Overexpressed
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c-FLIPL forms aggregates which impair degradation by HSV-1. ii) Mutation or removal
of the DEDs and modification of the C-terminus restore susceptibility to HSV-1 medi-
ated downregulation. iii) Resistance to HSV-1 induced downregulation is not correlated
with the ability of overexpressed c-FLIPL to block the function of the proteasome. iv)
DEDs and the ability to bind to the DISC are not essential for downregulation of c-FLIP
after HSV-1 infection. v) The findings support the hypothesis that HSV-1 directly at-
tacks the protein in order to downregulate c-FLIP. vi) Experiments with overexpressed
c-FLIPL should be performed with a mutant, which does not form aggregates, for ex-
ample c-FLIPL F23G/F114G.
Figure 4.1: Properties of c-FLIPL mutants. The structure of c-FLIPL wild type and mutants
[67] is depicted on the left side. Their ability to form aggregates when overex-
pressed in cells and to block the proteasome as published by Ishioka et al. and their
ability to resist HSV-1 induced downregulation is listed on the right side.
In uninfected cells, the c-FLIP amount is mainly determined by proteasomal turnover
[41, 89, 128]. Therefore, it had to be investigated whether HSV-1 induced downregu-
lation of c-FLIP is dependent on the proteasome. When the proteasome was blocked
by addition of the inhibitor MG132 after infection of iDCs with HSV-1, the loss of c-
FLIPL or c-FLIPS could not be prevented (figure 3.8). These experiments were difficult
to perform, because iDCs turned out to be highly susceptible to the toxic side effects of
MG132. Therefore, the earliest time point after infection was chosen, at which down-
regulation of c-FLIP could be observed. This was the case at 10 h p. i. with HSV-1 strain
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KOS at MOI 3. c-FLIPL and c-FLIPS were downregulated at this time point in HSV-1
infected iDCs compared to uninfected iDCs no matter if MG132 was added or not.
In summary, the data presented in this thesis indicate that increased proteasomal
turnover is not responsible for c-FLIP degradation after HSV-1 infection of iDCs. There-
fore, it can be concluded that HSV-1 induced c-FLIP degradation might be mediated
directly by a viral factor or a induced cellular factor or a combination of both. To proof
this, it was tested whether this factor is introduced into lysates of c-FLIP expressing
cells by addition of lysates of HSV-1 infected cells. Therefore, c-FLIPL F23G/F114G,
which is susceptible to HSV-1 induced downregulation when overexpressed in cells
(see above) or c-FLIPS-EGFP were transfected into A549 cells. Lysates of the transfected
cells were kept at -20◦C or incubated for 2 h at 37 ◦C. Immunoblot analysis showed that
c-FLIPL F23G/F114G and c-FLIPS-EGFP were detectable in comparable amounts in the
lysates, independent of the temperature at which the lysates were incubated (figure 3.9).
This indicates that lysates of uninfected cells do not contain factors, which can degrade
c-FLIP. However, when lysates of untransfected, but HSV-1 infected A549 cells were
added to the c-FLIP containing lysates, degradation of both c-FLIPL F23G/F114G and
c-FLIPS-EGFP was observed after incubation for 2 h at 37 ◦C. This degradation could
not be prevented by addition of MG132. These data support the hypothesis that after
HSV-1 infection of cells a viral factor is expressed or a cellular factor is induced which
directly degrades c-FLIP.
One candidate cellular factor could be the mitochondrial protease HtrA2/Omi. It
is released into the cytoplasm after proapoptotic events. HtrA2/Omi can promote or
even induce apoptosis by its protease activity [38, 61, 162, 174]. Proapoptotic events
after HSV-1 infection of cells might lead to the release of HtrA2/Omi from mitochon-
dria. Though the execution of apoptosis is blocked by viral antiapoptotic proteins [123],
HtrA2/Omi might remain in the cytoplasm and could degrade c-FLIP. Although a po-
tential direct interaction of HtrA2/Omi and c-FLIP has not been investigated yet, there
are some publications, which consistently show an increase of the amount of c-FLIP
when the action of HtrA2/Omi is blocked with a specific inhibitor [21, 159]. In future
experiments, the impact of inhibition of HtrA2/Omi on HSV-1 induced c-FLIP down-
regulation should be investigated.
Candidate viral factors, which could be involved in HSV-1 induced c-FLIP degra-
dation are probably expressed late in the viral replication cycle. This is indicated by
several results presented in this thesis and in the literature. As demonstrated by in-
fection of iDCs with UV-inactivated HSV-1, attachment of HSV-1 particles, entry into
the cell and release of viral DNA into the nucleus are not sufficient to induce down-
regulation of c-FLIP (figure 3.10) or apoptosis of iDCs (data not shown). At MOI 1.5,
c-FLIP downregulation and apoptosis in HSV-1 infected iDCs occur at 12 and 14 h p. i.
(figures 3.2 and 3.3), which corresponds to the late stage of the viral replication cycle.
As published by others [177] and confirmed by the microarray analysis presented in
this thesis, at 10 h p. i. all HSV-1 genes are expressed, even at MOI 1.5 and also in iDCs
(table 3). However, true late genes can be excluded as candidate viral factors, because
inhibition of HSV-1 DNA replication and expression of true late genes by aciclovir [36]
does not block c-FLIP downregulation and apoptosis in HSV-1 infected iDCs [115].
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In this work, some experiments were also carried out with a ICP27 (immediate early
regulatory protein) knockout mutant of HSV-1 (∆ICP27) [154]. ∆ICP27 is impaired in
the expression of some early and many late genes [146, 158], while immediate early
genes are expressed properly or are overexpressed. The reduction in the amount of
c-FLIP at 18 h p. i. was less pronounced in iDCs infected with ∆ICP27 compared to
HSV-1 wild type infected iDCs (figure 3.10). Therefore it must be assumed that one or
several viral genes, which are lower expressed in ∆ICP27 are involved in downregula-
tion of c-FLIP in HSV-1 infected iDCs. It has been shown that ICP27 is involved in the
retention of host mRNA in the nucleus at late time points post infection and thereby
shuts off expression of some cellular genes [146]. It is unlikely that this function of
∆ICP27 is responsible for c-FLIP downregulation, because c-FLIPL mRNA was found
in sufficient amounts in the cytoplasm of HSV-1 infected iDCs (figure 3.4). Moreover,
after infection of iDCs with ∆ICP27 the distribution of c-FLIPL mRNA in the nucleus
and cytoplasm was not different compared to infection with wild type HSV-1 (data not
shown). Unfortunately, it is impossible to make a statement about involvement of virus
genes in apoptosis induction after infection of iDCs with ∆ICP27, because ∆ICP27 in-
duces apoptosis in most cell types anyway [7, 8]. This is due to disturbed expression of
antiapoptotic viral genes after infection with this mutant.
In order to get an indication about a potential interaction of c-FLIP with a HSV-
1 protein, immunofluorescence analysis was performed with A549 cells, which were
transfected with c-FLIPL F23G/F114G. Consistent with results obtained by immunoblot
analysis (figure 3.8), the c-FLIP signal was reduced to approximately 50 % of the signal
observed in uninfected cells at 11 h p. i. with HSV-1 strain KOS at MOI 10. As published
by Ishioka et al. [67], c-FLIPL F23G/F114G is evenly distributed in uninfected cells
(figure 3.11A). In contrast, c-FLIPL F23G/F114G forms dot like or oval shaped accu-
mulations in many of HSV-1 infected cells (figure 3.11C,E). However, a co-localization
with viral proteins stained with anti-HSV-1 rabbit serum could not be detected (figure
3.11D,F). This result does not exclude the possibility that a viral protein does interact
with c-FLIP, because the serum does probably not stain all viral proteins expressed af-
ter infection of cells. Furthermore, it is possible that the interaction takes place at a
different time point.
Based on the literature published so far, a possible impact of two HSV-1 proteins
on the stability of c-FLIP is conceivable. First, it has been shown that the stability of
some c-FLIP isoforms can be regulated by phosphorylation on serine residues [86].
There is one viral serine/threonine protein kinase, US3, which is able to phosphory-
late procaspase-3 [18]. Because c-FLIP is a caspase homolog, it might be possible that it
is also phosphorylated by US3 and thereby its turnover is increased. Second, reactive
oxygen species (ROS) are suspected to influence c-FLIP stability [90, 101]. The viral
glycoprotein gJ can induce ROS formation [10] and could thereby destabilize c-FLIP.
Both viral proteins are expressed as leaky late genes during HSV-1 replication. There-
fore, they would be good candidates for a potential viral factor, which attacks c-FLIP,
based on the observations made earlier in this thesis. Surprisingly, when co-transfected
with c-FLIPL F23G/F114G in HEK cells, neither US3 nor gJ were able to reduce the
amount of c-FLIP. However, co-localization of US3 with c-FLIPL F23G/F114G was ob-
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served (figure 3.12). US3 formed dot like aggregates when overexpressed in HEK cells.
Co-transfected c-FLIPL F23G/F114G was in most cells aggregated in the same region as
US3. Furthermore, the structures formed by c-FLIPL F23G/F114G when co-transfected
with US3 were reminiscent of those observed with overexpressed c-FLIPL F23G/F114G
after HSV-1 infection (figure 3.11). A co-localization of US3 and c-FLIPL was confirmed
by further experiments performed by Martin J. Raftery (personal communication, Mar-
tin J. Raftery, Institute of Virology, Charité Medical School, Berlin, Germany). These
observations indicate that US3 might play a role in HSV-1 induced c-FLIP downregula-
tion. A contribution of US3 to c-FLIP downregulation after HSV-1 infection is supported
by the fact, that a ICP27 HSV-1 knockout mutant has a reduced ability to downregu-
late c-FLIP (figure 3.10) and US3 expression in this mutant is five times lower com-
pared to wild type virus [158]. US3 might phosphorylate c-FLIP and thereby mark
it for degradation by a protease. Because US3 alone is not sufficient for downregu-
lation of c-FLIP, the responsible protease must be newly expressed or activated after
HSV-1 infection of cells. HSV-1 encodes a protease, UL26 [142], but up to now it is
not investigated whether it also attacks cellular proteins. Further experiments should
be performed in order to clarify, whether UL26 is involved in HSV-1 induced c-FLIP
degradation. Peculiarly, US3 is almost exclusively discussed as an antiapoptotic factor
of HSV-1 [17, 26, 72, 103, 119, 118, 125], but downregulation of c-FLIP would rather
induce apoptosis. It is conceivable, that phosphorylation of c-FLIP is a side effect of
phosphorylation of caspases by US3, which is considered to prevent apoptosis. In most
cell types, strong antiapoptotic factors of HSV-1 could compensate for degradation of
c-FLIP and the antiapoptotic effect of caspase phosphorylation by US3 could dominate.
These antiapoptotic factors might not be functional in iDCs.
Taken together, in this thesis the mechanism of HSV-1 induced c-FLIP downregula-
tion was resolved to a great extent. It was shown that HSV-1 does not interfere with
c-FLIP mRNA transcription, transport or stability. Instead, c-FLIP is degraded late dur-
ing HSV-1 infection independent from the proteasome by a newly expressed or acti-
vated cellular or viral protease with possible involvement of the viral protein kinase
US3.
4.4 c-FLIP reduction without apoptosis in HSV-1 infected cell
types other than iDCs
Because HSV-1 induced c-FLIP downregulation was operative with overexpressed c-
FLIP in A549 cells (figure 3.7), it is likely that it is a general phenomenon occurring
also in cell types other than iDCs. Indeed, HSV-1 infection resulted in downregulation
of naturally expressed c-FLIPL (figure 3.14A) and c-FLIPS (data not shown) in all cell
types tested in this work, including epithelial cells (primary keratinocytes), connective
tissue cells (primary fibroblasts), endothelial cells (HUVEC), and cells of hematopoi-
etic origin (Hodgkin/Reed-Sternberg cell lines L428 and L1236). The extent of c-FLIP
downregulation in these cell types was comparable to iDCs, if a comparable infection
rate was achieved.
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Although c-FLIP was also downregulated by HSV-1 in primary keratinocytes, pri-
mary fibroblasts, HUVECs, and HRS cells, these cell types did not show an increased
number of apoptotic (AnnexinV+/PI−) cells after infection, in contrast to iDCs (figure
3.14B). However, in some of these cell types the number of viable cells (AnnexinV−/
PI−) was decreased after infection. This was mainly due to an increase in the number
of AnnexinV+/PI+ cells. It can be assumed that this cell population represents necrotic
cells, as the number of AnnexinV−/PI+ cells is also increased, which is not the case
in late stage apoptosis [155], observed for example after siRNA mediated knockdown
of c-FLIP in iDCs (figure 3.1). Necrosis observed after HSV-1 infection is probably a
consequence of successful viral replication.
These findings are in line with many publications, which report a resistance of HSV-1
infected cells to apoptosis. In most cell types, no apoptosis occurs after infection with
wild type HSV-1. However, when protein synthesis and consequently expression of
viral proteins is blocked after infection, apoptosis is observed in human epithelial cell
lines. Apoptosis is also induced after infection with a ICP27 HSV-1 knock out mutant,
which is impaired in expression of early and late genes [7, 8, 92]. From these observa-
tions it was concluded that HSV-1 induces apoptosis early in infection, but powerful
antiapoptotic viral factors expressed later in infection are able to prevent apoptosis to
ensue. Furthermore, dependent on the cell type, these antiapoptotic HSV-1 factors can
also protect infected cells from apoptosis induced by different stimuli, such as stau-
rosporine, sorbitol and Fas ligand [8, 43].
Downregulation of c-FLIP after HSV-1 infection is probably an apoptosis inducing
event. Because apoptosis after HSV-1 infection is only observed in iDCs, but not in
other cell types tested, it must be concluded that antiapoptotic factors of HSV-1 are not
sufficiently operative in iDCs.
4.5 Lower expression of LATs in apoptotic iDCs as compared to
nonapoptotic epithelial cells
In order to find differences in the expression of antiapoptotic viral genes in apoptotic
iDCs compared to nonapoptotic epithelial cells, a global analysis of HSV-1 gene expres-
sion was performed using a HSV-1 microarray. Because a high number of cells was nec-
essary to collect sufficient amounts of RNA for microarray analysis, it was not possible
to use primary keratinocytes in this set of experiments. It was therefore decided to use
the immortalized human keratinocyte cell line HaCaT and the human epithelial tumor
cell line HeLa. Consistent with the literature, wild type HSV-1 infection did not induce
apoptosis in HaCaT or HeLa, but in iDCs (figure 3.15B). In contrast, infection with an
apoptosis inducing ICP27 knockout HSV-1 mutant induced apoptosis in all three cell
types (figure 3.15C). These data show that iDCs, HeLa and HaCaT cells are susceptible
to HSV-1 induced apoptosis, but HeLa and HaCaT cells are protected against apoptosis
after wild type HSV-1 infection by antiapoptotic factors, which do not operate in iDCs.
The results obtained by microarray analysis show that the overall timing and extent
of HSV-1 gene transcription is similar in iDCs, HeLa and HaCaT. This is indicated by
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the fact that the maximum total number of transcripts and the time course of expression
of immediate early, early, leaky late and true late genes was similar in all three cell
types and comparable with data published by other groups (figures 3.16-3.19, tables
1-4, and [177]). Interestingly, the HSV-1 transcription cascade proceeded faster in iDCs
compared to HeLa or HaCaT at early time points post infection, which resulted in a
higher total transcript number in iDCs at 6 h p. i., a higher expression of some early
genes at 3 h p. i. and a higher expression of some leaky late genes at 6 h p. i. However,
the relative abundance of α0 transcripts, which have been shown to be the apoptosis
inducing factor after HSV-1 infection [25, 145, 147], was not different in iDCs compared
to HeLa or HaCaT at any time point. Therefore, it is unlikely that the observed faster
progression of viral transcription in iDCs is the cause of HSV-1 induced apoptosis.
Expression of antiapoptotic genes of HSV-1, UL54 (ICP27) [7, 8], α4 (ICP4) [102], US1
(ICP22) [8], US11 [70], US5 (gJ) [72, 73, 188], and US6 (gD) [188, 187, 189] was not signif-
icantly different in iDCs compared to HeLa or HaCaT (figure 3.20). The antiapoptotic
US3 kinase [72, 103] even showed a higher transcript abundance in iDCs compared to
HeLa or HaCaT at 6 h p. i. However, some of the antiapoptotic genes (US11, US3, US5
and US6) are members of coterminal transcript families, which can not be discriminated
with the microarray [177]. Therefore, further analyzes, for example by quantitative real
time PCR, would be necessary for a final conclusion about a potential differential ex-
pression of these genes.
Intriguingly, microarray analysis revealed a lower abundance of LATs in iDCs com-
pared to HeLa or HaCaT at late time points post infection (10 and 18 h p. i., fig-
ure 3.21). In HeLa or HaCaT, the time course and extent of expression of LATs de-
tected with the HSV-1 microarray in this thesis confirms data published by others
[177]. LATs are the only HSV-1 transcripts abundantly expressed during latent in-
fection of neurons [139, 176]. It has been shown that the first 1.5 kb of the LAT se-
quence can protect cells against apoptosis and that the antiapoptotic function of LAT
is responsible for its ability to increase the spontaneous reactivation of HSV-1 from
latency [2, 24, 65, 74, 76, 77, 117, 129, 130, 131]. The LATs species expressed during la-
tency represent mainly two stable introns. In contrast, during lytic replication mostly
polyadenylated forms of LATs are detectable [28, 32]. The design of the microarray al-
lows only detection of polyadenylated RNA species [177]. The function of LATs during
lytic expression is not fully understood, but LAT knockout HSV-1 mutants induce more
apoptosis in productively infected cells compared to wild type HSV-1 [2, 75].
Cell type specific regulation of LAT expression is a well known phenomenon, al-
though the regulation of LAT promoter activity is still not fully resolved. It was soon
recognized that LAT is highly and continuously expressed in latently infected neurons
but expressed to a lesser extent during lytic infection of other cell types [14, 15, 191].
LAT expression could be influenced by interferons via binding of STAT1 to the LAT
promoter [95]. Early growth response (EGR) proteins, which are expressed soon after
exposure of cells to stress signals, were also demonstrated to bind to the LAT promoter
and repress its activity [164]. Therefore, it is conceivable that iDC specific signaling
events reduce the expression of LATs.
The studies presented in this thesis do not exclude the possibility that expression of
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some of the antiapoptotic genes of HSV-1 is different on the protein level in iDCs com-
pared to HeLa or HaCaT, for example because of different proteasomal turnover. This
might also contribute to apoptosis. Furthermore, differences in expression or function
of cellular genes other than c-FLIP could influence sensitivity of iDCs to apoptosis after
HSV-1 infection. As indicated by the results presented in figure 3.1, iDCs might also
inherently be more sensitive to c-FLIP downregulation than other cell types. However,
HSV-1 infection can protect most cell types against various intrinsic and extrinsic apop-
tosis inducing events [8, 43]. Therefore, it is highly probable that apoptosis of HSV-1
infected iDCs is at least partly caused by a failure of viral antiapoptotic functions.
The following conclusions can be made based on the results obtained with the HSV-
1 microarray in iDCs, HeLa and HaCaT: i) The antiapoptotic HSV-1 genes UL54, α4,
US1, US11, US3, US5 and US6 are properly expressed during infection of iDCs. Still,
apoptosis is not prevented. ii) LATs are expressed in apoptotic iDCs to a much lower
extent at 10 and 18 h p. i. compared to nonapoptotic epithelial cells. This indicates that
LATs play an essential role in prevention of apoptosis late in lytic infection. iii) iDCs
might undergo apoptosis because the essential antiapoptotic function of LATs is not
sufficiently available.
4.6 Increased apoptosis in iDCs after infection with a LAT
knockout HSV-1 mutant
Because expression of LATs was reduced in iDCs compared to HeLa or HaCaT, but not
completely abrogated, it is conceivable that a further reduction in the amount of LATs
would lead to an increase in apoptosis after HSV-1 infection of iDCs. This was con-
firmed with a LAT knockout HSV-1 mutant (17N/H). iDCs from four out of five donors
showed an increased number of apoptotic cells after infection with 17N/H compared
to wild type HSV-1 (figure 3.22A,B). The increase in apoptosis could not be explained
by differences in infection efficiency between the mutant and wild type HSV-1 (fig-
ure 3.22C). It was also excluded that disturbed expression of other antiapoptotic HSV-
1 genes is responsible for the higher apoptosis inducing capability of 17N/H (figure
3.23B). 17N/H lacks the expression of the promoter region and the first 1.66 kb of the
coding region of LAT. It has been shown that it does not express any 2 kb or longer
forms of LATs, but one aberrant 1.1 kb transcript downstream of the deletion [22]. This
transcript was also detected in 17N/H infected iDCs in this work (figure 3.23A). How-
ever, this aberrant transcript is located downstream of the region, which was defined to
be involved in protection against apoptosis [2, 24, 65, 74, 131]. Therefore it is unlikely
that it has influenced the results of the experiments presented here. In conclusion, it
was demonstrated that expression of LATs can protect HSV-1 infected iDCs from apop-
tosis.
Recently it was published that c-FLIP can substitute for LAT in reactivation from
latency [77]. This indicates that LATs exert a FLIP-like function in order to facilitate
reactivation. It is possible that LATs do not only play a role in protection of latently
infected neurons against apoptosis, but also prevent apoptosis late in lytic infection of
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productively infected cells. This is supported by data obtained by other groups with
17N/H in lytically infected cells [2, 75]. In this thesis it is shown that LATs are not
expressed in sufficient amounts in iDCs and are therefore not able to compensate HSV-
1 induced c-FLIP downregulation.
4.7 Apoptosis of HSV-1 infected iDCs as a consequence of
altered balance between pro- and antiapoptotic events
This thesis provides a substantial contribution to the understanding of apoptosis in
HSV-1 infected iDCs. Although it has been shown that HSV-1 infects iDCs [114], blocks
maturation [143] and induces apoptosis [23, 80, 133], little is known about the mecha-
nism of HSV-1 induced apoptosis in this important cell type. Müller et al. have demon-
strated that HSV-1 downregulates the cellular antiapoptotic protein c-FLIP in infected
iDCs [115]. In this thesis it was discovered that c-FLIP is directly attacked by HSV-1 and
degraded by a viral or newly induced cellular protease with potential participation of
the viral kinase US3. Furthermore it was demonstrated that a reduction of the amount
of c-FLIP by RNA interference is sufficient to induce apoptosis in iDCs.
Another cellular apoptosis modulating protein is p53. It has been established that
p53 can induce apoptosis independent from transcription [30], for example by inhibit-
ing the mitochondrial antiapoptotic proteins Bcl-XL and Bcl-2 [112]. Müller et al. ob-
served an increase of the amount of p53, but not nuclear localization, in HSV-1 infected
iDCs [115]. A polymorphism in p53 which is associated with increased susceptibility to
cancer might be associated with a different ability of p53 to modulate apoptosis [34, 42].
A set of experiments conducted in the course of this thesis support the hypothesis that
p53 might be involved in apoptosis of iDCs, because the extent of apoptosis observed
in iDCs after infection with wild type HSV-1 turned out to be associated with the p53
polymorphism of the donor (diploma thesis of Stefan Kohl).
Bcl-2 is a mitochondrial antiapoptotic protein [1] which has been shown to be down-
regulated after infection of cells with apoptosis inducing HSV-1 deletion mutants. Re-
storation of Bcl-2 levels lead to a reduction of the amount of apoptosis observed af-
ter infection with HSV-1 deletion mutants [186]. Furthermore, it was found that Bcl-2
might protect iDCs against apoptosis [58]. However, apoptosis of iDCs after infection
with wild type HSV-1 is not associated with a reduction of the amount of Bcl-2 [115].
Therefore it is unlikely that Bcl-2 could play a role in HSV-1 induced apoptosis of iDCs.
NFκB is another cellular factor which is discussed to be involved in modulation of
apoptosis in HSV-1 infected cells. However, there has been some controversy whether
NFκB activation is involved in induction [163] or prevention [50] of apoptosis after
HSV-1 infection of cells. Activation of NFκB was also found after HSV-1 infection of
iDCs [134]. The results presented in this work also indicate the activation of NFκB after
infection of iDCs with HSV-1, because the observed increase of c-FLIP mRNA (figure
3.4) is likely mediated by NFκB [93, 111]. In iDCs, activation of NFκB is associated with
maturation and increased resistance to apoptosis [94, 122]. Based on these considera-
tions it is not likely that NFκB could be involved in apoptosis induction by HSV-1 in
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iDCs.
It is well established that HSV-1 first induces apoptosis in infected cells, probably by
transcription of α0 [25, 145, 147]. However, viral antiapoptotic proteins, such as US3,
gJ, gD and US11, are expressed during the apoptosis prevention window 3 - 6 h p. i. and
apoptosis is prevented [8, 92]. Surprisingly, no study was undertaken up to now to in-
vestigate whether impaired expression of antiapoptotic HSV-1 genes might contribute
to apoptosis of infected iDCs. Using a HSV-1 microarray it was shown in this work that
almost all antiapoptotic HSV-1 genes are expressed in iDCs to the same extent as in ep-
ithelial cells, which are resistant to apoptosis after HSV-1 infection. However, there was
one remarkable exception: LATs were 1.4 to 7.9 fold less abundant in iDCs compared
to epithelial cells at 10 h p. i. Lower expression of LATs in iDCs was still detectable at
18 h p. i., but was not seen at earlier time points (3 h or 6 h p. i.). Further experiments
in this thesis showed that a LAT knockout HSV-1 mutant induced more apoptosis in
iDCs compared to wild type HSV-1, which shows a residual expression of LAT. This
indicates that the observed lower expression of LAT in iDCs could have an significant
impact on susceptibility of iDCs to apoptosis after HSV-1 infection. This is the first time
that expression of HSV-1 antiapoptotic genes was studied after infection of iDCs and
these studies define a new role for LAT during productive infection. A first indication
that LAT might play a role in prevention of apoptosis also during lytic infection was
obtained in studies with LAT knockout HSV-1 mutants which induced more apoptosis
compared to wild type HSV-1 in HeLa and Neuro2A cells [2, 75].
Based on the results obtained in this work a new model of HSV-1 induced apop-
tosis can be proposed (figure 4.2). Like in other cell types, HSV-1 induces apoptosis
early in infection of iDCs, which can be counterbalanced by HSV-1 antiapoptotic pro-
teins expressed in the apoptosis prevention window between 3 h and 6 h p. i. A second
apoptosis inducing event occurs after 10 h p. i. in all cells, which is downregulation of
c-FLIP. Lytic LAT expression can counterbalance this event in most cell types, but not in
iDCs, which express only minor amounts of LATs. Therefore, a second apoptosis pre-
vention window could be defined post 10 h p. i. This conclusion is supported by two
observations, i) c-FLIP can substitute for LAT to enhance reactivation of HSV-1 [77] and
ii) a LAT knockout HSV-1 mutant is less effective in protection of HeLa cells against
apoptosis induced by Fas Ligand than the respective wild type virus [2].
The data presented in this work indicate that HSV-1 precisely regulates apoptosis in
different cell types in order to optimize virus spread, replication and establishment of
latency. Epithelial cells, which serve as host for productive replication are protected
against apoptosis throughout infection until high numbers of progeny virions are re-
leased [8, 43, 92]. Latently infected neurons are also protected against apoptosis to
ensure that HSV-1 persists in the organism [131]. In contrast, infection of iDCs proba-
bly serves different needs of HSV-1. First, HSV-1 might use iDCs as a vehicle to spread
within the organism. Therefore, iDCs are kept alive in the early stage of infection, but
antigen presentation and activation of T cells is blocked by UL47 [185] and by interfer-
ence of HSV-1 with maturation of iDCs [143]. At late times after infection, apoptosis of
iDCs is induced. The destruction of infected iDCs at the site of virus replication might
lead to a delay in the antiviral immune response [23, 115, 133]. Thereby, the virus gains
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Figure 4.2: Model of apoptosis modulation by HSV-1. In addition to the known pro- and
antiapoptotic events early after infection, a second proapoptotic event, degradation
of c-FLIP, occurs in all cell types late after infection. Lytically expressed LATs can
protect most infected cell types from apoptosis. Therefore, a second apoptosis pre-
vention window can be defined late in the lytic HSV-1 replication cycle, which is
defined by expression of LATs. In iDCs, LATs are insufficiently expressed and can
not counterbalance apoptosis.
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time which is needed for infection of neurons and efficient establishment of latency. Fi-
nally, bystander iDCs which are not infected take up debris of infected cells and present
HSV-1 antigens to T cells [23]. This leads to an immune response which is sufficient to
stop replication of the virus and keeps the host alive until reactivation of HSV-1 oc-
curs and the virus can be transmitted to other individuals. This is another intriguing
example how a long co-evolution of pathogen and host leads to a complex interaction
which ensures maximum dissemination of the pathogen while minimizing damage of
the host.
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Tables listing relative abundance of HSV-1 transcripts
Table 1: Relative abundance of HSV-1 transcripts in iDCs compared to HaCaT or HeLa 3 h p. i. with HSV-1 strain
KOS at MOI 1.5. Kinetic class of transcripts or coterminal transcript families is assigned according to Roiz-
man et al. [142]: IE, immediate early; E, early; L, Late; ?, unknown kinetics. UL8 and UL9 have early kinetics,
but UL8.5 and UL9.5 have late kinetics. Median values of two replicates (infection 2 and 3 as indicated in
table 3.1) are shown. Relative abundance is given in % (probe signal expressed as proportion of the total
viral signal given in line one). Bold face; relative abundance of this HSV-1 transcript is more than two fold
different in iDCs compared to the respective control cell (P≤ 0.05).
92
Table 2: Relative abundance of HSV-1 transcripts in iDCs compared to HaCaT or HeLa 6 h p. i. with HSV-1 strain
KOS at MOI 1.5. Kinetic class of transcripts or coterminal transcript families is assigned according to Roiz-
man et al. [142]: IE, immediate early; E, early; L, Late; ?, unknown kinetics. UL8 and UL9 have early kinetics,
but UL8.5 and UL9.5 have late kinetics. Median values were calculated out of three replicates (for iDCs and
HaCaT, infection 1-3 as indicated in table 3.1) or two replicates (for HeLa, infection 2 and 3 as indicated in
table 3.1). Relative abundance is given in % (probe signal expressed as proportion of the total viral signal
given in line one). Bold face; relative abundance of this HSV-1 transcript is more than two fold different in
iDCs compared to the respective control cell (P≤ 0.05).
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Tables listing relative abundance of HSV-1 transcripts
Table 3: Relative abundance of HSV-1 transcripts in iDCs compared to HaCaT or HeLa 10 h p. i. with HSV-1
strain KOS at MOI 1.5. Kinetic class of transcripts or coterminal transcript families is assigned according to
Roizman et al. [142]: IE, immediate early; E, early; L, Late; ?, unknown kinetics. UL8 and UL9 have early
kinetics, but UL8.5 and UL9.5 have late kinetics. Median values were calculated out of three replicates (for
iDCs and HaCaT, infection 1-3 as indicated in table 3.1) or two replicates (for HeLa, infection 1 and 3 as
indicated in table 3.1). Relative abundance is given in % (probe signal expressed as proportion of the total
viral signal given in line one). Bold face; relative abundance of this HSV-1 transcript is more than two fold
different in iDCs compared to the respective control cell (P≤ 0.05).
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Table 4: Relative abundance of HSV-1 transcripts in iDCs compared to HaCaT or HeLa 18 h p. i. with HSV-1
strain KOS at MOI 1.5. Kinetic class of transcripts or coterminal transcript families is assigned according to
Roizman et al. [142]: IE, immediate early; E, early; L, Late; ?, unknown kinetics. UL8 and UL9 have early
kinetics, but UL8.5 and UL9.5 have late kinetics. Median values were calculated out of three replicates (for
iDCs and HaCaT, infection 1-3 as indicated in table 3.1) or two replicates (for HeLa, infection 2 and 3 as
indicated in table 3.1). Relative abundance is given in % (probe signal expressed as proportion of the total
viral signal given in line one). Bold face; relative abundance of this HSV-1 transcript is more than two fold
different in iDCs compared to the respective control cell (P≤ 0.05).
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